WO2016207216A1 - New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents

New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
WO2016207216A1
WO2016207216A1 PCT/EP2016/064417 EP2016064417W WO2016207216A1 WO 2016207216 A1 WO2016207216 A1 WO 2016207216A1 EP 2016064417 W EP2016064417 W EP 2016064417W WO 2016207216 A1 WO2016207216 A1 WO 2016207216A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
pyrimidin
group
methyl
oxy
Prior art date
Application number
PCT/EP2016/064417
Other languages
French (fr)
Inventor
Zoltán SZLÁVIK
Attila Paczal
Balázs Bálint
András Kotschy
Maïa CHANRION
Olivier Geneste
James Edward Paul Davidson
James Brooke MURRAY
Szabolcs SIPOS
Ágnes Proszenyák
Original Assignee
Les Laboratoires Servier
Vernalis (R&D) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK16731155.4T priority Critical patent/DK3313849T3/en
Priority to MDE20180439T priority patent/MD3313849T2/en
Priority to CUP2017000162A priority patent/CU20170162A7/en
Application filed by Les Laboratoires Servier, Vernalis (R&D) Limited filed Critical Les Laboratoires Servier
Priority to HRP20230472TT priority patent/HRP20230472T1/en
Priority to TNP/2017/000529A priority patent/TN2017000529A1/en
Priority to US15/738,601 priority patent/US10322131B2/en
Priority to PL16731155.4T priority patent/PL3313849T3/en
Priority to LTEPPCT/EP2016/064417T priority patent/LT3313849T/en
Priority to MYPI2017704890A priority patent/MY190243A/en
Priority to MA42231A priority patent/MA42231B1/en
Priority to RU2018102361A priority patent/RU2745430C9/en
Priority to AU2016282827A priority patent/AU2016282827B2/en
Priority to BR112017027831A priority patent/BR112017027831A2/en
Priority to UAA201800619A priority patent/UA124759C2/en
Priority to EP16731155.4A priority patent/EP3313849B8/en
Priority to KR1020187002026A priority patent/KR102620976B1/en
Priority to SI201631700T priority patent/SI3313849T1/en
Priority to ES16731155T priority patent/ES2944942T3/en
Priority to NZ738469A priority patent/NZ738469A/en
Priority to EA201890124A priority patent/EA036503B1/en
Priority to CA2990083A priority patent/CA2990083C/en
Priority to JP2017566288A priority patent/JP6773695B2/en
Priority to FIEP16731155.4T priority patent/FI3313849T3/en
Priority to CN201680048558.4A priority patent/CN107922432B/en
Priority to CR20170590A priority patent/CR20170590A/en
Priority to RS20230299A priority patent/RS64131B1/en
Priority to MX2017017008A priority patent/MX2017017008A/en
Publication of WO2016207216A1 publication Critical patent/WO2016207216A1/en
Priority to PH12017502314A priority patent/PH12017502314A1/en
Priority to IL256320A priority patent/IL256320A/en
Priority to CONC2017/0012845A priority patent/CO2017012845A2/en
Priority to ECIEPI201782825A priority patent/ECSP17082825A/en
Priority to ZA2017/08626A priority patent/ZA201708626B/en
Priority to SA517390586A priority patent/SA517390586B1/en
Priority to HK18109701.1A priority patent/HK1250233A1/en
Priority to HK18113626.5A priority patent/HK1254477A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to new hydroxyacid derivatives, to a process for their preparation and to pharmaceutical compositions containing them.
  • the compounds of the present invention are new and have very valuable pharmacological characteristics in the field of apoptosis and cancerology.
  • Apoptosis or programmed cell death, is a physiological process that is crucial for embryonic development and maintenance of tissue homeostasis.
  • Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation and also biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, so inducing its disassembly and death. Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signalling pathways (Cory S. et al., Nature Review Cancer 2002, 2, 647-656).
  • apoptosis Deregulation of apoptosis is involved in certain pathologies. Increased apoptosis is associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and ischaemia. Conversely, deficits in the implementation of apoptosis play a significant role in the development of cancers and their chemoresistance, in auto-immune diseases, inflammatory diseases and viral infections. Accordingly, absence of apoptosis is one of the phenotypic signatures of cancer (Hanahan D. et al., Cell 2000, 100, 57-70).
  • the anti-apoptotic proteins of the Bcl-2 family are associated with numerous pathologies.
  • the involvement of proteins of the Bcl-2 family is described in numerous types of cancer, such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukaemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc.
  • Overexpression of the anti- apoptotic proteins of the Bcl-2 family is involved in tumorigenesis, in resistance to chemotherapy and in the clinical prognosis of patients affected by cancer.
  • Mcl-1 an anti-apoptotic Bcl-2 family member
  • Mcl-1 an anti-apoptotic Bcl-2 family member
  • the compounds of the present invention have pro-apoptotic properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.
  • the present invention relates more especially to compounds of formula (I):
  • ⁇ Ri represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a linear or branched (Ci-Ce)alkoxy group, a -S-(Ci-Ce)alkyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a hydroxy(Ci-Ce)alkyl group, a cyano group, -NR12R12', -Cy 5 , or a halogen atom,
  • R 2 , R3, R4 and R 5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a hydroxy(Ci-C 6 )alkyl group, a linear or branched (Ci-C 6 )alkoxy group, a -S-(Ci-Ce)alkyl group, a cyano group, a nitro group, -alkyl(C 0 -C 6 )-NRioRio', -0-alkyl(Ci-C 6 )-NRi 0 Rio',
  • R 7 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C 2 -Ce)alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a linear or branched (Ci-C 6 )alkoxy group, a -S-(Ci-Ce)alkyl group, a cyano group, a nitro group, -alkyl(C 0 -C 6 )-NRioRio', -0-alkyl(Ci-C 6 )-NRi 0 Rio', -O-Cyi, -alkyl(C 0 -C 6 )-Cyi, -alkenyl(C 2 -C 6 )-Cyi,
  • Rs represents a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C 6 ) group, or a heteroarylalkyl(Ci-Ce) group,
  • R9 represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, -Cy 3 , -alkyl(Ci-C 6 )-Cy 3 , -alkenyl(C 2 -C 6 )-Cy 3 , -alkynyl(C 2 -C 6 )-Cy 3 , -Cy 3 -Cy 4 , -alkynyl(C 2 -Ce)-0-Cy 3 , -Cy 3 -alkyl(Co-C 6 )-0-alkyl(Co-C 6 )-Cy 4 , a halogen atom, a cyano group, -C(0)-Ri 3 , or -C(0)-NRi 3 Ri 3 ',
  • Rio and Rio' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, -alkyl(Co-Ce)-Cyi,
  • the substituents of the pair form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group, and it being understood that one or more of the carbon atoms of the possible substituents, may be deuterated,
  • ⁇ Rii represents -Cy 5 -alkyl(Co-C6)-0-alkyl(Co-C 6 )-Cy6, -Cy 5 -alkyl(C 0 -C 6 )-Cy6, -Cy 5 -alkyl(Co-C6)-NR 12 -alkyl(Co-C 6 )-Cy6,
  • Ri 2 , Ri 2 ', Ri3 and Ri 3 ' independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-Ce)alkyl group,
  • ⁇ Ri4 represents a hydrogen atom, a hydroxy group, or a hydroxy(Ci-C 6 )alkyl group
  • ⁇ R a represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group
  • R b represents a -0-C(0)-0-Rc group, a -0-C(0)-NRcR c ' group, or a -0-P(0)(ORc) 2 group,
  • R c and R c ' independently of one another represent a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a cycloalkyl group, a (Ci-C 6 )alkoxy(Ci-C 6 )alkyl group, a (Ci-C 6 )alkoxycarbonyl(Ci-C 6 )alkyl group,
  • Cyi, Cy 2 , Cy 3 , Cy 4 and Cy 5 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group,
  • Cy 6 represents a heteroaryl group which is substituted by a group selected from -O-P(O)(OR 20 ) 2 ; -0-P(0)(0 ) 2 ; -(CH 2 ) p -O-(CHR 18 -CHR 19 -O) q -R 20 ; hydroxy; hydroxy(Ci-C 6 )alkyl; -(CH 2 ) r -Y-(CH 2 ) s -heterocycloalkyl; or -Y-(CH 2 ) q -NR 2 iR 2 i ',
  • ⁇ Ri5 represents a hydrogen atom; a -(CH 2 )p-0-(CHRi8-CHRi 9 -0) q -R 2 o group; a linear or branched (Ci-C 6 )alkoxy(Ci-C 6 )alkyl group; a -Y-(CH 2 ) q -NR 2 iR 2 i ' group; or a -(CH 2 ) r -Y-(CH 2 ) s -heterocycloalkyl group,
  • ⁇ Ri6 represents a hydrogen atom; a hydroxy group; a hydroxy(Ci-C 6 )alkyl group; a -(CH 2 ) r -Y-(CH 2 ) s -heterocycloalkyl group; a (CH 2 ) r -Y-X-O-P(O)(OR 20 ) 2 group; a -0-P(0)(0 " ) 2 group; a -(CH 2 ) p -O-(CHR 18 -CHR 19 -O) q -R 20 group; a -(CH 2 ) p -0-C(0)-NR 22 R 23 group; or a -Y-(CH 2 ) q -NR 2 iR 2 i ' group,
  • ⁇ Ri7 represents a hydrogen atom; a -(CH 2 )p-0-(CHRi8-CHRi 9 -0) q -R 2 o group; a -0-P(0)(OR 2 o) 2 group; a -0-P(0)(0 " ) 2 group; a hydroxy group; a hydroxy(Ci-C 6 )alkyl group; a -(CH 2 ) r -Y-(CH 2 ) s -heterocycloalkyl group; a -Y-(CH 2 ) q -NR 2 iR 2 i ' group; or an aldonic acid,
  • ⁇ X represents a -(CH 2 ) S - group or a -C(O)- group
  • ⁇ Y represents a bond or an oxygen atom
  • Ri 8 represents a hydrogen atom or a (Ci-C 6 )alkoxy(Ci-C 6 )alkyl group
  • ⁇ Rig represents a hydrogen atom or a hydroxy(Ci-Ce)alkyl group
  • R 2 o represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group
  • R 2 i and R 21 ' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a hydroxy(Ci-C 6 )alkyl group,
  • R 22 represents a (Ci-C 6 )alkoxy(Ci-C 6 )alkyl group, a -(CH 2 ) P -NR 2 4R 2 4' group, or a -(CH 2 ) p -O-(CHR 18 -CHR 19 -O) q -R 20 group,
  • R 23 represents a hydrogen atom or a (Ci-C 6 )alkoxy(Ci-C 6 )alkyl group
  • the substituents of the pair (R 22 , R 23 ) form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 18 ring members, which may contain in addition to the nitrogen atom from 1 to 5 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom, a linear or branched (Ci-C 6 )alkyl group or a heterocycloalkyl group,
  • R 2 4 and R24' independently of one another represent a hydrogen atom or a linear or branched (Ci-Ce)alkyl group
  • the substituents of the pair (R24, R 24 ') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C 6 )alkyl group,
  • ⁇ n is an integer equal to 0 or 1 ,
  • ⁇ p is an integer equal to 0, 1 or 2
  • ⁇ q is an integer equal to 1 , 2, 3 or 4,
  • ⁇ r and s are independently an integer equal to 0 or 1, with the proviso that R15, Ri 6 and R17 cannot represent together a hydrogen atom and, when Ri represents a methyl group, R15 cannot represent a methoxyethoxy group, it being understood that:
  • aryl means a phenyl, naphthyl, biphenyl, indanyl or indenyl group
  • heteroaryl means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
  • cycloalkyl means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,
  • heterocycloalkyl means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 5 groups selected from optionally substituted linear or branched (Ci-Ce)alkyl, optionally substituted linear or branched (C 2 -C 6 )alkenyl group, optionally substituted linear or branched (C 2 -C 6 )alkynyl group, optionally substituted linear or branched (Ci-Ce)alkoxy, optionally substituted (Ci-Ce)alkyl-S-, hydroxy, oxo (Ci-
  • At least one of the groups selected from R 2 , R 3 , R4 and R 5 does not represent a hydrogen atom.
  • compounds of formula (I) to which preference is given are compounds wherein n is an integer equal to 1.
  • an advantageous possibility consists of compounds of formula (I-a): wherein R l s R 2 , R3, R4, R5, R6, R7, Rs, R14 and A are as defined for formula (I).
  • Ri represents a linear or branched (Ci-C 6 )alkyl group or a halogen atom. More preferably, Ri represents a methyl group, an ethyl group, a bromine atom or a chlorine atom.
  • Atropisomers are stereoisomers arising because of hindered rotation about a single bond, where energy differences due to steric strain or other contributors create a barrier to rotation that is high enough to allow for isolation of individual conformers.
  • atropisomers are as follows:
  • Preferred atropisomer is (5S a ).
  • R14 represents a hydrogen atom, a hydroxy group, a hydroxymethyl group or a hydroxy ethyl group.
  • R14 represents a hydrogen atom.
  • R 2 represents a halogen atom, a hydroxy group, a linear or branched (Ci-C 6 )alkoxy group. More preferably, R 2 represents a methoxy group, a hydroxy group, a fluorine atom, a bromine atom or a chlorine atom. Even more preferably, R 2 represents a chlorine atom.
  • R 3 advantageously represents a hydrogen atom, a hydroxy group, a linear or branched (Ci-C 6 )alkoxy group or -0-alkyl(Ci-C6)-NRioRio'.
  • R 3 represents -0-alkyl(Ci-C 6 )-NRioRio'.
  • R4 and R 5 preferably represent a hydrogen atom.
  • the substituents of the pair (R l s R5) are identical and the substituents of the pair (R 2 , R4) are identical.
  • the substituents of the pair (R l s R 5 ) are identical and represent a (Ci-C6)alkyl group, preferably a methyl group, whereas the substituents of the pair (R 2 , R4) are identical and represent a halogen atom, preferably a chlorine atom, or a hydrogen atom.
  • R 7 preferably represents a hydrogen atom.
  • Rs represents a hydrogen atom, a -CHRaRb group, an optionally substituted linear or branched (Ci-Cs)alkyl group, or a heteroarylalkyl(Ci-Ce) group.
  • Rs represents a -CHRaRb group in which Ra represents a hydrogen atom or a methyl group and Rb represents a -0-C(0)-0-(Ci-Cs)alkyl group; a -0-C(0)-0-cycloalkyl group; a -0-C(0)-NRcRc' group, in which Rc and R c ' independently of one another represent a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a (Ci-C6)alkoxy(Ci-C6)alkyl group, a (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl group, or the substituents of the pair (Rc, Rc') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen; or a -0-P(0)(OH) 2 group.
  • Preferred Rs groups are as follows: hydrogen; methyl; ethyl; (5-methyl-2-oxo-l ,3-dioxol-4-yl)methyl; a -CHRaRb group in which Ra represents a methyl group and Rb represents a -0-C(0)-0-CH 2 CH 3 group or a -0-C(0)-N(CH 3 ) 2 group. Even more preferably, Rs represents hydrogen.
  • R9 represents a linear or branched (Ci-C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, an aryl group or a heteroaryl group.
  • R9 represents a linear or branched (C 2 -C 6 )alkynyl group, an aryl group or a heteroaryl group. More preferably, R9 represents a prop-l-yn-l-yl group, a but-l-yn-l-yl group, a phenyl group or a furan-2-yl group.
  • R9 represents a 4-(benzyloxy)phenyl group, a 4-(pyridin-4-ylmethoxy)phenyl group, a 4-phenylbut-l-yn-l-yl group, a 4-fluorophenyl group or a 5-fluorofuran-2-yl group. Even more preferentially, R9 represents a 4-fluorophenyl group.
  • Rio and Rio' independently of one another represent a linear or branched (Ci-C 6 )alkyl group, or the substituents of the pair (R 10 , Rio') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C 6 )alkyl group.
  • Rio and Rio' represent a methyl group, or the substituents of the pair (R 10 , Rio') form together a 4-methyl-piperazinyl group or a 4-ethyl-piperazinyl group. In a more preferred embodiment, the substituents of the pair (Rio, Rio') form together a 4-methyl-piperazinyl group. In another preferred embodiment, Rio and Rio' represent a methyl group.
  • Rn represents -Cy 5 -alkyl(Co-C 6 )-Cy 6 . More particularly, Rn represents -Cy 5 -Cy 6 .
  • Cy 5 preferably represents a heteroaryl group, particularly, a pyrimidinyl group, a pyrazolyl group, a triazolyl group, a pyrazinyl group or a pyridinyl group. More preferably, Cy 5 represents a pyrimidin-4-yl group, a pyrazol-5-yl group, a triazol-5-yl group, a pyrazin-2-yl group or a pyridin-4-yl group. In the preferred compounds of the invention, Cy 5 represents a pyrimidin-4-yl group.
  • Cy 5 represents a heteroaryl group which is substituted by an optionally substituted linear or branched (Ci-C 6 )alkyl group, an optionally substituted linear or branched (Ci-C 6 )alkoxy group, a -NR'R" group, or a linear or branched (Ci-Ce)polyhaloalkyl group, it being understood that R' and R" independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C 6 )alkyl group.
  • Cy 6 represents
  • Cy 6 advantageously represents a 3-pyridinyl group, a 4-pyridinyl group, a pyridazin-4-yl group, a pyrazin-2-yl group, or a pyrimidin-4-yl group, it being understood that these heteroaryl groups are substituted by a group selected from -0-P(0)(OR 2 o) 2 ;
  • Cy 6 represents a 5-(hydroxymethyl)pyridin-3-yl group or a 2-(hydroxymethyl)pyrimidin-4- yl group.
  • Ri 6 and Rn represent a hydrogen atom and R15 represents a -(CH 2 ) p -0-(CHRi 8 -CHRi 9 -0) q -R 2 o group; a linear or branched (Ci-C 6 )alkoxy(Ci-C 6 )alkyl group; a -Y-(CH 2 ) q -NR 2 iR 2 i ' group; or a -(CH 2 ) r -Y-(CH 2 ) s -heterocycloalkyl group, in which Ri8, Ri , R 2 o, R 2 i, R 2 i ', Y, p, q, r and s are as defined for formula (I).
  • R15 and R17 represent a hydrogen atom and Ri6 represents a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH 2 ) r -Y-(CH 2 ) s -heterocycloalkyl group; a -O-P(O)(OR 20 ) 2 group; a -0-P(0)(0 " ) 2 group; a -(CH 2 ) P -0-(CHR 18 -CHR 19 -O) q -R 2 o group; a -(CH 2 ) p -0-C(0)-NR 22 R 23 group; a (CH 2 ) r -Y-X-O-P(O)(OR 20 ) 2 group; or a -Y-(CH 2 ) q -NR 2 iR 2 i ' group, in which R 18 , R 19 , R 20 , R 2 i, R 2 i ', R 22
  • R15 and Ri 6 represent a hydrogen atom and Rn represents a -(CH 2 ) p -0-(CHRi 8 -CHRi 9 -0) q -R 2 o group; a -O-P(O)(OR 20 ) 2 group; a -0-P(0)(0 " ) 2 group; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH 2 ) r -Y-(CH 2 )s-heterocycloalkyl group; a -Y-(CH 2 ) q -NR 2 iR 2 i ' group; or an aldonic acid, in which Ri 8 , R19, R 2 o, R 2 i, R 2 i ', Y, p, q, r and s are as defined for formula (I).
  • heterocycloalkyl as defined for R15, Ri 6 and Ri7 represents any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by from 1 to 5 groups selected from linear or branched (Ci-Ce)alkyl, linear or branched (Ci-C 6 )alkoxy, hydroxy, or hydroxy(Ci-C 6 )alkyl.
  • R15 represents a -(CH 2 ) p -0-CH 2 -CH(CH 2 OH)-OH group; a -(CH 2 ) p -0-(CH 2 -CH 2 -0) q -H group; a -(CH 2 ) p -0-(CH 2 -CH 2 -0) q -CH 3 group; a methoxymethyl group; a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy group; a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxymethyl group; or a -Y-(CH 2 ) q -N(CH 2 -CH 2 -OH) 2 group, in which Y, p and q are as defined for formula (I).
  • Ri 6 represents a hydroxy group; a hydroxymethyl group; a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy group; a -0-P(0)(OH) 2 group; a -(CH 2 ) p -0-CH 2 -CH(CH 2 OH)-OH group; a -(CH 2 ) p -0-(CH 2 -CH 2 -0) q -H group; a -(CH 2 ) p -0-(CH 2 -CH 2 -0) q -CH 3 group, in which p and q are as defined for formula (I); a -0-CH(CH 2 -OCH 3 ) 2 group; a -CH 2 -0-C(0)-NR 22 R 23 group, in which R 22 is as defined for formula (I) and R 23 represents a hydrogen atom, or in which R 22 and R 23 represent a (Ci-C 6 )alk
  • heterocycloalkyl group represents an aldohexose of formula:
  • each R 2 o is independent.
  • Rn represents a hydroxy group; a hydroxymethyl group; a hydroxyethyl group; a -0-(CH 2 -CH 2 -0) q -CH3 group; a -0-CH 2 -CH(CH 2 OH)-OH group; a -(CH 2 ) p -0-(CH 2 -CH 2 -0) q -H group; a -0-P(0)(OH) 2 group; a -0-P(0)(0 " ) 2 group; a -0-CH(CH 2 -OCH 3 ) 2 group; a -0-(CH 2 ) 2 -NR 2 iR 2 i ' group; a -CH 2 -NR 2 iR 2 i ' group, in which R 2 i and R 21 ' are as defined for formula (I); a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy group; D-mannonic acid
  • heterocycloalkyl group represents an aldohexose of formula:
  • each R 2 o is independent.
  • the invention relates also to a process for the preparation of compounds of formula (I), which process is characterised in that there is used as starting material the compound of formula (II): wherein A is as defined for formula (I) in which 1 is linked to the chlorine atom and 2 is linked to the bromine atom, which compound of formula (II) is subjected to coupling with a compound of formula (III):
  • R6, R 7 , Ri 4 , A and n are as defined for formula (I) and Alk is as defined before, compound of formula (IV) which is further subjected to coupling with compound of formula (V): wherein R L S R 2 , R 3 , R4 and R 5 are as defined for formula (I), and RBI and RB 2 represent a hydrogen atom, a linear or branched (Ci-C 6 ) alkyl group, or R B i and RB 2 form with the oxygen carrying them an optionally methylated ring, to yield the compound of formula (VI):
  • R l s R 2 , R3, R4, R5, 5, R7, R14, A and n are as defined for formula (I) and Alk is as defined before, the Alk-O-C(O)- ester function of which compound of formula (VI) is hydro lysed to yield the carboxylic acid, which may optionally be reacted with an alcohol of formula Rs'-OH or a chlorinated compound of formula Rs'-Cl wherein Rs ' represents a linear or branched (Ci-Cs)alkyl group, a -CHR a R b group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C 6 ) group, or a heteroarylalkyl(Ci-Ce) group, Ra and Rb are as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is
  • the compounds according to the invention will be useful in the treatment of chemo- or radio -resistant cancers.
  • the present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients.
  • pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragees, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.
  • the dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.
  • the present invention relates also to the combination of a compound of formula (I) with an anticancer agent selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies, and also to pharmaceutical compositions comprising that type of combination and their use in the manufacture of medicaments for use in the treatment of cancer.
  • an anticancer agent selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies
  • the present invention relates to the combination of a compound of formula (I) with an EGFR inhibitor, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a mTOR/PBK inhibitor, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a MEK inhibitor, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a HER2 inhibitor, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a RAF inhibitor, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a EGFR/HER2 inhibitor, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a taxane, and also to pharmaceutical compositions comprising that type of combination.
  • the present invention relates to the combination of a compound of formula (I) with a proteasome inhibitor, an immunomodulator or an alkylating agent, and also to pharmaceutical compositions comprising that type of combination.
  • the combination of a compound of formula (I) with an anticancer agent may be administered simultaneously or sequentially.
  • the administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients.
  • the compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.
  • the compounds of the invention may also be used in combination with radiotherapy in the treatment of cancer.
  • the compounds of the invention may be linked to monoclonal antibodies or fragments thereof or linked to scaffold proteins that can be related or not to monoclonal antibodies.
  • Antibody fragments must be understood as fragments of Fv, scFv, Fab, F(ab')2, F(ab'), scFv-Fc type or diabodies, which generally have the same specificity of binding as the antibody from which they are descended.
  • antibody fragments of the invention can be obtained starting from antibodies by methods such as digestion by enzymes, such as pepsin or papain, and/or by cleavage of the disulfide bridges by chemical reduction.
  • the antibody fragments comprised in the present invention can be obtained by techniques of genetic recombination likewise well known to the person skilled in the art or else by peptide synthesis by means of, for example, automatic peptide synthesizers such as those supplied by the company Applied Biosystems, etc.
  • Scaffold proteins that can be related or not to monoclonal antibodies are understood to mean a protein that contains or not an immunoglobulin fold and that yields a binding capacity similar to a monoclonal antibody.
  • the man skilled in the art knows how to select the protein scaffold. More particularly, it is known that, to be selected, such a scaffold should display several features as follow (Skerra A., J. Mol. Recogn.
  • Such a protein scaffold can be, but without limitation, a structure selected from the group consisting in fibronectin and preferentially the tenth fibronectin type III domain (FNfnlO), lipocalin, anticalin (Skerra A., J. Biotechnol.
  • the protein Z derivative from the domain B of staphylococcal protein A, thioredoxin A or any protein with a repeated domain such as an "ankyrin repeat” (Kohl et al., PNAS 2003, 100(4), 1700-1705), "armadillo repeat", “leucine-rich repeat” or “tetratricopeptide repeat”.
  • a scaffold derivative from toxins such as, for example, scorpion, insect, plant or mollusc toxins
  • protein inhibitors of neuronal nitric oxide synthase PIN
  • Flash chromatography was performed on ISCO CombiFlash Rf 200i with pre-packed silica-gel cartridges (RediSe/? ® i? f Gold High Performance). Thin layer chromatography was conducted with 5 x 10 cm plates coated with Merck Type 60 F254 silica-gel.
  • Microwave heating was performed in an Anton Parr MonoWave or CEM Discover® instrument.
  • Preparative HPLC purifications were performed on an Armen Spot Liquid Chromatography system with a Gemini-NX ® 10 ⁇ CI 8, 250 mm x 50 mm i.d. column running at a flow rate of 118 mL min "1 with UV diode array detection (210 - 400 nm) using 25 mM aqueous NH 4 HCO 3 solution and MeCN as eluents unless specified otherwise.
  • Analytical LC-MS The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on Agilent HP 1200 with Agilent 6140 quadrupole LC/MS, operating in positive or negative ion electrospray ionisation mode. Molecular weight scan range is 100 to 1350. Parallel UV detection was done at 210 nm and 254 nm. Samples were supplied as a 1 mM solution in ACN, or in THF/H 2 0 (1 : 1) with 5 loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.
  • Acidic LCMS ZORBAX Eclipse XDB-C18, 1.8 ⁇ , 50 mm x 4.6 mm i.d. column at 40 °C, at a flow rate of 1 mL min "1 using 0.02 % v/v aqueous formic acid (Solvent A) and 0.02 % v/v formic acid in acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100 % Solvent B over various/certain duration of time.
  • 1 H-NMPv measurements were performed on Bruker Avance III 500 MHz spectrometer and Bruker Avance III 400 MHz spectrometer, using DMSO-d 6 or CDCI 3 as solvent.
  • 1H NMR data is in the form of delta values, given in part per million (ppm), using the residual peak of the solvent (2.50 ppm for DMSO-d 6 and 7.26 ppm for CDCI 3 ) as internal standard.
  • Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br s (broad singlet), dd (doublet of doublets), td (triplet of doublets), dt (doublet of triplets), ddd (doublet of doublet of doublets).
  • AIBN 2-[(l -cyano- 1 -methyl-ethyl)azo]-2-methyl-propanenitrile AtaPhos bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)
  • the obtained intermediate was dissolved in dioxane-water 1 : 1 (10 mL/mmol) and 10 eq. LiOH x H 2 0 was added. The mixture was stirred at r.t. until no further conversion was observed. Then it was diluted with brine, neutralized with 2M aqueous HC1 solution, and extracted with DCM. The combined organic phases were dried over MgSC ⁇ , filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH 4 HCO 3 solution and MeCN as eluents. The diastereoisomer eluting later was collected.
  • Step A The product of Step A was dissolved in dioxane-water (1 : 1, 10 mL/mmol) and 10 eq. LiOH x H 2 0 was added. The mixture was stirred at r.t. until no further conversion was observed. Then it was neutralized with 2M HC1 and directly injected onto an RP18 column and chromatographied using 5 mM aqueous NH 4 HCO 3 solution and MeCN as eluents. The diastereomer eluting later was collected.
  • Step B 4-Chloro-6-iodo-thieno[2, 3-dJpyrimidine
  • Step C 5-Bromo-4-chloro-6-iodo-thieno[2, 3-dJpyrimidine
  • a 2 L round bottomed flask equipped with mechanical stirrer, thermometer and a bubbler was charged with 600 mL MeCN.
  • 50.9 g NBS (0.29 mol) and 8.5 mL tetrafluoroboric acid diethyl ether complex were added.
  • the reaction mixture was stirred at r.t. for 16 hours. Further 22.9 g (0.12 mol) NBS was added to the mixture in three portions. After cooling the suspension to
  • Step D 5-Bromo-4-chloro-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine
  • Step E [2- (Br omomethyl)phenyl] acetate
  • Step F Ethyl 2-acetoxy-3-(2-hydroxyphenyl)propanoate 23.10 g anhydrous LiCl (545 mmol) and 65.36 g anhydrous ZnCl 2 (479.6 mmol) were placed in a 2 L flask, then dried at 160 °C under 0.1 mmHg for 1 hour. After cooling to r.t. under argon atmosphere, 26.49 g magnesium turnings (1090 mmol) and 1 L dry pre-cooled (0 °C) THF were added. The resulting mixture was immersed into an ice-bath, and then stirred for 30 minutes.
  • Step G Ethyl (2R)-2-acetoxy-3-(2-hydroxyphenyl)propanoate and ethyl (2S)-2-acetoxy-3- (2-hydroxyphenyl)propanoate
  • Step K 2-Chloro-3-methyl-4-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenol
  • Step M Ethyl (2R)-2-acetoxy-3-[2-[ (2-chloropyrimidin-4-yl)methoxy] phenyl] propanoate 9.06 g ethyl (2i?)-2-acetoxy-3-(2-hydroxyphenyl)propanoate (from Step G, 36 mmol), 7.12 g 2-chloro-4-(chloromethyl)pyrimidine (44 mmol), 5.97 g K 2 C0 3 (44 mmol) and 1.22 g KI (1.22 mmol) were placed in a 250 mL flask. 70 mL DMF was added and the mixture was stirred at r.t. under N 2 until no further conversion was observed.
  • Step N Ethyl (2R)-3-[2-[ (2-chloropyrimidin-4-yl)methoxy]phenyl]-2-hydroxy-propanoate 8.568 g ethyl (2i?)-2-acetoxy-3-[2-[(2-chloropyrimidin-4-yl)methoxy]phenyl]propanoate (from Step M) (23 mmol) was dissolved in 100 mL ethanol, then 1.8 mL sodium ethoxide solution (1.0M in ethanol) was added and it was stirred until no further conversion was observed. The reaction mixture was diluted with water and it was extracted with ethyl acetate. The combined organics were dried over Na 2 S04, filtered and concentrated under reduced pressure.
  • Reaction mixture was cooled down to r.t., then 2.17 g l-[2-[2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]ethyl]-4- methyl-piperazine (from Step L, 55 mmol), 560 mg AtaPhos (2.5 mmol) and 250 mL H 2 0 were added, and the mixture was stirred under nitrogen at 70 °C until no further conversion was observed. Then it was diluted with EtOAc and brine. After phase separation the aqueous phase was extracted with EtOAc. The organic layers were combined and dried over Na 2 S0 4 , filtered and concentrated under reduced pressure.
  • Step A l-bromo-2-(2-methoxyethoxymethyl)benzene
  • Step B Preparation 4e To a solution of 1.0 g product from Step A (2.76 mmol, 1 eq.) in 15 mL dry THF 4.24 mL 'PrMgCl x LiCl (5.52 mmol, 1.3M in THF, 2 eq.) was added at 0 °C over 2 minutes. After 10 minutes stirring, 1.40 mL 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (6.9 mmol, 2.5 eq.) was added then it was stirred at 0 °C until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine.
  • Step A 4-[(2-bromophenyl)methoxymethyl] -2,2-dimethyl- 1,3-dioxolane
  • Step A Methyl 2,3,4-tri-O-acetyl-a-O-mannopyranoside
  • Step A 1, 2, 3, 4-tetra-0-acetyl-a ⁇ -O-mannopyranose
  • Step B Preparations 4o and 4p
  • Example 1 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i/] pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(3- hydroxyphenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid
  • Example 1 was obtained.
  • Example 2 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(4- hydroxyphenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid
  • Example 2 was obtained. HPvMS calculated for 860.2559; found 431.1371 (M+2H) 2+
  • Example 3 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2-[3- (hydroxymethyl)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] propanoic acid Starting from Preparation 1 and [3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)phenyl]methanol using General procedure I, Example 3 was obtained. HRMS calculated for C 47 H 44 CIFN 6 O 6 S: 874.2715; found 438.141 (M+2H) 2+
  • Example 4 was obtained. HRMS calculated for C 47 H 44 CIFN 6 O 6 S: 874.2715; found 438.1449 (M+2H) 2+
  • Example 5 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i/] pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 2- [(2,2- dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid
  • Example 7 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy ⁇ -3-(2- ⁇ [2-(2- ⁇ 2- [2-(2-methoxyethoxy)ethoxy]ethoxy ⁇ phenyl)pyrimidin-4-yl]methoxy ⁇ phenyl) propanoic acid Starting from Preparation 1 and Preparation 4c using General procedure I, Example 7 was obtained. HRMS calculated for CssHsgClFNgOgS: 1006.3502; found 504.1828
  • Example 8 Starting from Preparation 1 and [2-(methoxymethyl)phenyl]-4,4,5,5-tetramethyl-l,3,2- dioxaborolane using General procedure I, Example 8 was obtained. HRMS calculated for C 48 H 46 CIFN 6 O 7 S: 888.2872; found 445.1518 (M+2H) 2+
  • Example 9 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 2- [(2- methoxyethoxy)methyl]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid
  • Example 9 was obtained. HRMS calculated for C 5 oH 5 oClFN 6 0 7 S: 932.3134; found 467.164 (M+2H) 2+
  • Example 10 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 2- [(2- hydroxyethoxy)methyl]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid
  • Example 13 was obtained. HRMS calculated for 962.324; found 482.1694 (M+2H) 2+
  • Example 14 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 16 methyl 6-0- ⁇ 3-[4-( ⁇ 2-[(2R)-2-carboxy-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy ⁇ ethyl]phenoxy ⁇ methyl)pyrimidin-2-yl]phenyl ⁇ -a-D- mannopyranoside
  • Example 18 methyl 6-0- ⁇ 4-[4-( ⁇ 2-[(2R)-2-carboxy-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy ⁇ ethyl]phenoxy ⁇ methyl)pyrimidin-2-yl]phenyl ⁇ -a-D- mannopyranoside
  • Example 18 was obtained. HRMS calculated for 1036.3243; found 519.1714
  • Example 19 methyl 6-0- ⁇ 4-[4-( ⁇ 2-[(2R)-2-carboxy-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy ⁇ ethyl]phenoxy ⁇ methyl)pyrimidin-2-yl]phenyl ⁇ -2,3,4-tri-0-methyl- a-D-mannopyranoside
  • Example 21 6-0- ⁇ 2-[4-( ⁇ 2-[(2R)-2-carboxy-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4-[3-(4- methylpiperazin-l-yl)propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy ⁇ ethyl]phenoxy ⁇ methyl)pyrimidin-2-yl]phenyl ⁇ -D-mannonic acid
  • Example 20 was obtained as the earlier eluting compound.
  • HRMS calculated for C 52 H 52 CIFN 6 O 1 1 S: 1022.3087; found 512.1611 (M+2H) 2+
  • Example 21 was obtained as the later eluting compound.
  • Example 22 l,2-0-[(lR)-l-( ⁇ 4-[4-( ⁇ 2-[(2R)-2-carboxy-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl- 4-[3-(4-methylpiperazin-l-yl)propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 22 was obtained.
  • Example 24 was obtained. HRMS calculated for C 48 H 46 N 6 0 6 FSC1: 888.2872; found 445.1512 (M+2H) 2+
  • Example 25 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2-[2-(2,3- dihydroxypropoxy)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] propanoic acid
  • Step A Ethyl (2R)-2-hydroxy-3-f2-ff2-f2-(2-methoxyethoxy)phenylJpyrimidin-4-ylJ methoxy] phenyl] propanoate
  • Step B Ethyl (2K)-2-[5-bromo-6-(4-fluorophenyl)thieno[2,3-dJpyrimidin-4-yl]oxy-3-[2- [[2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate
  • Step C Ethyl (2R)-2-[5-bromo-6-(4-fluorophenyl)thieno[2,3-dJpyrimidin-4-ylJoxy-3-[2- [[2-[2-(2-hydroxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate
  • Example 27 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 2- [(2,3- dihydroxypropoxy)methyl] phenyl ⁇ pyrimidin-4-yl)methoxy] phenyl ⁇ propanoic acid Starting from Preparation 1 and Preparation 4f using General Procedure I, after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed.
  • Example 28 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2-[3- (phosphonooxy)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] propanoic acid
  • the reaction mixture was injected directly to a preconditioned (EtOAc/MeOH [containing 1.2 % NH 3 ] - 80/20) 220 g flash silica gel column using EtOAc /MeOH (containing 1.2 % NH 3 ) as eluents with gradient method giving the desired product as a mixture of the diastereoisomers.
  • the diastereoisomers were separated via preparative reversed phase chromatography using 50 mM aqueous NH 4 HC0 3 solution and MeOH as eluents. The diastereoisomer eluting later was collected as Example 28.
  • Step A Ethyl (2JL)-2- [5- [3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] - 6- ( 4-fluorophenyl) thienof 2, 3-dJpyrimidin-4-ylJoxy-3-f 2-f [ 2-f 3-f 2-(p-tolylsulfonyloxy) ethoxy] phenyl] pyrimidin-4-yl]methoxy] phenyl] propanoate
  • Example 32 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 4- [2- (2-hydroxyethoxy)ethoxy]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid Starting from Preparation 3 and 10 eq. of 2-(2-hydroxyethoxy)ethanol using General procedure II, Example 32 was obtained. HRMS calculated for CsoHsoNeOsFSCl: 948.3083; found 475.1613 (M+2H) 2+
  • Example 33 was obtained. HRMS calculated for C 53 H 56 N 6 O 9 FSCI: 1006.3502; found 504.183 (M+2H) 2+
  • Example 34 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 4- [2- (dimethylamino)ethoxy]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid
  • Example 34 Starting from Preparation 3 and 2-(dimethylamino)ethanol using General procedure II, Example 34 was obtained. HRMS calculated for CsoHsiNyOeFSCl: 931.3294; found 466.6709 (M+2H) 2+
  • Example 35 (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2- [(2- ⁇ 3- [(2,2- dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid Starting from Preparation 2 and (2,2-dimethyl-l,3-dioxolan-4-yl)methanol using General procedure II, Example
  • Example 36 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 36 Starting from Preparation 5 and 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol as the appropriate amine using General procedure III, Example 36 was obtained. HRMS calculated for CseHeiClFNyOnS: 1093.3822; found 547.7006 (M+2H) 2+
  • Example 37 (2R)-3-(2- ⁇ [2-(3- ⁇ [(l,4 , -bipiperidin-l , -ylcarbonyl)oxy]methyl ⁇ phenyl) pyrimidin-4-yl]methoxy ⁇ phenyl)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy ⁇ propanoic acid
  • Example 38 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(3- ⁇ 2- [2-(2- hydroxyethoxy)ethoxy] ethoxy ⁇ phenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid Starting from Preparation 2 and 10 eq. of 2-[2-(2-hydroxyethoxy)ethoxy]ethanol using General procedure II, Example 38 was obtained. HRMS calculated for C 52 H 54 CIFN 6 O 9 S: 992.3345; found 497.1748 (M+2H) 2+
  • Example 40 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 41 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 43 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2-[(2- ⁇ 3- [( ⁇ [2- (dimethylamino)ethyl] carbamoyl ⁇ oxy)methyl] phenyl ⁇ pyrimidin-4-yl)methoxy] phenyl ⁇ propanoic acid Starting from Preparation 5 and N',N'-dimethylethane-l,2-diamine as the appropriate amine using General procedure III, Example 43 was obtained. HRMS calculated for 988.3509; found 989.3586 (M+H) +
  • Example 44 Starting from Preparation 5 and 2-pyrrolidin-l-ylethanamine as the appropriate amine using General procedure III, Example 44 was obtained. HRMS calculated for C 54 H 56 C1FN80 7 S: 1014.3665; found 508.1916 (M+2H) 2+
  • Example 45 (2R)-3-[2-( ⁇ 2-[3-( ⁇ [bis(2-methoxyethyl)carbamoyl]oxy ⁇ methyl)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl]-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy ⁇ propanoic acid Starting from Preparation 5 and 2-methoxy-N-(2-methoxyethyl)ethanamine as the appropriate amine using General
  • Example 48 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(3- ⁇ 2- [2-(2- methoxyethoxy)ethoxy]ethoxy ⁇ phenyl)pyrimidin-4-yl]methoxy ⁇ phenyl)propanoic acid Starting from Preparation 2 and 2-[2-(2-methoxyethoxy)ethoxy]ethanol using General procedure II, Example 48 was obtained. HRMS calculated for C 53 H 56 N 6 O 9 FSCI: 1006.3502; found 504.1829 (M+2H) 2+
  • Example 49 was obtained. HRMS calculated for C 52 H 55 N 7 O 8 FSCI: 991.3505; found 496.6833 (M+2H) 2+
  • Example 50 (2R)-2- ⁇ [(5S fl )-5- ⁇ 2,3-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] oxy ⁇ -3- ⁇ 2-[(2- ⁇ 3- [( ⁇ [2- (piperidin-l-yl)ethyl]carbamoyl ⁇ oxy)methyl]phenyl ⁇ pyrimidin-4-yl)methoxy]phenyl ⁇ propanoic acid
  • Example 51 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 52 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 53 Starting from Preparation 3 and 2-[bis(2-hydroxyethyl)amino]ethanol using General procedure II, Example 53 was obtained. HRMS calculated for C 52 H 55 N 7 O 8 FSCI: 991.3505; found 496.6822 (M+2H) 2+
  • Example 54 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(4- ⁇ 2- [2-(2- hydroxyethoxy)ethoxy] ethoxy ⁇ phenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid
  • Example 55 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 57 4- [4-( ⁇ 2- [(2R)-2-carboxy-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [3-(4-methyl piperazin-l-yl)propoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy ⁇ ethyl]phenoxy ⁇ methyl)pyrimidin-2-yl]phenyl phosphate disodium salt
  • TEA 1.5 mmol, 3 eq.
  • POCl 3 1.5 mmol, 3 eq.
  • Example 62 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 63 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 64 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(2- ⁇ 2- [2-(2- hydroxyethoxy)ethoxy] ethoxy ⁇ phenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid
  • Example 65 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 66 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(3- ⁇ [(phosphono oxy)methoxy] methyl ⁇ phenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid
  • Example 67 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy ⁇ -3-(2- ⁇ [2-(3- ⁇ [(phosphono oxy)carbonyl] oxy ⁇ phenyl)pyrimidin-4-yl] methoxy ⁇ phenyl)propanoic acid
  • Example 68 (2R)-2- ⁇ [(5S «)-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 69 l-[(ethoxycarbonyl)oxy] ethyl (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4-[2- (4-methylpiperazin-l-yl)ethoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy ⁇ -3- ⁇ 2-[(2- ⁇ 3-[(l,3-dimethoxypropan-2-yl)oxy]phenyl ⁇ pyrimidin-4-yl)methoxy] phenyl ⁇ propanoate
  • Step A ethyl l-chloroethyl carbonate
  • Example 13 1 eq. of Example 13 was dissolved in DMF (20 ml/mmol) under nitrogen. 6.7 eq. CS 2 CO 3 and 8 eq. of ethyl l-chloroethyl carbonate from Step A was added. The reaction mixture was stirred at room temperature until no further conversion was observed. The mixture was diluted with brine and it was extracted with DCM, dried with Na 2 S0 4 , filtered and concentrated under reduced pressure. The crude product was purified via preparative reverse phase chromatography using 5 mM aqueous NH 4 HCO 3 solution and acetonitrile as eluents to obtain Example 69. HRMS calculated for CseHgoClFNeOnS: 1078.3713; found 1079.3796 and 1079.3786 (M+H)
  • Example 70 l-[(dimethylcarbamoyl)oxy] ethyl (2R)-2- ⁇ [(5S « )-5- ⁇ 3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy]phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 71 (2R)-2- ⁇ [5- ⁇ 2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl ⁇ -6- (4-fluorophenyl)thieno [2,3- ⁇ pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2- [3-(hydroxymethyl)phenyl]
  • Example 72 (2R)-2- ⁇ [5- ⁇ 3,5-dichloro-2,6-dimethyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2- [3- (hydroxymethyl)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] propanoic acid
  • Example 73 (2R)-2- ⁇ [5- ⁇ 2,6-dimethyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl ⁇ -6- (4-fluorophenyl)thieno [2,3- ⁇ pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2- [4-(phosphonooxy)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] propanoic acid
  • Example 74 (2R)-2- ⁇ [5- ⁇ 3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl) ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy ⁇ -3- [2-( ⁇ 2- [4- (phosphonooxy)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] propanoic acid
  • Example 75 2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 76 2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 77 2-0-[(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno [2,3-d ⁇ pyrimidin-4-yl] -3,4-dideoxy-3- [2-( ⁇ 2-[3- (hydroxymethyl)phenyl] pyrimidin-4-yl ⁇ methoxy)phenyl] pentonic acid
  • Example 78 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 79 (2R)-2- ⁇ [(5S «)-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 80 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 81 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • Example 82 (2R)-2- ⁇ [(5S fl )-5- ⁇ 3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl ⁇ -6-(4-fluorophenyl)thieno[2,3-i
  • the relative binding potency of each compound was determined via Fluorescence Polarisation (FP).
  • FP Fluorescence Polarisation
  • the method utilised a Fluorescein labelled ligand (Fluorescein- pAla- Ahx-A-REIGAQLRRMADDLNAQY-OH; mw 2,765) which binds to the Mcl-l protein (such that Mcl-l corresponds to the UniProtKB ® primary accession number: Q07820) leading to an increased anisotropy measured in milli-polarisation (mP) units using a reader.
  • mP milli-polarisation
  • the cytotoxicity studies were carried out on the H929 multiple myeloma tumour line.
  • the cells are distributed onto microplates and exposed to the test compounds for 48 hours.
  • the cell viability is then quantified by a colorimetric assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942).
  • IC 50 the concentration of compound that inhibits cell viability by 50%
  • Example 9 8.15E-09 1.40E-09
  • Example 27 2.2E-09 1.39E-08
  • Example 11 4.05E-09 1.99E-09
  • Example 29 4.6E-09 2.27E-08
  • Example 12 4.25E-09 3.82E-09
  • Example 30 4.5E-09 3.60E-09
  • Example 16 7.2E-09 3.71E-08
  • Example 34 7.1E-09 4.76E-09
  • Example 37 6.3E-09 2.05E-08
  • Example 60 ND ND
  • Example 38 2.8E-09 2.76E-09
  • Example 61 ND ND
  • Example 39 3.05E-09 3.25E-09
  • Example 62 ND ND
  • Example 40 3.75E-09 6.15E-09
  • Example 63 ND ND
  • Example 41 3.45E-09 9.08E-08
  • Example 64 ND ND
  • Example 42 4.45E-09 4.45E-08
  • Example 65 ND ND
  • Example 43 4.55E-09 3.11E-08
  • Example 66 ND ND
  • Example 45 3.2E-09 4.58E-09
  • Example 68 ND ND
  • Example 47 4.05E-09 1.82E-08
  • Example 70 ND ND
  • Example 48 3.85E-09 ND
  • Example 71 ND ND
  • Example 50 6.6E-09 ND
  • Example 73 ND ND
  • Example 51 4.15E-09 ND
  • Example 74 ND ND
  • Example 52 3.7E-09 ND
  • Example 75 ND ND
  • Example 53 4.65E-9 ND
  • Example 76 ND ND
  • Example 55 6.35E-09 ND
  • Example 78 ND ND
  • Example 56 4.75E-09 ND
  • Example 79 7.6E-09 ND
  • Example 57 4.6E-09 2.27E-08
  • Example 80 ND ND
  • the ability of the compounds of the invention to induce apoptosis, by measuring cleaved PARP levels, is evaluated in a xenograft model of AMO-1 multiple myeloma cells.
  • AMO-1 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain). 12 to 14 days after the graft, the animals are treated by intraveinous or oral routes with the various compounds. After treatment, the tumour masses are recovered and lysed, and the cleaved form of PARP is quantified in the tumour lysates.
  • the quantification is carried out using the "Meso Scale Discovery (MSD) ELISA platform” test, which specifically assays the cleaved form of PARP. It is expressed in the form of an activation factor corresponding to the ratio between the quantity of cleaved PARP in the treated mice divided by the quantity of cleaved PARP in the control mice.
  • MSD Meso Scale Discovery
  • the anti-tumour activity of the compounds of the invention is evaluated in a xenograft model of AMO-1 multiple myeloma cells.
  • lxlO 7 AMO-1 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain).
  • mice are treated with the various compounds in a daily schedule (5 -day treatment).
  • the tumour mass is measured twice weekly from the start of treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R14, A and n are as defined in the description. Medicaments.

Description

NEW HYDROXYACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
The present invention relates to new hydroxyacid derivatives, to a process for their preparation and to pharmaceutical compositions containing them.
The compounds of the present invention are new and have very valuable pharmacological characteristics in the field of apoptosis and cancerology. Apoptosis, or programmed cell death, is a physiological process that is crucial for embryonic development and maintenance of tissue homeostasis.
Apoptotic-type cell death involves morphological changes such as condensation of the nucleus, DNA fragmentation and also biochemical phenomena such as the activation of caspases which cause damage to key structural components of the cell, so inducing its disassembly and death. Regulation of the process of apoptosis is complex and involves the activation or repression of several intracellular signalling pathways (Cory S. et al., Nature Review Cancer 2002, 2, 647-656).
Deregulation of apoptosis is involved in certain pathologies. Increased apoptosis is associated with neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease and ischaemia. Conversely, deficits in the implementation of apoptosis play a significant role in the development of cancers and their chemoresistance, in auto-immune diseases, inflammatory diseases and viral infections. Accordingly, absence of apoptosis is one of the phenotypic signatures of cancer (Hanahan D. et al., Cell 2000, 100, 57-70).
The anti-apoptotic proteins of the Bcl-2 family are associated with numerous pathologies. The involvement of proteins of the Bcl-2 family is described in numerous types of cancer, such as colon cancer, breast cancer, small-cell lung cancer, non-small-cell lung cancer, bladder cancer, ovarian cancer, prostate cancer, chronic lymphoid leukaemia, lymphoma, myeloma, acute myeloid leukemia, pancreatic cancer, etc. Overexpression of the anti- apoptotic proteins of the Bcl-2 family is involved in tumorigenesis, in resistance to chemotherapy and in the clinical prognosis of patients affected by cancer. Notably, Mcl-1 , an anti-apoptotic Bcl-2 family member, is overexpressed in various types of cancer (Beroukhim R. et al., Nature 2010, 899-905). There is, therefore, a therapeutic need for compounds that inhibit the anti-apoptotic activity of the proteins of the Bcl-2 family.
In addition to being new, the compounds of the present invention have pro-apoptotic properties making it possible to use them in pathologies involving a defect in apoptosis, such as, for example, in the treatment of cancer and of immune and auto-immune diseases.
The present invention relates more especially to compounds of formula (I):
Figure imgf000003_0001
in which 1 is linked to the oxygen atom and 2 is linked to the phenyl ring,
♦ Ri represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (Ci-Ce)alkoxy group, a -S-(Ci-Ce)alkyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a hydroxy(Ci-Ce)alkyl group, a cyano group, -NR12R12', -Cy5, or a halogen atom,
♦ R2, R3, R4 and R5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a hydroxy(Ci-C6)alkyl group, a linear or branched (Ci-C6)alkoxy group, a -S-(Ci-Ce)alkyl group, a cyano group, a nitro group, -alkyl(C0-C6)-NRioRio', -0-alkyl(Ci-C6)-NRi0Rio',
-0-alkyl(Ci-C6)-Rn, -C(O)-ORi0, -O-C(O)-Ri0, -C(0)-NRi0Rio', -NRi0-C(O)-Ri0', -NRio-C(0)-ORio', -alkyl(Ci-C6)-NRio-C(0)-Rio',
Figure imgf000004_0001
-S02-alkyl(Ci-C6),
or the substituents of one of the pairs (R2, R3), (R3, R4), (R4, R5), when grafted onto two adjacent carbon atoms, form together with the carbon atoms carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that resulting ring may be substituted by a group selected from a linear or branched (Ci-C6)alkyl group, -NRi2Ri2', -alkyl(Co-Ce)-Cyi, or an oxo, 5 represents -0-alkyl(Ci-C6)-Rn,
R7 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-Ce)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a linear or branched (Ci-C6)alkoxy group, a -S-(Ci-Ce)alkyl group, a cyano group, a nitro group, -alkyl(C0-C6)-NRioRio', -0-alkyl(Ci-C6)-NRi0Rio', -O-Cyi, -alkyl(C0-C6)-Cyi, -alkenyl(C2-C6)-Cyi, -alkynyl(C2-C6)-Cyi, -0-alkyl(Ci-C6)-Rn, -C(0)-ORio, -0-C(0)-Rio,
Figure imgf000004_0002
-NRi0-C(O)-Ri0', -NRi0-C(O)-ORi0', -alkyl(C1-C6)-NR1o-C(0)-R1o', -S02-NR10Rio', -S02-alkyl(C1-C6),
Rs represents a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C6) group, or a heteroarylalkyl(Ci-Ce) group,
R9 represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, -alkyl(Ci-C6)-Cy3, -alkenyl(C2-C6)-Cy3, -alkynyl(C2-C6)-Cy3, -Cy3-Cy4, -alkynyl(C2-Ce)-0-Cy3, -Cy3-alkyl(Co-C6)-0-alkyl(Co-C6)-Cy4, a halogen atom, a cyano group, -C(0)-Ri3, or -C(0)-NRi3Ri3',
Rio and Rio' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, -alkyl(Co-Ce)-Cyi,
or the substituents of the pair (Rio, Rio') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group, and it being understood that one or more of the carbon atoms of the possible substituents, may be deuterated,
♦ Rii represents -Cy5-alkyl(Co-C6)-0-alkyl(Co-C6)-Cy6, -Cy5-alkyl(C0-C6)-Cy6, -Cy5-alkyl(Co-C6)-NR12-alkyl(Co-C6)-Cy6,
♦ Ri2, Ri2', Ri3 and Ri3' independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-Ce)alkyl group,
♦ Ri4 represents a hydrogen atom, a hydroxy group, or a hydroxy(Ci-C6)alkyl group,
♦ Ra represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,
♦ Rb represents a -0-C(0)-0-Rc group, a -0-C(0)-NRcRc' group, or a -0-P(0)(ORc)2 group,
♦ Rc and Rc' independently of one another represent a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a cycloalkyl group, a (Ci-C6)alkoxy(Ci-C6)alkyl group, a (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl group,
or the substituents of the pair (Rc, Rc') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a linear or branched (Ci-Ce)alkyl group,
♦ Cyi, Cy2, Cy3, Cy4 and Cy5 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group,
♦ Cy6 represents
Figure imgf000005_0001
or Cy6 represents a heteroaryl group which is substituted by a group selected from -O-P(O)(OR20)2; -0-P(0)(0 )2; -(CH2)p-O-(CHR18-CHR19-O)q-R20; hydroxy; hydroxy(Ci-C6)alkyl; -(CH2)r-Y-(CH2)s-heterocycloalkyl; or -Y-(CH2)q-NR2iR2i ',
♦ Ri5 represents a hydrogen atom; a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a linear or branched (Ci-C6)alkoxy(Ci-C6)alkyl group; a -Y-(CH2)q-NR2iR2i ' group; or a -(CH2)r-Y-(CH2)s-heterocycloalkyl group,
♦ Ri6 represents a hydrogen atom; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a (CH2)r-Y-X-O-P(O)(OR20)2 group; a -0-P(0)(0")2 group; a -(CH2)p-O-(CHR18-CHR19-O)q-R20 group; a -(CH2)p-0-C(0)-NR22R23 group; or a -Y-(CH2)q-NR2iR2i ' group,
♦ Ri7 represents a hydrogen atom; a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a -0-P(0)(OR2o)2 group; a -0-P(0)(0")2 group; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a -Y-(CH2)q-NR2iR2i ' group; or an aldonic acid,
♦ X represents a -(CH2)S- group or a -C(O)- group,
♦ Y represents a bond or an oxygen atom,
♦ Ri8 represents a hydrogen atom or a (Ci-C6)alkoxy(Ci-C6)alkyl group,
♦ Rig represents a hydrogen atom or a hydroxy(Ci-Ce)alkyl group,
♦ R2o represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,
♦ R2i and R21 ' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a hydroxy(Ci-C6)alkyl group,
or the substituents of the pair (R2i, R2i ') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C6)alkyl group,
♦ R22 represents a (Ci-C6)alkoxy(Ci-C6)alkyl group, a -(CH2)P-NR24R24' group, or a -(CH2)p-O-(CHR18-CHR19-O)q-R20 group,
♦ R23 represents a hydrogen atom or a (Ci-C6)alkoxy(Ci-C6)alkyl group,
or the substituents of the pair (R22, R23) form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 18 ring members, which may contain in addition to the nitrogen atom from 1 to 5 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom, a linear or branched (Ci-C6)alkyl group or a heterocycloalkyl group,
♦ R24 and R24' independently of one another represent a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,
or the substituents of the pair (R24, R24') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C6)alkyl group,
♦ n is an integer equal to 0 or 1 ,
♦ p is an integer equal to 0, 1 or 2,
♦ q is an integer equal to 1 , 2, 3 or 4,
♦ r and s are independently an integer equal to 0 or 1, with the proviso that R15, Ri6 and R17 cannot represent together a hydrogen atom and, when Ri represents a methyl group, R15 cannot represent a methoxyethoxy group, it being understood that:
"aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group,
"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
"cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,
"heterocycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 5 groups selected from optionally substituted linear or branched (Ci-Ce)alkyl, optionally substituted linear or branched (C2-C6)alkenyl group, optionally substituted linear or branched (C2-C6)alkynyl group, optionally substituted linear or branched (Ci-Ce)alkoxy, optionally substituted (Ci-Ce)alkyl-S-, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-OR', -0-C(0)-R', -C(0)-NR'R", -NR'R", -(C=NR')-OR", linear or branched (Ci-Ce)polyhaloalkyl, trifluoromethoxy, or halogen, it being understood that R' and R" independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C6)alkyl group, and it being understood that one or more of the carbon atoms of the preceding possible substituents, may be deuterated, their enantiomers, diastereoisomers and atropisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
Among the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoro acetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid etc.
Among the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine etc.
Advantageously, at least one of the groups selected from R2, R3, R4 and R5 does not represent a hydrogen atom.
More especially, compounds of formula (I) to which preference is given are compounds wherein n is an integer equal to 1.
In another embodiment of the invention, an advantageous possibility consists of compounds of formula (I-a):
Figure imgf000009_0001
wherein Rl s R2, R3, R4, R5, R6, R7, Rs, R14 and A are as defined for formula (I).
In the preferred compounds of the invention, Ri represents a linear or branched (Ci-C6)alkyl group or a halogen atom. More preferably, Ri represents a methyl group, an ethyl group, a bromine atom or a chlorine atom.
Atropisomers are stereoisomers arising because of hindered rotation about a single bond, where energy differences due to steric strain or other contributors create a barrier to rotation that is high enough to allow for isolation of individual conformers. For compounds according to the invention, atropisomers are as follows:
Figure imgf000009_0002
Preferred atropisomer is (5Sa).
Advantageously, R14 represents a hydrogen atom, a hydroxy group, a hydroxymethyl group or a hydroxy ethyl group. Preferably, R14 represents a hydrogen atom.
Advantageously, R2 represents a halogen atom, a hydroxy group, a linear or branched (Ci-C6)alkoxy group. More preferably, R2 represents a methoxy group, a hydroxy group, a fluorine atom, a bromine atom or a chlorine atom. Even more preferably, R2 represents a chlorine atom.
R3 advantageously represents a hydrogen atom, a hydroxy group, a linear or branched (Ci-C6)alkoxy group or -0-alkyl(Ci-C6)-NRioRio'. Advantageously, R3 represents -0-alkyl(Ci-C6)-NRioRio'.
In some preferred embodiment of the invention,
Figure imgf000010_0001
wherein Ri, Rio and Rio' are as defined for formula (I). In the preferred compounds of the invention,
Figure imgf000010_0002
wherein Rio and Rio' are as defined for formula (I).
R4 and R5 preferably represent a hydrogen atom. In an advantageous embodiment, the substituents of the pair (Rl s R5) are identical and the substituents of the pair (R2, R4) are identical. In the preferred compounds of the invention, the substituents of the pair (Rl s R5) are identical and represent a (Ci-C6)alkyl group, preferably a methyl group, whereas the substituents of the pair (R2, R4) are identical and represent a halogen atom, preferably a chlorine atom, or a hydrogen atom.
In the preferred compounds of the invention,
Figure imgf000011_0001
wherein Rn is as defined for formula (I). R7 preferably represents a hydrogen atom. Preferably, Rs represents a hydrogen atom, a -CHRaRb group, an optionally substituted linear or branched (Ci-Cs)alkyl group, or a heteroarylalkyl(Ci-Ce) group. Preferably, Rs represents a -CHRaRb group in which Ra represents a hydrogen atom or a methyl group and Rb represents a -0-C(0)-0-(Ci-Cs)alkyl group; a -0-C(0)-0-cycloalkyl group; a -0-C(0)-NRcRc' group, in which Rc and Rc' independently of one another represent a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a (Ci-C6)alkoxy(Ci-C6)alkyl group, a (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl group, or the substituents of the pair (Rc, Rc') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen; or a -0-P(0)(OH)2 group. Preferred Rs groups are as follows: hydrogen; methyl; ethyl; (5-methyl-2-oxo-l ,3-dioxol-4-yl)methyl; a -CHRaRb group in which Ra represents a methyl group and Rb represents a -0-C(0)-0-CH2CH3 group or a -0-C(0)-N(CH3)2 group. Even more preferably, Rs represents hydrogen.
In the preferred compounds of the invention, R9 represents a linear or branched (Ci-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, an aryl group or a heteroaryl group. Advantageously, R9 represents a linear or branched (C2-C6)alkynyl group, an aryl group or a heteroaryl group. More preferably, R9 represents a prop-l-yn-l-yl group, a but-l-yn-l-yl group, a phenyl group or a furan-2-yl group. In a more preferred embodiment, R9 represents a 4-(benzyloxy)phenyl group, a 4-(pyridin-4-ylmethoxy)phenyl group, a 4-phenylbut-l-yn-l-yl group, a 4-fluorophenyl group or a 5-fluorofuran-2-yl group. Even more preferentially, R9 represents a 4-fluorophenyl group.
In the preferred compounds of the invention, Rio and Rio' independently of one another represent a linear or branched (Ci-C6)alkyl group, or the substituents of the pair (R10, Rio') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C6)alkyl group. More preferably, Rio and Rio' represent a methyl group, or the substituents of the pair (R10, Rio') form together a 4-methyl-piperazinyl group or a 4-ethyl-piperazinyl group. In a more preferred embodiment, the substituents of the pair (Rio, Rio') form together a 4-methyl-piperazinyl group. In another preferred embodiment, Rio and Rio' represent a methyl group. Advantageously, Rn represents -Cy5-alkyl(Co-C6)-Cy6. More particularly, Rn represents -Cy5-Cy6.
Cy5 preferably represents a heteroaryl group, particularly, a pyrimidinyl group, a pyrazolyl group, a triazolyl group, a pyrazinyl group or a pyridinyl group. More preferably, Cy5 represents a pyrimidin-4-yl group, a pyrazol-5-yl group, a triazol-5-yl group, a pyrazin-2-yl group or a pyridin-4-yl group. In the preferred compounds of the invention, Cy5 represents a pyrimidin-4-yl group.
In another embodiment of the invention, Cy5 represents a heteroaryl group which is substituted by an optionally substituted linear or branched (Ci-C6)alkyl group, an optionally substituted linear or branched (Ci-C6)alkoxy group, a -NR'R" group, or a linear or branched (Ci-Ce)polyhaloalkyl group, it being understood that R' and R" independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C6)alkyl group.
Preferably, Cy6 represents
Figure imgf000013_0001
Cy6 advantageously represents a 3-pyridinyl group, a 4-pyridinyl group, a pyridazin-4-yl group, a pyrazin-2-yl group, or a pyrimidin-4-yl group, it being understood that these heteroaryl groups are substituted by a group selected from -0-P(0)(OR2o)2;
-0-P(0)(0 )2; -(CH2)p-O-(CHR18-CHR19-O)q-R20; hydroxy(Ci-C6)alkyl;
-(CH2)r-Y-(CH2)s-heterocycloalkyl; or -Y-(CH2)q-NR2iR2i '. More preferably, Cy6 represents a 5-(hydroxymethyl)pyridin-3-yl group or a 2-(hydroxymethyl)pyrimidin-4- yl group.
Advantageously, Ri6 and Rn represent a hydrogen atom and R15 represents a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a linear or branched (Ci-C6)alkoxy(Ci-C6)alkyl group; a -Y-(CH2)q-NR2iR2i ' group; or a -(CH2)r-Y-(CH2)s-heterocycloalkyl group, in which Ri8, Ri , R2o, R2i, R2i ', Y, p, q, r and s are as defined for formula (I).
In the preferred compounds of the invention, R15 and R17 represent a hydrogen atom and Ri6 represents a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a -O-P(O)(OR20)2 group; a -0-P(0)(0")2 group; a -(CH2)P-0-(CHR18-CHR19-O)q-R2o group; a -(CH2)p-0-C(0)-NR22R23 group; a (CH2)r-Y-X-O-P(O)(OR20)2 group; or a -Y-(CH2)q-NR2iR2i ' group, in which R18, R19, R20, R2i, R2i ', R22, R23, X, Y, p, q, r and s are as defined for formula (I).
In some preferred embodiment of the invention, R15 and Ri6 represent a hydrogen atom and Rn represents a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a -O-P(O)(OR20)2 group; a -0-P(0)(0")2 group; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a -Y-(CH2)q-NR2iR2i ' group; or an aldonic acid, in which Ri8, R19, R2o, R2i, R2i ', Y, p, q, r and s are as defined for formula (I).
In a preferred embodiment of the invention, "heterocycloalkyl" as defined for R15, Ri6 and Ri7 represents any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by from 1 to 5 groups selected from linear or branched (Ci-Ce)alkyl, linear or branched (Ci-C6)alkoxy, hydroxy, or hydroxy(Ci-C6)alkyl.
Advantageously, R15 represents a -(CH2)p-0-CH2-CH(CH2OH)-OH group; a -(CH2)p-0-(CH2-CH2-0)q-H group; a -(CH2)p-0-(CH2-CH2-0)q-CH3 group; a methoxymethyl group; a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy group; a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxymethyl group; or a -Y-(CH2)q-N(CH2-CH2-OH)2 group, in which Y, p and q are as defined for formula (I).
In the preferred compounds of the invention, Ri6 represents a hydroxy group; a hydroxymethyl group; a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy group; a -0-P(0)(OH)2 group; a -(CH2)p-0-CH2-CH(CH2OH)-OH group; a -(CH2)p-0-(CH2-CH2-0)q-H group; a -(CH2)p-0-(CH2-CH2-0)q-CH3 group, in which p and q are as defined for formula (I); a -0-CH(CH2-OCH3)2 group; a -CH2-0-C(0)-NR22R23 group, in which R22 is as defined for formula (I) and R23 represents a hydrogen atom, or in which R22 and R23 represent a (Ci-C6)alkoxy(Ci-C6)alkyl group, or in which the substituents of the pair (R22, R23) form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 18 ring members, which may contain in addition to the nitrogen atom from 1 to 5 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a linear or branched (Ci-Ce)alkyl group or a heterocycloalkyl; a -0-(CH2)2-NR2iR2i ' group; a -CH2-NR2iR2i ' group, in which R2i and R21 ' are as defined for formula (I); a (CH2)r-0-X-0-P(0)(OR2o)2 group, in which X and r are as defined for formula (I), and s is integer equal to 1; or a -(CH2)r-Y- (CH2)s-heterocycloalkyl group, in which Y is a bond, r and s are integers equal to 0 and the heterocycloalkyl group represents an aldohexose of formula:
Figure imgf000015_0001
in which each R2o is independent. More preferably, the heterocycloalkyl group represents an aldohexose of formula:
Figure imgf000015_0002
in which each R2o is independent.
In some preferred embodiment of the invention, Rn represents a hydroxy group; a hydroxymethyl group; a hydroxyethyl group; a -0-(CH2-CH2-0)q-CH3 group; a -0-CH2-CH(CH2OH)-OH group; a -(CH2)p-0-(CH2-CH2-0)q-H group; a -0-P(0)(OH)2 group; a -0-P(0)(0")2 group; a -0-CH(CH2-OCH3)2 group; a -0-(CH2)2-NR2iR2i ' group; a -CH2-NR2iR2i ' group, in which R2i and R21 ' are as defined for formula (I); a (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy group; D-mannonic acid; or a -(CH2)r-Y-(CH2)s-heterocycloalkyl group in which Y is a bond, s is an integer equal to 0, r is as defined for formula (I) and the heterocycloalkyl group represents an aldohexose of formula:
Figure imgf000015_0003
in which each R2o is independent. More preferably, the heterocycloalkyl group represents an aldohexose of formula:
Figure imgf000016_0001
in which each R2o is independent.
Among the preferred compounds of the invention there may be mentioned:
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2- (3 -hydroxyphenyl)pyrimidin-4-yl]methoxy } phenyl)propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2- (4-hydroxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [3-(hydroxymethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [4-(hydroxymethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {2-[(2,2-dimethyl-l ,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3- {2-[(2- {2-[2-(2-methoxyethoxy)ethoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2- (2- {2- [2-(2-methoxyethoxy)ethoxy] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid; - (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [2-(methoxymethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2i?)-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl)propoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy} -3- {2-[(2-{2-[(2- methoxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2i?)-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl)propoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {2-[(2- hydroxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; - (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2-{[2- (2-{[(2,2-dimethyl-l,3-dioxolan-4-yl)methoxy]methyl}phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid;
- (2i?)-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl)propoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2-{3-[(2- hydroxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3 - [( 1 ,3 -dimethoxypropan-2-yl)oxy]phenyl} pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4- [( 1 ,3 -dimethoxypropan-2-yl)oxy]phenyl} pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [4-(2,3-dihydroxypropoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- methyl 6-0- {3-[4-( {2-[(2i?)-2-carboxy-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl} -a-D- mannopyranoside; - methyl 6-0- {3-[4-( {2-[(2i?)-2-carboxy-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-2,3,4-tri-0 methyl-a-D-mannopyranoside;
- methyl 6-0-{4-[4-({2-[(2i?)-2-carboxy-2-{[(55* iJ)-5-{3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-a-D- mannopyranoside;
- methyl 6-0- {4-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-2,3,4-tri-0- methyl-a-D-mannopyranoside;
- 6-0- {4-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin- 4-yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl} -D-mannopyranose;
- 6-0- {2-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin- 4-yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl} -D-mannonic acid;
- l,2-0-[(li?)-l-({4-[4-({2-[(2i?)-2-carboxy-2-{[(5¾-5-{3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]benzyl}oxy)ethylidene]- β-D-mannopyranose;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[(a-D-mannopyranosyloxy)methyl]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [4-(2-hydroxyethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [2-(2,3-dihydroxypropoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid; (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3-[2-( {2 [2-(2-hydroxyethoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid; (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2 {2-[(2,3-dihydroxypropoxy)methyl]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
(2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2 [3-(phosphonooxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
4-[4-({2-[(2i?)-2-carboxy-2- {[(5¾)-5- {3-chloro-2-methyl-4-[3-(4-methyl piperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl phosphate;
(2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2 [3-(2-hydroxyethoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid; (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2 {4-[2-(2-methoxyethoxy)ethoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
(2R)-2- { [(5Sa)-5 - {3 -chloro-2-methyl-4- [3 -(4-methylpiperazin- 1 -yl)propoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[2-(2- hydroxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2 (4- {2- [2-(2-methoxyethoxy)ethoxy] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid;
(2R)-2- { [(5Sa)-5 - {3 -chloro-2-methyl-4- [3 -(4-methylpiperazin- 1 -yl)propoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[2- (dimethylamino)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2 {3-[(2,2-dimethyl-l ,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy} -3-[2-( {2-[3-(l 5- hydroxy-3-oxo-2,7, 10, 13-tetraoxa-4-azapentadec- 1 -yl)phenyl]pyrimidin-4- yl}methoxy)phenyl]propanoic acid;
- (2i?)-3-(2- {[2-(3- {[(1 ,4'-bipiperidin- -ylcarbonyl)oxy]methyl}phenyl)
pyrimidin-4-yl]methoxy}phenyl)-2- {[(55'iJ)-5- {3-chloro-2-methyl-4-[2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2- {[2-(3- {2-[2-(2- hydroxyethoxy)ethoxy]ethoxy}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2-(2- hydroxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2-(2- methoxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2-(4- methylpiperazin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]
phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2- (morpholin-4-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2- (dimethylamino)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid; (2i?)-2-{[(55'ii)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-
(pyrrolidin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)meth^ phenyl}propanoic acid;
(2R)-3 - [2-( {2-[3 -( { [bis(2-methoxyethyl)carbamoyl]oxy} methyl)phenyl] pyrimidin-4-yl}methoxy)phenyl]-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}propanoic acid;
(2i?)-2-{[(55'ii)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2-{[2-(3- {[(1,4,7,10, 13-pentaoxa- 16-azacyclooctadecan- 16- ylcarbonyl)oxy]methyl}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid; (2R)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} - 6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-[2-({2-[3-(2,3- dihydroxypropoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
(2i?)-2-{[(55'ii)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2-{[2-(3-{2-[2-(2- methoxyethoxy)ethoxy] ethoxy} phenyl)pyrim ^
acid;
(2R)-3 -(2- { [2-(3 - {2-[bis(2-hydroxyethyl)amino] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)-2-{[(55'a)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}propanoic acid;
(2R)-2- {[(5Sa)-5- {2,3-dimethyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4- fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[( {[2-(piperidin- 1 - yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
(2i?)-2-{[(55'ii)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy} -3- {2-[(2-{3-[2- (morpholin-4-yl)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2- (dimethylamino)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2R)-3 -(2- { [2-(4- {2-[bis(2-hydroxyethyl)amino] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)-2- {[(55'iJ)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2- {[2-(4- {2-[2-(2- hydroxyethoxy)ethoxy]ethoxy}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[(2,2- dimethyl-l ,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl} propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[2- (morpholin-4-yl)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; 4-[4-({2-[(2i?)-2-carboxy-2- {[(5¾)-5- {3-chloro-2-methyl-4-[3-(4-methyl piperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl phosphate disodium salt; l-[(ethoxycarbonyl)oxy]ethyl (2R)-2- {[(55e)-5- {3-chloro-2-methyl-4-[2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy} -3- {2-[(2- {3-[(l ,3-dimethoxypropan-2-yl)oxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoate;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2-[5-(hydroxy methyl)pyridin-3-yl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2'-(hydroxy methyl)-2,5'-bipyrimidin-4-yl]methoxy}phenyl)propanoic acid. The invention relates also to a process for the preparation of compounds of formula (I), which process is characterised in that there is used as starting material the compound of formula (II):
Figure imgf000023_0001
wherein A is as defined for formula (I) in which 1 is linked to the chlorine atom and 2 is linked to the bromine atom, which compound of formula (II) is subjected to coupling with a compound of formula (III):
Figure imgf000023_0002
wherein R^, R7, Ri4 and n are as defined for formula (I), and Alk represents a linear or branched (Ci-Ce)alkyl group, to yield the compound of formula (IV):
Figure imgf000023_0003
wherein R6, R7, Ri4, A and n are as defined for formula (I) and Alk is as defined before, compound of formula (IV) which is further subjected to coupling with compound of formula (V):
Figure imgf000024_0001
wherein RL S R2, R3, R4 and R5 are as defined for formula (I), and RBI and RB2 represent a hydrogen atom, a linear or branched (Ci-C6) alkyl group, or RBi and RB2 form with the oxygen carrying them an optionally methylated ring, to yield the compound of formula (VI):
Figure imgf000024_0002
wherein Rl s R2, R3, R4, R5, 5, R7, R14, A and n are as defined for formula (I) and Alk is as defined before, the Alk-O-C(O)- ester function of which compound of formula (VI) is hydro lysed to yield the carboxylic acid, which may optionally be reacted with an alcohol of formula Rs'-OH or a chlorinated compound of formula Rs'-Cl wherein Rs ' represents a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C6) group, or a heteroarylalkyl(Ci-Ce) group, Ra and Rb are as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,
it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino. ..) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.
The compounds of formulae (II), (III), (V), Rs'-OH and Rs'-Cl are either commercially available or can be obtained by the person skilled in the art using conventional chemical reactions described in the literature. Pharmacological study of the compounds of the invention has shown that they have pro- apoptotic properties. The ability to reactivate the apoptotic process in cancerous cells is of major therapeutic interest in the treatment of cancers and of immune and auto-immune diseases.
More especially, the compounds according to the invention will be useful in the treatment of chemo- or radio -resistant cancers.
Among the cancer treatments envisaged there may be mentioned, without implying any limitation, treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
The present invention relates also to pharmaceutical compositions comprising at least one compound of formula (I) in combination with one or more pharmaceutically acceptable excipients. Among the pharmaceutical compositions according to the invention there may be mentioned more especially those that are suitable for oral, parenteral, nasal, per- or trans-cutaneous, rectal, perlingual, ocular or respiratory administration, especially tablets or dragees, sublingual tablets, sachets, paquets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and drinkable or injectable ampoules.
The dosage varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication, or of any associated treatments, and ranges from 0.01 mg to 1 g per 24 hours in one or more administrations.
Furthermore, the present invention relates also to the combination of a compound of formula (I) with an anticancer agent selected from genotoxic agents, mitotic poisons, antimetabolites, proteasome inhibitors, kinase inhibitors and antibodies, and also to pharmaceutical compositions comprising that type of combination and their use in the manufacture of medicaments for use in the treatment of cancer.
Advantageously, the present invention relates to the combination of a compound of formula (I) with an EGFR inhibitor, and also to pharmaceutical compositions comprising that type of combination.
In another embodiment, the present invention relates to the combination of a compound of formula (I) with a mTOR/PBK inhibitor, and also to pharmaceutical compositions comprising that type of combination.
In a preferred embodiment, the present invention relates to the combination of a compound of formula (I) with a MEK inhibitor, and also to pharmaceutical compositions comprising that type of combination.
Preferably, the present invention relates to the combination of a compound of formula (I) with a HER2 inhibitor, and also to pharmaceutical compositions comprising that type of combination.
Advantageously, the present invention relates to the combination of a compound of formula (I) with a RAF inhibitor, and also to pharmaceutical compositions comprising that type of combination.
In another embodiment, the present invention relates to the combination of a compound of formula (I) with a EGFR/HER2 inhibitor, and also to pharmaceutical compositions comprising that type of combination. In a preferred embodiment, the present invention relates to the combination of a compound of formula (I) with a taxane, and also to pharmaceutical compositions comprising that type of combination.
In another embodiment, the present invention relates to the combination of a compound of formula (I) with a proteasome inhibitor, an immunomodulator or an alkylating agent, and also to pharmaceutical compositions comprising that type of combination.
The combination of a compound of formula (I) with an anticancer agent may be administered simultaneously or sequentially. The administration route is preferably the oral route, and the corresponding pharmaceutical compositions may allow the instantaneous or delayed release of the active ingredients. The compounds of the combination may moreover be administered in the form of two separate pharmaceutical compositions, each containing one of the active ingredients, or in the form of a single pharmaceutical composition, in which the active ingredients are in admixture.
The compounds of the invention may also be used in combination with radiotherapy in the treatment of cancer.
Finally, the compounds of the invention may be linked to monoclonal antibodies or fragments thereof or linked to scaffold proteins that can be related or not to monoclonal antibodies.
Antibody fragments must be understood as fragments of Fv, scFv, Fab, F(ab')2, F(ab'), scFv-Fc type or diabodies, which generally have the same specificity of binding as the antibody from which they are descended. According to the present invention, antibody fragments of the invention can be obtained starting from antibodies by methods such as digestion by enzymes, such as pepsin or papain, and/or by cleavage of the disulfide bridges by chemical reduction. In another manner, the antibody fragments comprised in the present invention can be obtained by techniques of genetic recombination likewise well known to the person skilled in the art or else by peptide synthesis by means of, for example, automatic peptide synthesizers such as those supplied by the company Applied Biosystems, etc. Scaffold proteins that can be related or not to monoclonal antibodies are understood to mean a protein that contains or not an immunoglobulin fold and that yields a binding capacity similar to a monoclonal antibody. The man skilled in the art knows how to select the protein scaffold. More particularly, it is known that, to be selected, such a scaffold should display several features as follow (Skerra A., J. Mol. Recogn. 2000, 13, 167-187): phylogenetically good conservation, robust architecture with a well-known three- dimensional molecular organization (such as, for example, crystallography or NMR), small size, no or only a low degree of post-translational modifications, easy to produce, express and purify. Such a protein scaffold can be, but without limitation, a structure selected from the group consisting in fibronectin and preferentially the tenth fibronectin type III domain (FNfnlO), lipocalin, anticalin (Skerra A., J. Biotechnol. 2001, 74(4):257-75), the protein Z derivative from the domain B of staphylococcal protein A, thioredoxin A or any protein with a repeated domain such as an "ankyrin repeat" (Kohl et al., PNAS 2003, 100(4), 1700-1705), "armadillo repeat", "leucine-rich repeat" or "tetratricopeptide repeat". There could also be mentioned a scaffold derivative from toxins (such as, for example, scorpion, insect, plant or mollusc toxins) or protein inhibitors of neuronal nitric oxide synthase (PIN).
The following Preparations and Examples illustrate the invention but do not limit it in any way.
General Procedures
All reagents obtained from commercial sources were used without further purification. Anhydrous solvents were obtained from commercial sources and used without further drying.
Flash chromatography was performed on ISCO CombiFlash Rf 200i with pre-packed silica-gel cartridges (RediSe/?®i?f Gold High Performance). Thin layer chromatography was conducted with 5 x 10 cm plates coated with Merck Type 60 F254 silica-gel.
Microwave heating was performed in an Anton Parr MonoWave or CEM Discover® instrument. Preparative HPLC purifications were performed on an Armen Spot Liquid Chromatography system with a Gemini-NX® 10 μΜ CI 8, 250 mm x 50 mm i.d. column running at a flow rate of 118 mL min"1 with UV diode array detection (210 - 400 nm) using 25 mM aqueous NH4HCO3 solution and MeCN as eluents unless specified otherwise. Analytical LC-MS: The compounds of the present invention were characterized by high performance liquid chromatography-mass spectroscopy (HPLC-MS) on Agilent HP 1200 with Agilent 6140 quadrupole LC/MS, operating in positive or negative ion electrospray ionisation mode. Molecular weight scan range is 100 to 1350. Parallel UV detection was done at 210 nm and 254 nm. Samples were supplied as a 1 mM solution in ACN, or in THF/H20 (1 : 1) with 5 loop injection. LCMS analyses were performed on two instruments, one of which was operated with basic, and the other with acidic eluents.
Basic LCMS: Gemini-NX, 3 μιη, CI 8, 50 mm x 3.00 mm i.d. column at 23 °C, at a flow rate of 1 mL min"1 using 5 mM ammonium bicarbonate (Solvent A) and acetonitrile (Solvent B) with a gradient starting from 100 % Solvent A and finishing at 100 % Solvent B over various/certain duration of time.
Acidic LCMS: ZORBAX Eclipse XDB-C18, 1.8 μιη, 50 mm x 4.6 mm i.d. column at 40 °C, at a flow rate of 1 mL min"1 using 0.02 % v/v aqueous formic acid (Solvent A) and 0.02 % v/v formic acid in acetonitrile (Solvent B) with a gradient starting from 100% Solvent A and finishing at 100 % Solvent B over various/certain duration of time. 1H-NMPv measurements were performed on Bruker Avance III 500 MHz spectrometer and Bruker Avance III 400 MHz spectrometer, using DMSO-d6 or CDCI3 as solvent. 1H NMR data is in the form of delta values, given in part per million (ppm), using the residual peak of the solvent (2.50 ppm for DMSO-d6 and 7.26 ppm for CDCI3) as internal standard. Splitting patterns are designated as: s (singlet), d (doublet), t (triplet), q (quartet), quint (quintet), m (multiplet), br s (broad singlet), dd (doublet of doublets), td (triplet of doublets), dt (doublet of triplets), ddd (doublet of doublet of doublets).
Combination gas chromatography and low resolution mass spectrometry were performed on Agilent 6850 gas chromatograph and Agilent 5975C mass spectrometer using 15 m x 0.25 mm column with 0.25 μιη HP-5MS coating and helium as carrier gas. Ion source: EI+, 70 eV, 230 °C, quadrupole: 150 °C, interface: 300 °C.
HRMS were determined on a Shimadzu IT-TOF, ion source temperature 200 °C, ESI +/-, ionization voltage: (+-)4.5 kV. Mass resolution min. 10000.
Elementary analyses were performed on a Thermo Flash EA 11 12 Elemental Analyzer.
List of abbreviations
Abbreviation Name
Ac acetyl
AIBN 2-[(l -cyano- 1 -methyl-ethyl)azo]-2-methyl-propanenitrile AtaPhos bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)
dichloropalladium(II)
DCM methylene chloride
DIPA diisopropylamine
DMF dimethylformamide
DSC N,N'-disuccinimidyl carbonate
eq. equivalent
Et ethyl
HMDS hexamethyldisilazane
'Pr isopropyl
Me methyl
MeCN acetonitrile NBS N-bromosuccinimide
nBu n-butyl
Ph phenyl
PPh3 triphenylphosphine
r.t. room temperature
'Bu tert-butyl
'BuXPhos 2-di(tert-butylphosphino)-2',4',6'-triisopropylbiphi
TEA triethylamine
THF tetrahydrofurane
General procedure I
Step A
1 eq. of Preparation 1, 2 eq. of the appropriate boronic acid derivative, 2 eq. cesium carbonate and 0.1 eq. bis(PPh3)palladium(II) dichloride were placed in a flask. A mixture of 1,4-dioxane and water (4: 1, 10 mL/mmol) was added and the resulting mixture was stirred at 60 °C under argon atmosphere until no further conversion was observed. The reaction mixture was diluted with brine and the pH was set to 6 with 2M aqueous HCl solution, and then extracted with DCM. The volatiles from the separated organic phase were evaporated under reduced pressure and the crude product was purified by flash chromatography using DCM and methanol as eluents. Step B
The obtained intermediate was dissolved in dioxane-water 1 : 1 (10 mL/mmol) and 10 eq. LiOH x H20 was added. The mixture was stirred at r.t. until no further conversion was observed. Then it was diluted with brine, neutralized with 2M aqueous HCl solution, extracted with DCM. The combined organic phases were dried over MgS04, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HC03 solution and MeCN as eluents. The diastereoisomer eluting later was collected. General procedure II
Step A
1 eq. Preparation 2 or 1 eq. Preparation 3, 2 eq. of the appropriate alcohol (unless otherwise stated) and 2 eq. PPh3 were dissolved in dry toluene (0.2M for the phenol). 2 eq. di-tert-butyl azodicarboxylate was added and the mixture was stirred at 60 °C under nitrogen until no further conversion was observed. The volatiles were evaporated under reduced pressure and the crude intermediate was purified via flash chromatography using ethyl acetate and methanol as eluents.
Step B
The obtained intermediate was dissolved in dioxane-water 1 : 1 (10 mL/mmol) and 10 eq. LiOH x H20 was added. The mixture was stirred at r.t. until no further conversion was observed. Then it was diluted with brine, neutralized with 2M aqueous HC1 solution, and extracted with DCM. The combined organic phases were dried over MgSC^, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected.
General procedure III
Step A
To a solution of 1 eq. Preparation 5 in dry acetonitrile (15 mL/mmol) 1.5 eq. DSC and 3 eq. TEA was added and the mixture was stirred for one hour at r.t. To the resulting mixture 2 eq. of the appropriate amine was added and was further stirred for 1 hour at r.t. The reaction mixture was injected directly onto a flash silica column (160 g/mmol, conditioned with EtOAc) and chromatographied using EtOAc and MeOH (containing 1.2 % NH3) as eluents. Step B
The product of Step A was dissolved in dioxane-water (1 : 1, 10 mL/mmol) and 10 eq. LiOH x H20 was added. The mixture was stirred at r.t. until no further conversion was observed. Then it was neutralized with 2M HC1 and directly injected onto an RP18 column and chromatographied using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereomer eluting later was collected.
General Procedure IV Step A
1 eq. of the appropriate phenol derivative, 2 eq. of the appropriate alcohol derivative, and
2 eq. PPh3 were dissolved in dry toluene (0.2M for the phenol) under N2 atmosphere then 2 eq. di-tert-butyl azodicarboxylate was added and the mixture was stirred at 60 °C until no further conversion was observed. The reaction mixture was concentrated under reduced pressure and the residue was purified via flash chromatography using heptane and EtOAc as eluents.
Step B
1 eq. of the phenol derivative obtained in Step A was dissolved in dry THF. The solution was cooled to -78 °C under argon and then 1.2 eq. nBuLi (1.6M in hexane) was added dropwise. After 15 minutes, 1.5 eq. 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane was added dropwise. The cooling bath was removed and the mixture was slowly allowed to warm up to r.t. Then the mixture was quenched with NH4CI solution and extracted with EtOAc. The combined organic layers were concentrated under reduced pressure and the crude product was purified via flash chromatography using heptane and EtOAc as eluents. General procedure V
1 eq. Preparation 1, 3 eq. the appropriate boronic acid derivative, 4.5 eq. cesium carbonate and 0.15 eq. bis(PPh3)palladium(II) dichloride in dioxane (30 mL/mmol) and water (15 mL/mmol) were stirred under N2 atmosphere at 60 °C until no further conversion was observed. The reaction mixture was cooled to r.t., then 20 eq. LiOH x H20 (832 mg/mmol) was added and the mixture was stirred until no further conversion was observed. The reaction mixture was diluted with brine, the pH was adjusted to 6 using 1M HC1, then the mixture was filtered and the precipitate was washed with dioxan. The volatiles of the filtrate were evaporated under reduced pressure and the residue was purified via preparative reversed phase chromatography using 25 mM aqueous NH4HCO3 solution and MeCN as eluents.
Preparation 1: Ethyl (2R)-2- [5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl] -6-(4-fluor ophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy-3- [2- [(2-chloro pyrimidin-4-yl)methoxy] phenyl] propanoate
Step A: 6-Iodo-3H-thienof2, 3-dJpyrimidin-4-one
A 2 L round bottomed flask equipped with mechanical stirrer, thermometer and reflux condenser was charged with the solution of 433 mL acetic acid, 13 mL sulfuric acid and 87 mL water. 69.3 g 3H-thieno[2,3-d]pyrimidin-4-one (0.46 mol), 51.9 g periodic acid (0.23 mol) and 104 g iodine (0.41 mol) were added to the stirred solution heated to 60 °C for 1 hour. The resulting suspension was cooled to r.t., filtered off, washed with a mixture of acetic acid and water (5: 1) and then with diethyl ether. The resulting beige crystalline solid was air dried to give 6-iodo-3H-thieno[2,3-d]pyrimidin-4-one.
1H NMR (500 MHz, DMSO-de) δ 12.57 (br s, 1H), 8.09 (s, 1H), 7.65 (s, 1H)
13C NMR (125 MHz, DMSO-d6) δ 168.3, 155.9, 146.1, 130.8, 126.7, 76.4
Step B: 4-Chloro-6-iodo-thieno[2, 3-dJpyrimidine
A I L round bottomed flask equipped with mechanical stirrer, thermometer, reflux condenser and a CaCl2-tube was charged with 113 mL phosphorous oxychloride and 35 mL N,N-dimethylaniline (0.29 mol). 75.54g 6-iodo-3H-thieno[2,3-d]pyrimidin-4-one (from Step A)(0.27 mol) was added to the mixture in portions during 5 minutes. The reaction mixture was stirred at 105 °C for 1 hour. The resulting suspension was cooled to 10 °C, filtered and washed with hexane. The crude product was added to ice water and stirred for 10 minutes, filtered off, washed with cold water, diethyl ether and air dried to give 4-chloro-6-iodo-thieno[2,3-(i]pyrimidine as a beige crystalline solid.
1H NMR (500 MHz, DMSO-de) δ 8.89 (s, 1H), 7.98 (s, 1H)
13C NMR (125 MHz, DMSO-d6) δ 172.3, 152.9, 151.9, 131.1, 128.9, 86.5
Step C: 5-Bromo-4-chloro-6-iodo-thieno[2, 3-dJpyrimidine A 2 L round bottomed flask equipped with mechanical stirrer, thermometer and a bubbler was charged with 600 mL MeCN. 84.9 g 4-chloro-6-iodo-thieno[2,3-<i]pyrimidine (from Step B) (0.29 mol), 50.9 g NBS (0.29 mol) and 8.5 mL tetrafluoroboric acid diethyl ether complex were added. The reaction mixture was stirred at r.t. for 16 hours. Further 22.9 g (0.12 mol) NBS was added to the mixture in three portions. After cooling the suspension to
0 °C and stirring for further 1 hour the precipitate was filtered off, washed with acetonitrile and air dried to give 5-bromo-4-chloro-6-iodo-thieno[2,3-<i]pyrimidine as beige crystalline solid.
1H NMR (400 MHz, DMSO-de) δ 8.88 (s, 1H)
13C NMR (100 MHz, DMSO-de) δ 171.3, 152.9, 152.3, 126.0, 112.4, 92.9
Step D: 5-Bromo-4-chloro-6-(4-fluorophenyl)thieno[2,3-d]pyrimidine
75.08 g 5-bromo-4-chloro-6-iodo-thieno[2,3-(i]pyrimidine (from Step C) (200 mmol), 53.63 g 2-(4-fluorophenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (240 mmol), 130 g cesium carbonate (400 mmol), 2.245 g Pd(OAc)2 (10 mmol) and 8.50 g 'BuXPhos (20 mmol) were placed in a 2 L flask. 600 mL THF and 200 mL water were added, and then stirred overnight at 70 °C under argon atmosphere. THF was evaporated, and then the product was collected by filtration. Crude product was sonicated in 250 mL MeCN and filtered again. Then 5-bromo-4-chloro-6-(4-fluorophenyl)thieno[2,3-<i]pyrimidine was crystalized from EtOH/THF (2: 1). 1H NMR (400 MHz, DMSO-d6): 9.02 (s, 1H), 7.80-7.77 (m, 2H), 7.47-7.43 (m, 2H)
Step E: [2- (Br omomethyl)phenyl] acetate
60.07 g 2-methylphenyl acetate (400 mmol) and 106.8 g NBS (600 mmol) were placed in a
1 L flask. 500 mL cyclohexane was added, and then with intensive stirring 3.284 g AIBN (20 mmol) was added over 30 minutes. The mixture was stirred at 80 °C until no further conversion was observed, then cooled to r.t. The precipitate was filtered off and washed with cyclohexane. The mother liquor was concentrated under reduced pressure, and the crude product was used in Step B without further purification.
Step F: Ethyl 2-acetoxy-3-(2-hydroxyphenyl)propanoate 23.10 g anhydrous LiCl (545 mmol) and 65.36 g anhydrous ZnCl2 (479.6 mmol) were placed in a 2 L flask, then dried at 160 °C under 0.1 mmHg for 1 hour. After cooling to r.t. under argon atmosphere, 26.49 g magnesium turnings (1090 mmol) and 1 L dry pre-cooled (0 °C) THF were added. The resulting mixture was immersed into an ice-bath, and then stirred for 30 minutes.
100 g [2-(bromomethyl)phenyl] acetate (from Step E) (~ 436 mmol) was dissolved in 120 mL dry THF and was added to the precooled inorganics over 15 minutes. After addition of the reagent the resulting mixture was stirred for 45 minutes while keeping the temperature between 0-5 °C. To the mixture 64.82 mL ethyl 2-oxoacetate (654 mmol, 50 % in toluene) was added over 5 minutes and the resulting mixture was stirred for another 15 minutes.
From the mixture the remaining inorganics were removed by filtration, and then 500 mL MeOH was added to the filtrate. This mixture was stirred until the intramolecular acetyl group migration from the phenolic oxygen to the alkyl oxygen was completed. To the mixture 30 mL acetic acid was added then the volatiles were evaporated under reduced pressure. To the residue 350 mL water was added and it was extracted with EtOAc. The combined organic layers were washed with saturated NaHC03 and with brine, and then dried over MgSC^, filtered and evaporated under reduced pressure. To the residue 100 mL hexane was added and it was stirred for 30 minutes at 0 °C. The formed white crystals were collected by filtration and washed with hexane yielding ethyl 2-acetoxy-3-(2- hydroxyphenyl)-(rac). 1H NMR (500 MHz, DMSO-d6) δ 9.53 (s, 1H), 7.06 (t, 1H), 7.04 (d, 1H), 6.79 (d, 1H), 6.71 (t, 1H), 5.10 (dd, 1H), 4.05 (q, 2H), 3.06 (dd, 1H), 2.94 (dd, 1H), 2.00 (s, 3H), 1.09 (t, 3H)
Step G: Ethyl (2R)-2-acetoxy-3-(2-hydroxyphenyl)propanoate and ethyl (2S)-2-acetoxy-3- (2-hydroxyphenyl)propanoate
Enantiomers of ethyl 2-acetoxy-3-(2-hydroxyphenyl)propanoate (from Step F) were separated via chiral chromatography. Column: OD; Eluents: heptane / EtOH; the enantiomer eluting earlier was collected as ethyl (25)-2-acetoxy-3-(2-hydroxyphenyl) propanoate with 99.8 % ee and the enantiomer eluting later was collected as ethyl (2R)-2- acetoxy-3-(2-hydroxyphenyl)propanoate with 99.9 % ee. Step H: ( 4-Bromo-2-chloro-phenoxy)-trimethyl-silane
20.8 g 4-bromo-2-chloro-phenol (100 mmol) was dissolved in 150 mL dry THF then
24.2 g HMDS (150 mmol) was added. The reaction mixture was stirred at 85 °C under argon atmosphere for 1.5 hours then concentrated under reduced pressure resulting in the product used without further purification. 1H NMR (200 MHz, CDC13): 7.49 (d, 1H), 7.23 (dd, 1H), 6.75 (d, 1H), 0.26 (s, 9H)
Step I: 4-Bromo-2-chloro-3-methyl-phenol
48 mL nBuLi solution in hexanes (2.5M, 120 mmol) was added dropwise to a solution of 12.1 g dry DIPA (120 mmol) in 250 mL dry THF at -78 °C under argon atmosphere. The mixture was stirred for 30 minutes at the same temperature then 28.0 g (4-bromo-2-chloro- phenoxy)-trimethyl-silane (from Step H) (100 mmol) was added dropwise. After 2.5 hours
21.3 g Mel (150 mmol) was added dropwise then the cooling bath was removed and the mixture was stirred overnight. The reaction was quenched with 100 mL NH4OH solution and 200 mL NH4CI solution and extracted with EtOAc, dried over Na2SC"4, filtered and concentrated under reduced pressure. The resulting dark mass was re fluxed with pure hexane several times (150-150 mL aliquots) and decanted leaving a black tar behind. Combined organic phases were concentrated under reduced pressure affording 19.0 g 4-bromo-2-chloro-3-methyl-phenol, the crude product used without further purification. 1H NMR (200 MHz, CDC13): 7.32 (d, 1H), 6.76 (d, 1H), 5.62 (s, 1H), 2.49 (s, 3H) Step J: (4-Bromo-2-chloro-3-methyl-phenoxy)-trimethyl-silane
20.8 g HMDS (129 mmol) was added to the solution of 19.0 g 4-bromo-2-chloro-3-methyl- phenol (from Step I) (86.0 mmol) in 150 mL dry THF. The mixture was stirred at 85 °C under argon balloon for 1.5 hours and then concentrated under reduced pressure. The obtained (4-bromo-2-chloro-3-methyl-phenoxy)-trimethyl-silane was used without further purification. 1H NMR (200 MHz, CDC13): 7.30 (d, 1H), 6.63 (d, 1H), 2.50 (s, 3H), 0.28 (s, 9H)
Step K: 2-Chloro-3-methyl-4-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenol
A solution of 25.2 g (4-bromo-2-chloro-3-methyl-phenoxy)-trimethyl-silane (from Step J)
(86.0 mmol) in 250 mL dry THF was cooled to -78 °C under argon and then 38 mL nBuLi in hexanes (2.5M, 94.6 mmol) was added dropwise. After 5 minutes, 19.2 g 2-isopropoxy- 4,4,5, 5-tetramethyl-l,3,2-dioxaborolane (103 mmol) was added dropwise. The cooling bath was removed and the mixture was slowly allowed to warm up to r.t. Then the mixture was added to 200 mL NH4C1 solution and extracted with EtOAc. Combined organic layers were concentrated under reduced pressure and passed through a pad of silica gel using hexane and EtOAc as eluents. The crude product was recrystallized from a mixture of EtOAc and hexane to obtain 2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl) phenol. 1H NMR (500 MHz, DMSO-d6): 10.40 (s, 1H), 7.42 (d, 1H), 6.80 (d, 1H), 2.49 (s, 3H), 1.27 (s, 12H) Step L: 1-f 2-f 2-Chloro-3-methyl-4-(4, 4, 5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)phenoxyJ ethyl] -4-methyl-piperazine
10.0 g 2-chloro-3-methyl-4-(4,4, 5, 5-tetramethyl-l, 3,2-dioxaborolan-2-yl)phenol (from Step K) (37.2 mmol), 8.7 g 2-(4-methylpiperazin-l-yl)ethanol (60.3 mmol) and 15.8 g PPh3 (60.3 mmol) were dissolved in 100 mL dry toluene and then 27 mL diethyl azodicarboxylate (60.3 mmol, 40 % solution in toluene) was added dropwise. The mixture was stirred at 50 °C under argon for 1.5 hours. The volatiles were evaporated under reduced pressure and 100 mL Et20 was added. The precipitated white crystals were filtered off and washed with Et20. The filtrate was concentrated under reduced pressure and purified via flash chromatography using CHC13 and MeOH as eluents. The resulting light brown oil was crystallized from hexane to give l-[2-[2-chloro-3-methyl-4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]ethyl]-4-methyl-piperazine as an off-white solid. 1H NMR (500 MHz, DMSO-d6): 7.56 (d, 1H), 6.99 (d, 1H), 4.15 (t, 2H), 2.72 (t, 2H), 2.51 (s, 3H), 2.50 (br s, 4H), 2.29 (br s, 4H), 2.13 (s, 3H), 1.29 (s, 12H)
Step M: Ethyl (2R)-2-acetoxy-3-[2-[ (2-chloropyrimidin-4-yl)methoxy] phenyl] propanoate 9.06 g ethyl (2i?)-2-acetoxy-3-(2-hydroxyphenyl)propanoate (from Step G, 36 mmol), 7.12 g 2-chloro-4-(chloromethyl)pyrimidine (44 mmol), 5.97 g K2C03 (44 mmol) and 1.22 g KI (1.22 mmol) were placed in a 250 mL flask. 70 mL DMF was added and the mixture was stirred at r.t. under N2 until no further conversion was observed. Then the reaction mixture was diluted with water and then it was extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to give ethyl (2i?)-2-acetoxy-3-[2-[(2-chloropyrimidin-4-yl)methoxy] phenyl]propanoate. 1H NMR (500 MHz, DMSO-de) δ 8.86 (d, 1H), 7.69 (d, 1H), 7.25 (td, 1H), 7.23 (dd, 1H), 7.03 (d, 1H), 6.95 (td, 1H), 5.30 (d, 1H), 5.25 (d, 1H), 5.16-5.13 (m, 1H), 4.07 (qm, 2H), 3.28 (dd, 1H), 3.09 (dd, 1H), 2.00 (s, 3H), 1.09 (t, 3H)
Step N: Ethyl (2R)-3-[2-[ (2-chloropyrimidin-4-yl)methoxy]phenyl]-2-hydroxy-propanoate 8.568 g ethyl (2i?)-2-acetoxy-3-[2-[(2-chloropyrimidin-4-yl)methoxy]phenyl]propanoate (from Step M) (23 mmol) was dissolved in 100 mL ethanol, then 1.8 mL sodium ethoxide solution (1.0M in ethanol) was added and it was stirred until no further conversion was observed. The reaction mixture was diluted with water and it was extracted with ethyl acetate. The combined organics were dried over Na2S04, filtered and concentrated under reduced pressure. The crude product was purified via flash chromatography using heptane and EtOAc as eluents to give ethyl (2i?)-3-[2-[(2-chloropyrimidin-4-yl)methoxy]phenyl]-2- hydroxy-propanoate. 1H NMR (500 MHz, DMSO-d6) δ 8.84 (d, 1H), 7.70 (d, 1H), 7.20 (m, 1H), 7.19 (dm, 1H), 7.00 (dm, 1H), 6.91 (m, 1H), 5.52 (d, 1H), 5.27 (d, 1H), 5.24 (d, 1H), 4.06 (m, 1H), 4.04 (m, 1H), 3.13 (dd, 1H), 2.84 (dd, 1H), 1.11 (t, 3H)
Step O: Preparation 1
17.18 g 5-bromo-4-chloro-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidine (from Step D, 50 mmol) and 18.52 g ethyl (2i?)-3-[2-[(2-chloropyrimidin-4-yl)methoxy]phenyl]-2- hydroxy-propanoate (from Step N, 55 mmol) were dissolved in 250 mL dry THF, then 48.87 g CS2CO3 (150 mmol) was added and the mixture was stirred at 70 °C under N2 until no further conversion was observed. Reaction mixture was cooled down to r.t., then 2.17 g l-[2-[2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy]ethyl]-4- methyl-piperazine (from Step L, 55 mmol), 560 mg AtaPhos (2.5 mmol) and 250 mL H20 were added, and the mixture was stirred under nitrogen at 70 °C until no further conversion was observed. Then it was diluted with EtOAc and brine. After phase separation the aqueous phase was extracted with EtOAc. The organic layers were combined and dried over Na2S04, filtered and concentrated under reduced pressure. The product was separated via flash chromatography using EtOAc and MeOH (containing 1.2 % N¾) as eluents. Preparation 1 was obtained as a mixture of the atropisomers. 1H NMR (500 MHz, DMSO-d6) δ 8.87(dd, IH), 8.60 (s, IH), 7.69 (dd, IH), 7.35-7.26 (m, 2H), 7.22 (t, 2H), 7.20-7.10 (m, 2H), 7.02-6.91 (m, IH), 6.87 (d, IH), 6.72 (t, IH), 6.15 (d, IH), 5.47 (dd, IH), 5.22 (s, 2H), 4.29-4.1 1 (m, 2H), 4.10-4.00 (m, 2H), 3.15-2.15 (br s, 8H), 3.13 (dd, 2H), 2.73-2.65 (m, 2H), 2.09 (s, 3H), 1.86 (s, 3H), 1.06 (t, 3H)
(M+2H)2+ = 416.1 197
Preparation 2: Ethyl (2R)-2- [5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl] -6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy-3- [2- [ [2-(3- hydr oxyphenyl)pyrimidin-4-yl] methoxy] phenyl] pr opanoate
Using General Procedure I Step A and 3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)phenol as the appropriate boronic acid derivative, Preparation 2 was obtained as a mixture of the diastereoisomers.
IH NMR (500 MHz, DMSO-d6) δ 9.65 (br s, IH), 8.95 (d, IH), 8.58 (s, IH), 7.88-7.80 (m, 2H), 7.57 (d, IH), 7.33 (d, IH), 7.32-7.27 (m, 2H), 7.3 (t, IH), 7.24-7.14 (m, 4H), 7.05 (d, IH), 6.94-6.90 (dm, IH), 6.78-6.73 (tm, IH), 6.30 (dd, IH), 5.51 (dd, IH), 5.30 (d, IH), 5.24 (d, IH), 4.26-4.00 (m, 4H), 3.17 (dd, IH), 2.76 (br s, 2H), 2.58 (dd, IH), 2.42 (br s, 3H), 3.00-2.30 (br s, 8H), 1.86 (s, 3H), 1.06 (t, 3H)
(M+2H)2+ = 445.1524
Preparation 3: Ethyl (2R)-2- [5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl] -6-(4-fluor ophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy-3- [2- [ [2-(4- hydr oxyphenyl)pyrimidin-4-yl] methoxy] phenyl] pr opanoate
Using General Procedure I Step A and 4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)phenol as the appropriate boronic acid derivative, Preparation 3 was obtained as a mixture of the diastereoisomers.
1H NMR (500 MHz, DMSO-d6) δ 10.01 (s, IH), 8.86 (d, IH), 8.58 (s, IH), 8.24 (d, 2H), 7.46 (d, IH), 7.33 (d, IH), 7.32-7.27 (m, 2H), 7.21 (t, 2H), 7.21-7.15 (m, 2H), 7.04 (d, IH), 6.87 (d, 2H), 6.74 (t, IH), 6.29 (d, IH), 5.52 (dd, IH), 5.26 (d, IH), 5.20 (d, IH), 4.19 (br s, 2H), 4.10-4.00 (m, 2H), 3.16 (dd, IH), 3.03-2.41 (m, 13H), 2.56 (dd, IH), 1.86 (s, 3H), 1.05 (t, 3H)
(M+2H)2+ = 445.1517 Preparation 4a: 2- [2- [(2,2-dimethyl- 1 ,3-dioxolan-4-yl)methoxy] henyl] -4,4,5,5- tetr amethyl- 1 ,3,2-dioxaborolane
Using General Procedure IV, 2-iodophenol as the appropriate phenol and (2,2-dimethyl- l,3-dioxolan-4-yl)methanol as the appropriate alcohol, Preparation 4a was obtained. 1H NMR (500 MHz, DMSO-d6) δ 7.50 (dd, 1H), 7.41 (tm, 1H), 6.98 (d, 1H), 6.93 (td, 1H), 4.37-4.31 (m, 1H), 4.08-4.02 (m, 2H), 4.03 (dd, 1H), 3.96 (dd, 1H), 1.36 (s, 3H), 1.30 (s, 3H), 1.27 (s, 12H)
Preparation 4b: 2- [2- [2-(2-methoxyethoxy)ethoxy] phenyl] -4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolane
Using General Procedure IV, 2-iodophenol as the appropriate phenol and 2-(2- methoxyethoxy)ethanol as the appropriate alcohol, Preparation 4b was obtained. 1H NMR (500 MHz, DMSO-d6) δ 7.48 (dm, 1H), 7.42-7.37 (m, 1H), 6.94 (dm, 1H), 6.92- 6.90 (m, 1H), 4.05-4.01 (m, 2H), 3.76-3.72 (m, 2H), 3.70-3.67 (m, 2H), 3.46-3.43 (m, 2H), 3.24 (s, 3H), 1.26 (s, 12H) Preparation 4c: 2- [2- [2- [2-(2-methoxyethoxy)ethoxy] ethoxy] phenyl] -4,4,5,5- tetramethyl- 1 ,3,2-dioxaborolane
Using General Procedure IV, 2-iodophenol as the appropriate phenol and 2-[2-(2- methoxyethoxy)ethoxy]ethanol as the appropriate alcohol, Preparation 4c was obtained. 1H NMR (500 MHz, DMSO-d6) δ 7.48 (dm, 1H), 7.49-7.46 (m, 1H), 6.94 (dm, 1H), 6.93- 6.89 (m, 1H), 4.04-4.01 (m, 2H), 3.75-3.72 (m, 2H), 3.71-3.39 (m, 8H), 3.22 (s, 3H), 1.26 (s, 12H)
Preparation 4d: 2- [2-(2-methoxyethoxymethyl)phenyl] -4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolane
Step A: l-bromo-2-(2-methoxyethoxymethyl)benzene
To 20 mL of 2-methoxyethanol (672 mmol, 20 eq) 4.03 g sodium hydride (100.8 mmol, 60 % in oil, 3 eq.) was adde in small portions at 0 °C. After 30 minutes stirring, 8.40 g l-bromo-2-(bromomethyl)benzene (33.6 mmol, 1 eq.) was added, then the reaction mixture was removed from the cooling bath and further was stirred at r.t. until no further conversion was observed. Reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. Crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain l-bromo-2-(2-methoxyethoxymethyl) benzene. 1H NMR (400 MHz, DMSO-d6) δ 7.60 (d, 1H), 7.49 (d, 1H), 7.39 (t, 1H), 7.24 (t, 1H), 4.52 (s, 2H), 3.63 (dd, 2H), 3.51 (dd, 2H), 3.27 (s, 3H)
Step B: Preparation 4d
Product from Step A was converted to the appropriate boronic ester using General Procedure IV Step B to obtain Preparation 4d. 1H NMR (400 MHz, DMSO-d6) δ 7.80 (d, 1H), 7.50 (d, 1H), 7.43 (t, 1H), 7.28 (t, 1H), 4.85 (s, 2H), 3.66 (dd, 2H), 3.59 (dd, 2H), 3.41 (s, 3H), 1.36 (s, 12H)
Preparation 4e: 4,4,5,5-tetramethyl-2-[2-(2-tetrahydropyran-2-yloxyethoxymethyl) phenyl] - 1 ,3,2-dioxaborolane
Step A: 2-[2-[ (2-iodophenyl)methoxy]ethoxy]tetrahydropyran
To a solution of 2.34 g (2-iodophenyl)methanol (10 mmol, 1 eq.) in 25 mL dry DMF 440 mg sodium hydride (11 mmol, 60 % in oil, 1.1 eq.) was added in small portions at 0 °C. After 30 minutes stirring, 2.5 g 2-(2-bromoethoxy)tetrahydropyran (12 mmol, 1.2 eq.) was added, then the reaction mixture was removed from the cooling bath and further was stirred at 50 °C until no further conversion was observed. Reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. Crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain 2-[2-[(2-iodophenyl)methoxy]ethoxy]tetrahydropyran. 1H NMR (400 MHz, CDC13) δ 7.83 (d, 1H), 7.50 (d, 1H), 7.36 (t, 1H), 6.99 (t, 1H), 4.70 (t, 1H), 4.59 (s, 2H), 3.98-3.88 (m, 2H), 3.79-3.76 (m, 2H), 3.73-3.68 (m, 1H), 3.56-3.51 (m, 1H), 1.94-1.83 (m, 1H), 1.80-1.73 (m, 1H), 1.70-1.52 (m, 4H)
Step B: Preparation 4e To a solution of 1.0 g product from Step A (2.76 mmol, 1 eq.) in 15 mL dry THF 4.24 mL 'PrMgCl x LiCl (5.52 mmol, 1.3M in THF, 2 eq.) was added at 0 °C over 2 minutes. After 10 minutes stirring, 1.40 mL 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (6.9 mmol, 2.5 eq.) was added then it was stirred at 0 °C until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4e. 1H NMR (400 MHz, CDC13) δ 7.80 (d, 1H), 7.53 (d, 1H), 7.44 (t, 1H), 7.28 (t, 1H), 4.87 (s, 1H), 4.68 (t, 2H), 3.94-3.87 (m, 2H), 3.76-3.64 (m, 3H), 3.54-3.49 (m, 1H), 1.93-1.82 (m, 1H), 1.78-1.71 (m, 1H), 1.69-1.52 (m, 4H)
Preparation 4f: 2- [2- [(2,2-dimethyl- 1 ,3-dioxolan-4-yl)methoxym ethyl] phenyl] -4,4,5,5- tetr amethyl- 1 ,3,2-dioxaborolane
Step A: 4-[(2-bromophenyl)methoxymethyl] -2,2-dimethyl- 1,3-dioxolane
To a solution of 1.3 mL (2,2-dimethyl- l,3-dioxolan-4-yl)methanol (11 mmol, 1.1 eq) in 25 mL dry DMF 440 mg sodium hydride (11 mmol, 60 % in oil, 1.1 eq.) was adde in small portions at 0 °C. After 30 minutes stirring, 2.5 g l-bromo-2-(bromomethyl)benzene (10 mmol, 1 eq.) was added, then the reaction mixture was removed from the cooling bath and was stirred at rt until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain 4-[(2-bromophenyl)methoxymethyl]-2,2-dimethyl- 1,3-dioxolane. 1H NMR (400 MHz, CDC13) δ 7.55 (d, 1H), 7.49 (d, 1H), 7.33 (t, 1H), 7.17 (t, 1H), 4.65 (dd, 2H), 4.36 (qui, 1H), 4.11 (dd, 1H), 3.82 (dd, 1H), 3.67 (dd, 1H), 3.59 (dd, 1H), 1.46 (s, 3H), 1.39 (s, 3H)
Step B: Preparation 4f
Product from Step A was converted to the appropriate boronic ester using General Procedure IV Step B to obtain Preparation 4f. 1H NMR (400 MHz, DMSO-d6) δ 7.65 (d, 1H), 7.45 (t, 1H), 7.41 (d, 1H), 7.29 (t, 1H), 4.68 (dd, 2H), 4.20 (qui, 1H), 3.98 (dd, 1H), 3.62 (dd, 1H), 3.51-3.42 (m, 2H), 1.30 (s, 3H), 1.30 (s, 12H), 1.26 (s, 3H)
Preparation 4g: 4,4,5,5-tetramethyl-2-[3-(2-tetrahydropyran-2-yloxyethoxymethyl) phenyl] - 1 ,3,2-dioxaborolane Step A: 2-[2-[(3-iodophenyl)methoxy]ethoxy]tetrahydropyran
To a solution of 2.34 g (3-iodophenyl)methanol (10 mmol, 1 eq.) in 25 mL dry DMF 440 mg sodium hydride (11 mmol, 60 % in oil, 1.1 eq.) was added in small portions at 0 °C. After 30 minutes stirring, 2.5 g 2-(2-bromoethoxy)tetrahydropyran (12 mmol, 1.2 eq.) was added, then the reaction mixture was removed from the cooling bath and was stirred at 50 °C until no further conversion was observed. Reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain 2-[2-[(3- iodophenyl)methoxy]ethoxy]tetrahydropyran. MS (EI, 70 eV) m/z (% relative intensity, [ion]): 85 (100), 217 (57), 233 (15), 278 (15), 362 (1)
Step B: Preparation 4g
To a solution of 1.0 g product from Step A (2.76 mmol, 1 eq.) in 15 mL dry THF 4.24 mL 'PrMgCl x LiCl (5.52 mmol, 1.3M in THF, 2 eq.) was added at 0 °C over 2 minutes. After 10 minutes stirring, 1.40 mL 2-isopropoxy-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (6.9 mmol, 2.5 eq.) was added then it was stirred at 0 °C until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain Preparation 4g. 1H NMR (400 MHz, CDC13) δ 7.79 (s, 1H), 7.75 (d, 1H), 7.51 (d, 1H), 7.38 (t, 1H), 4.67 (t, 1H), 4.63 (d, 1H), 4.59 (d, 1H), 3.95-3.83 (m, 2H), 3.71-3.62 (m, 3H), 3.55-3.48 (m, 1H), 1.94-1.47 (m, 6H), 1.37 (s, 12H) Preparation 4h: 2-[3-[2-methoxy-l-(methoxymethyl)ethoxy]phenyl]-4,4,5,5- tetr amethyl- 1 ,3,2-dioxaborolane
To the solution of 880 mg (4 mmol, 1 eq.) 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) phenol and 1371 mg (5.0 mmol, 1.25 eq.) [2-methoxy-l-(methoxymethyl)ethyl] 4-methylbenzenesulfonate in 16 mL DMF, 1954 mg (6.0 mmol, 1.5 eq.) cesium carbonate was added and it was stirred at 75 °C for 16 hours, then at 85 °C for 8 hours. The reaction mixture was cooled to r.t. and it was concentrated under reduced pressure. To the residue 25 mL brine was added and it was extracted with 3 x 25 mL ethyl acetate. The combined organic layer was dried over MgSC^ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give Preparation 4h. HRMS calculated for C17H27BO5 : 322.1952; found 323.2025 (M+H)
Preparation 4i: 2- [4- [2-methoxy- l-(methoxymethyl)ethoxy] henyl] -4,4,5,5-tetra methyl- 1 ,3,2-dioxaborolane
To the solution of 880 mg (4 mmol, 1.0 eq.) 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenol and 1371 mg (5.0 mmol, 1.25 eq.) [2-methoxy- l-(methoxymethyl)ethyl] 4-methylbenzenesulfonate in 16 mL DMF, 1954 mg (6.0 mmol, 1.5 eq.) cesium carbonate was added and it was stirred at 75 °C for 16 hours. The reaction mixture was cooled to r.t. and it was concentrated under reduced pressure. To the residue 25 mL brine was added and it was extracted with 3 x 25 mL ethyl acetate. The combined organic layer was dried over MgSC"4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give Preparation 4i. HRMS calculated for C17H27BO5 : 322.1952; found 323.2036 (M+H)
Preparation 4j: [(2R)-4,5-diacetoxy-6-methoxy-2- [ [3-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)phenoxy] methyl] tetrahydropyran-3-yl] acetate
Step A: Methyl 2,3,4-tri-O-acetyl-a-O-mannopyranoside
2.25 g (4 mmol) methyl 2,3,4-tri-O-acetyl-6-triphenylmethyl-a-D-mannopyranoside was dissolved in 30 mL acetic acid at 85 °C, then 15 mL water was added and it was stirred at 90 °C for 1 hour. It was cooled to r.t. then it was poured into ice cold brine. The mixture was filtered and the filtrate was extracted with dichloromethane. The combined organic layer was dried over MgS04, it was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give methyl 2,3,4-tri-O-acetyl-a-D-mannopyranoside. 1H NMR (500 MHz, DMSO-dg): 5.11-5.03 (m, 3H), 4.85 (t, 1H), 4.73 (d, 1H), 3.65 (m, 1H), 3.48 (m, 1H), 3.42 (m, 1H), 3.33 (s, 3H), 2.11-1.91 (s, 9H)
Step B: Preparation 4j
Starting from methyl 2,3,4-tri-O-acetyl-a-D-mannopyranoside and 3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenol using General Procedure IV Step A, Preparation 4j was obtained. 1H NMR (500 MHz, DMSO-dg): 7.31 (t, 1H), 7.26 (m, 1H), 7.15 (m, 1H), 7.06 (m, 1H), 5.25 (t, 1H), 5.12 (m, 1H), 5.11 (m, 1H), 4.79 (d, 1H), 4.13 (dd, 1H), 4.05 (dd, 1H), 3.99 (m, 1H), 3.36 (s, 3H), 2.15-1.92 (s, 9H), 1.29 (s, 12H)
Preparation 4k: 4,4,5,5-tetramethyl-2- [3- [ [(2S)-3,4,5,6-tetramethoxytetrahydropyran- 2-yl] methoxy] phenyl] - 1 ,3,2-dioxaborolane Step A: methyl- 6-triphenylmethyl 2, 3, 4-tri-O-methyl-a-O-mannopyranoside
To the solution of 8.08 g (18.51 mmol) methyl 6-triphenylmethyl-a-D-mannopyranoside in 150 mL DMF 2.89 g sodium hydride (60 % in mineral oil, 72.2 mmol, 3.9 eq.) was added portionwise at 0 °C and it was stirred at this temperature for 30 minutes. Then 5.20 mL Mel (11.8 g, 83.3 mmol, 4.5 eq.) was added dropwise at 0 °C and it was stirred at r.t. for 16 hours. To the reaction mixture 10 mL MeOH was added and it was stirred for 15 minutes, then it was concentrated under reduce pressure. The residue was diluted with 200 mL water and extracted with DCM. The combined organic layer was dried over MgS04, it was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give methyl-6-triphenylmethyl 2,3,4-tri-O-methyl-a-D-mannopyranoside. 1H NMR (500 MHz, DMSO-dg): 7.44-7.23 (m, 15H), 4.85 (d, 1H), 3.58 (dd, 1H), 3.48 (m, 1H), 3.39 (s, 3H), 3.36 (s, 3H), 3.33 (dd, 1H), 3.31 (s, 3H), 3.28 (t, 1H), 3.23 (dd, 1H), 3.11 (s, 3H), 3.1 (dd, 1H) Step B: methyl 2,3,4-tri-O-methyl-a-D-mannopyranoside
1.914 g methyl-6-triphenylmethyl 2,3,4-tri-O-methyl-a-D-mannopyranoside (4.0 mmol) was dissolved in 30 mL acetic acid at 85 °C, then 15 mL water was added and it was stirred at 90 °C for 1 hour. It was cooled to r.t. and it was poured into ice cold brine. The mixture was filtered and the filtrate was extracted with dichloromethane. The combined organic layer was dried over MgSC^, it was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give methyl 2,3,4-tri-O-methyl-a-D-mannopyranoside. 1H NMR (500 MHz, DMSO-dg): 4.72 (d, 1H), 4.63 (br s, 1H), 3.56 (dd, 1H), 3.54 (dd, 1H), 3.47 (dd, 1H), 3.36 (s, 3H), 3.34 (s, 3H), 3.32 (m, 1H), 3.32 (s, 3H), 3.26 (s, 3H), 3.24 (m, 1H), 3.22 (m, 1H)
Step C: Preparation 4k
Starting from methyl 2,3,4-tri-O-methyl-a-D-mannopyranoside and 3-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenol using General Procedure IV Step A, Preparation 4k was obtained. 1H NMR (500 MHz, DMSO-dg): 7.31 (dd, 1H), 7.25 (dm, 1H), 7.19 (m, 1H), 7.09 (dm, 1H), 4.77 (d, 1H), 4.14 (dd, 1H), 4.09 (dd, 1H), 3.60 (m, 1H), 3.59 (dd, 1H), 3.41 (t, 1H), 3.38 (dd, 1H), 3.37 (s, 3H), 3.36 (s, 3H), 3.34 (s, 3H), 3.33 (s, 3H), 1.29 (s, 12H)
Preparation 41: [(2R)-4,5-diacetoxy-6-methoxy-2- [ [4-(4,4,5,5-tetramethyl- 1 ,3,2- dioxaborolan-2-yl)phenoxy] methyl] tetrahydropyran-3-yl] acetate
Starting from methyl 2,3,4-tri-O-acetyl-a-D-mannopyranoside (from Preparation 4j Step A) and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenol using General Procedure IV Step A, Preparation 41 was obtained. 1H NMR (500 MHz, DMSO-d6): 7.60(m, 2H), 6.92 (m, 2H), 5.23 (t, 1H), 5.13 (dd, 1H), 5.11 (dd, 1H), 4.80 (d, 1H), 4.14 (dd, 1H), 4.06 (dd, 1H), 4.02 (m, 1H), 3.36 (s, 3H), 2.14-1.92 (s, 9H), 1.27 (s, 12H)
Preparation 4m: 4,4,5,5-tetramethyl-2- [4- [ [(2S)-3,4,5,6-tetramethoxytetrahydro pyran-2-yl] methoxy] phenyl] - 1 ,3,2-dioxaborolane
Starting from methyl 2,3,4-tri-O-methyl-a-D-mannopyranoside (from Preparation 4j Step A) and 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenol using General Procedure IV Step A, Preparation 4m was obtained. 1H NMR (500 MHz, DMSO-d6): 7.61 (m, 2H), 6.96 (m, 2H), 4.77 (d, 1H), 4.16 (dd, 1H), 4.10 (dd, 1H), 3.61 (m, 1H), 3.60 (d, 1H), 3.38 (m, 2H), 3.37-3.28 (s, 12H), 1.27 (s, 12H)
Preparation 4n: [(2R)-4,5,6-triacetoxy-2-[[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)phenoxy] methyl] tetrahydropyran-3-yl] acetate
Step A: 1, 2, 3, 4-tetra-0-acetyl-a^-O-mannopyranose
2.36 g l,2,3,4-tetra-O-acetyl-6-triphenylmethyl-a/p-Z)-mannopyranose (4.0 mmol) was dissolved in 30 mL acetic acid at 65 °C, then 15 mL water was added and it was stirred at 65 °C for 1 hour. It was cooled to r.t. and it was poured into ice cold brine. The mixture was filtered and the filtrate was extracted with dichloromethane. The combined organic layer was dried over MgSC^, it was filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give l,2,3,4-tetra-0-acetyl-a/p-D-mannopyranose. 1H NMR (500 MHz, DMSO-dg): 6.06-5.97 (d, 1H), 5.20-5.06 (t, 1H), 5.31-5.18 (dd, 1H), 5.35-5.14 (dd, 1H), 4.89-4.87 (t, 1H), 3.84-3.74 (m, 1H), 3.52-3.34 (m, 2H), 2.20-1.90 (s, 12H)
Step B: Preparation 4n
Starting from l,2,3,4-tetra-0-acetyl-a/p-D-mannopyranose and 4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)phenol using General Procedure IV Step A, Preparation 4n was obtained as the mixture of stereoisomers. 1H NMR (500 MHz, DMSO-d6): 7.60 (m, 2H), 6.91 (m, 2H), 6.15-6.00 (d, 1H), 5.43-5.15 (m, 3H), 4.23-4.20 (m, 1H), 4.14-4.00 (m, 2H), 2.19-1.92 (s, 12H), 1.27 (s, 12H)
Preparation 4o: [(3R,4S,6S)-3,4,5-triacetoxy-6-[[4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenyl] methoxy]tetrahydropyran-2-yl] methyl acetate
and
Preparation 4p: [(2R,3«S,6R,7S)-6,7-diacetoxy-2-methyl-2- [ [4-(4,4,5,5-tetr amethyl- 1 ,3,2-dioxaborolan-2-yl)phenyl] methoxy] -5,6,7,7a- tetrahydro-3«H- [ 1 ,3] dioxolo [4,5-6] pyran-5-yl] methyl acetate Step A: l-bromo-2, 3, 4, 6-tetra-0-acetyl-a^-D-mannopyranose
1 mL acetic anhydride was added to 30 mL HBr in acetic acid (33 %) and it was stirred at r.t. for 16 hours. It was cooled to 0 °C, and the solution of 7.50 g 1, 2,3,4, 6-penta-O-acetyl- α/β-D-mannopyranose (19.2 mmol) in 30 mL dichloromethane was added dropwise at 0 °C. The reaction mixture was stirred at this temperature for 2 hours then at r.t. for 16 hours. The mixture was cooled to 0 °C and it was poured onto 100 mL ice-water. It was diluted with 120 mL DCM then the phases were seprated. Organic layer was washed with ice cold water, saturated NaHCC"3 and water again. The organic layer was dried over MgS04, it was filtered and concentrated under reduced pressure to give l-bromo-2,3,4,6-tetra- O-acetyl-a/p-D-mannopyranose. 1H NMR (500 MHz, DMSO-d6): 6.77 (d, 1H), 5.50 (dd, 1H), 5.35 (dd, 1H), 5.23 (t, 1H), 4.17 (m, 1H), 4.25 (dd, 1H), 4.08 (dd, 1H), 2.13 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 1.96 (s, 3H)
Step B: Preparations 4o and 4p
To the solution of 819 mg [4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl] methanol (3.50 mmol, 1 eq.), 2015 mg l-bromo-2, 3,4, 6-tetra-0-acetyl-a/p-D- mannopyranose (4.90 mmol, 1.4 eq.), 467 mg s-collidine (3.85 mmol, 1.1 eq.) in 100 mL DCM 1708 mg silver trifluoromethanesulfonate (6.65 mmol, 1.9 eq.) in 15 mL toluene was added dropwise at -78 °C and the mixture was stirred at this temperature for 10 minutes. The mixture was let to warm slowly to r.t. (3 hours), then it was stirred for 10 hours. The mixture was filtered through a Celite pad, the filtrate was concentrated. The residue was purified by flash chromatography on silica gel using heptane and ethyl acetate as eluents to give Preparation 4o as first eluted product 1H NMR (500 MHz, DMSO-d6): 7.69 (m, 2H), 7.39 (m, 2H), 5.15-5.10 (m, 3H), 4.96 (d, 1H), 4.71 (d, 1H), 4.57 (d, 1H), 4.15 (dd, 1H), 4.04 (dd, 1H), 3.96 (m, 1H), 2.12-1.91 (s, 12H), 1.29 (s, 12H);
and Preparation 4p as later eluted product. 1H NMR (500 MHz, DMSO-d6): 7.63 (m, 2H), 7.31 (m, 2H), 5.68 (d, 1H), 5.32 (dd, 1H), 5.05 (t, 1H), 4.59 (d, lh) 4.54 (dd, 1H), 4.53 (d, 1H), 4.12 (dd, 1H), 4.03 (dd, 1H), 3.94 (m, 1H), 2.01-1.97 (s, 9H), 1.70 (s, 3H), 1.29 (s, 12H)
Preparation 4q: [5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidin-2-yl] methanol 113 mg (5-bromopyrimidin-2-yl)methanol (0.6 mmol) and 609 mg 4,4,5,5-tetramethyl-2- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (2.4 mmol) were dissolved in 6 mL dioxane, then 353 mg KOAc (3.6 mmol) and 66 mg PdCl2 xdppf (0.09 mmol) were added. The mixture was stirred under nitrogen at 60 °C for 2 hours. The resulting mixture was used without further manipulation. MS (M+H): 237.1
Preparation 5: Ethyl (2R)-2- [5- [3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl] -6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy-3- [2- [ [2- [3- (hydroxymethyl)phenyl] pyrimidin-4-yl] m ethoxy] phenyl] propanoate
Using General Procedure I Step A and [3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl]methanol as the approprite boronic ester, Preparation 5 was obtained as a mixture diastereoisomers. MS: [M+H]+= 903.2
Example 1 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i/] pyrimidin-4-yl] oxy}-3-(2-{ [2-(3- hydroxyphenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid Starting from Preparation 2 using General procedure I Step B, Example 1 was obtained. HPvMS calculated for C46H42C1FN606S: 860.2559; found 431.1349 (M+2H)2+
Example 2 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3-(2-{ [2-(4- hydroxyphenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid Starting from Preparation 3 using General procedure I Step B, Example 2 was obtained. HPvMS calculated for
Figure imgf000050_0001
860.2559; found 431.1371 (M+2H)2+
Example 3 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3- [2-({2-[3- (hydroxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid Starting from Preparation 1 and [3-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)phenyl]methanol using General procedure I, Example 3 was obtained. HRMS calculated for C47H44CIFN6O6S: 874.2715; found 438.141 (M+2H)2+
Example 4 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2-[4- (hydroxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Starting from Preparation 1 and [4-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2- yl)phenyl]methanol using General procedure I, Example 4 was obtained. HRMS calculated for C47H44CIFN6O6S: 874.2715; found 438.1449 (M+2H)2+ Example 5: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i/] pyrimidin-4-yl] oxy}-3-{2- [(2-{2- [(2,2- dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl} propanoic acid
Starting from Preparation 1 and Preparation 4a using General procedure I, Example 5 was obtained. HRMS calculated for
Figure imgf000051_0001
974.324; found 488.1698 (M+2H)2+
Example 6 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3-{2- [(2-{2- [2- (2-methoxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4b using General procedure I, Example 6 was obtained. HRMS calculated for
Figure imgf000051_0002
962.324; found 482.1695 (M+2H)2+
Example 7: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-{2- [2-(2-methoxyethoxy)ethoxy]ethoxy}phenyl)pyrimidin-4-yl]methoxy}phenyl) propanoic acid Starting from Preparation 1 and Preparation 4c using General procedure I, Example 7 was obtained. HRMS calculated for CssHsgClFNgOgS: 1006.3502; found 504.1828
(M+2H)2+
Example 8 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[2- (methoxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Starting from Preparation 1 and [2-(methoxymethyl)phenyl]-4,4,5,5-tetramethyl-l,3,2- dioxaborolane using General procedure I, Example 8 was obtained. HRMS calculated for C48H46CIFN6O7S: 888.2872; found 445.1518 (M+2H)2+ Example 9: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{2- [(2- methoxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4d using General procedure I, Example 9 was obtained. HRMS calculated for C5oH5oClFN607S: 932.3134; found 467.164 (M+2H)2+ Example 10: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{2- [(2- hydroxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4e using General procedure I, after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed. Then it was neutralized with 10 % aqueous K2CO3 solution, diluted with brine, extracted with DCM. The combined organic phases were dried over MgS04, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 10. HRMS calculated for C49H48N607FSC1: 918.2978; found 460.1572 (M+2H)2+ Example 11 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-(2-{ [2-(2- { [(2,2-dimethyl- 1 ,3-dioxolan-4-yl)methoxy] methyl}phenyl)pyrimidin-4-yl] methoxy} phenyl)propanoic acid Starting from Preparation 1 and Preparation 4f using General procedure I, Example 11 was obtained. HRMS calculated for
Figure imgf000053_0001
988.3397; found 495.1762
(M+2H)2+
Example 12 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{3- [(2- hydroxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4g using using General procedure I, after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed. Then it was neutralized with 10 % aqueous K2CO3 solution, diluted with brine, extracted with DCM. The combined organic phases were dried over MgSC^, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 12. HRMS calculated for C49H48CIFN6O7S: 918.2978; found 460.1556 (M+2H)2+ Example 13: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3-{2- [(2-{3- [(1,3- dimethoxypropan-2-yl)oxy] phenyl} pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4h using General procedure I, Example 13 was obtained. HRMS calculated for
Figure imgf000053_0002
962.324; found 482.1694 (M+2H)2+ Example 14 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{4-[(l,3- dimethoxypropan-2-yl)oxy] phenyl} pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4i using General procedure I, Example 14 was obtained. HRMS calculated for
Figure imgf000054_0001
962.324; found 482.1678 (M+2H)2+
Example 15 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2-[4-(2,3- dihydroxypropoxy)phenyl] pyrimidin-4-yl}methoxy)phenyl] propanoic acid
Starting from Preparation 3 and (2,2-dimethyl-l,3-dioxolan-4-yl)methanol using General procedure II after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed. Then it was neutralized with 10 % aqueous K2CO3 solution, diluted with brine, extracted with DCM. The combined organic phases were dried over MgSC^, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 15. HRMS calculated for C49H48 6O8FSCI: 934.2927; found 468.1531 (M+2H)2+
Example 16: methyl 6-0-{3-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-a-D- mannopyranoside
Starting from Preparation 1 and Preparation 4j using General procedure V, Example 16 was obtained. HRMS calculated for 1036.3243; found 519.1696
(M+2H)2+ Example 17: methyl 6-0-{3-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-2,3,4-tri-0-methyl- α-D-mannopyranoside
Starting from Preparation 1 and Preparation 4k using General procedure I, Example 17 was obtained. HRMS calculated for CjgHgoClFNgOnS: 1078.3713; found 540.1936 (M+2H)2+
Example 18: methyl 6-0-{4-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-a-D- mannopyranoside Starting from Preparation 1 and Preparation 41 using General procedure V, Example 18 was obtained. HRMS calculated for
Figure imgf000055_0001
1036.3243; found 519.1714
(M+2H)2+
Example 19: methyl 6-0-{4-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl-4- [3-(4-methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ] pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-2,3,4-tri-0-methyl- a-D-mannopyranoside
Starting from Preparation 1 and Preparation 4m using General procedure I, Example 19 was obtained. HRMS calculated for CjgHgoClFNgOnS: 1078.3713; found 540.1925
(M+2H)2+ Example 20: 6-0-{4-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl-4-[3-(4- methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-D-mannopyranose
and
Example 21: 6-0-{2-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl-4-[3-(4- methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-D-mannonic acid Starting from Preparation 1 and Preparation 4n using General procedure V, Example 20 was obtained as the earlier eluting compound. HRMS calculated for C52H52CIFN6O1 1S: 1022.3087; found 512.1611 (M+2H)2+
Example 21 was obtained as the later eluting compound. HRMS calculated for C52H52ClFN6Oi2S: 1038.3036; found 520.1604 (M+2H)2+
Example 22: l,2-0-[(lR)-l-({4-[4-({2-[(2R)-2-carboxy-2-{[(5S«)-5-{3-chloro-2-methyl- 4-[3-(4-methylpiperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i | pyrimidin-4-yl] oxy} ethyl] phenoxy}methyl)pyrimidin-2-yl] benzyl} oxy)ethylidene] -β- D-mannopyranose Starting from Preparation 1 and Preparation 4o using General procedure V, Example 22 was obtained. HRMS calculated for C55H56ClFN6Oi2S: 1078.335; found 1079.343 (M+H)+
Example 23 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{4- [(a- D-mannopyranosyloxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 1 and Preparation 4p using General procedure V, Example 23 was obtained. HRMS calculated for
Figure imgf000056_0001
1036.3243; found 519.1682
(M+2H)2+
Example 24 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3- [2-({2-[4-(2- hydroxyethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Starting from Preparation 1 and [4-(2-hydroxyethyl)phenyl]boronic acid using General procedure I, Example 24 was obtained. HRMS calculated for C48H46N606FSC1: 888.2872; found 445.1512 (M+2H)2+ Example 25 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2-[2-(2,3- dihydroxypropoxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Starting from Preparation 1 and Preparation 4a using General procedure I after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed. Then it was neutralized with 10 % aqueous K2CO3 solution, diluted with brine, extracted with DCM. The combined organic phases were dried over MgSC^, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 25. HRMS calculated for C49H48CIFN6O8S: 934.2927; found 468.1536 (M+2H)2+
Example 26 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2-[2-(2- hydroxy ethoxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Step A: Ethyl (2R)-2-hydroxy-3-f2-ff2-f2-(2-methoxyethoxy)phenylJpyrimidin-4-ylJ methoxy] phenyl] propanoate
A solution of 1.01 g ethyl (2i?)-3-[2-[(2-chloropyrimidin-4-yl)methoxy]phenyl]-2- hydroxy-propanoate (from Preparation 1 Step E) (3 mmol, 1 eq.), 1.17 g [2-(2- methoxyethoxy)phenyl]boronic acid (6 mmol, 2 eq.), 2.93 g cesium carbonate (9 mmol, 3 eq.) and 210 mg Pd(PPh3)2Cl2 in 30 mL dioxane/H20 (1 : 1) were stirred at 70 °C until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgSC^, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain ethyl (2i?)-2-hydroxy-3-[2- [[2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate as colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 8.92 (d, 1H), 7.60 (dd, 1H), 7.59 (d, 1H), 7.45 (dd, 1H), 7.24-7.15 (m, 3H), 7.08 (t, 1H), 7.02 (d, 1H), 6.91 (t, 1H), 5.55 (d, 1H), 5.27 (d, 1H), 5.23 (d, 1H), 4.40-4.32 m, 1H), 4.17-4.11 (m, 2H), 4.06 (q, 2H), 3.62-3.60 (m, 2H), 3.22 (s, 3H), 3.17 (dd, 1H), 2.88 (dd, 1H), 1.18 (t, 3H)
Step B: Ethyl (2K)-2-[5-bromo-6-(4-fluorophenyl)thieno[2,3-dJpyrimidin-4-yl]oxy-3-[2- [[2-[2-(2-methoxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate
A suspension of 995 mg product obtained in Step A (2.2 mmol, 1.1 eq.), 687 mg 5-bromo- 4-chloro-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidine (from Preparation 1 Step D) (2 mmol, 1 eq.) and 1.95 g cesium carbonate (6 mmol, 3 eq.) in 10 mL dry THF were stirred at 70 °C until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain ethyl (2i?)- 2-[5-bromo-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy-3-[2-[[2-[2-(2-methoxy ethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate. 1H NMR (400 MHz, DMSO- d6) δ 8.90 (d, 1H), 8.62 (s, 1H), 7.77-7.72 (m, 2H), 7.61 (d, 1H), 7.55 (dd, 1H), 7.49 (dd, 1H), 7.45-7.38 (m, 3H), 7.25 (dd, 1H), 7.15 (d, 1H), 7.09-7.01 (m, 2H), 6.94 (t, 1H), 5.79 (dd, 1H), 5.31 (d, 1H), 5.25 (d, 1H), 4.17 (q, 2H), 4.15-4.10 (m, 2H), 3.64-3.56 (m, 3H), 3.33 (dd, 1H), 3.21 (s, 3H), 1.14 (t, 3H)
Step C: Ethyl (2R)-2-[5-bromo-6-(4-fluorophenyl)thieno[2,3-dJpyrimidin-4-ylJoxy-3-[2- [[2-[2-(2-hydroxyethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate
To the solution of 760 mg product obtained in Step B (1 mmol, 1 eq.) in 10 mL dry DCM, 1 mL BBr3 (1 mmol, 1M in DCM, 1 eq.) was added dropwise at r.t., then the mixture was stirred until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgS04, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using heptane and EtOAc as eluents to obtain ethyl (2i?)-2-[5- bromo-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy-3-[2-[[2-[2-(2-hydroxyethoxy) phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate. 1H NMR (400 MHz, CDC13) δ 8.99 (d, 1H), 8.53 (s, 1H), 7.92 (dd, 1H), 7.79 (d, 1H), 7.69-7.62 (m, 2H), 7.54-7.45 (m, 2H), 7.27-7.12 (m, 5H), 6.98 (7, 1H), 6.94 (d, 1H), 5.87 (dd, 1H), 5.34 (d, 1H), 5.29 (d, 1H), 4.41 (t, 2H), 4.29 (q, 2H), 3.94 (t, 2H), 3.72 (dd, 1H), 3.42 (dd, 1H), 1.28 (t, 3H) Step D: Ethyl (2R)-2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxyj 'phenyl] '- 6- ( 4-fluorophenyl) thienof 2, 3-dJpyrimidin-4-ylJoxy-3-f 2-f [ 2-f 2-(2-hydroxyethoxy)phenyl] pyrimidin-4-yl]methoxy] phenyl] propanoate
To a solution of 200 mg of product Step C (0.27 mmol, 1 eq.) in 4 mL dioxane/H20 (1 : 1), 127 mg l-[2-[2-chloro-3-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenoxy] ethyl] -4-methyl-piperazine (from Preparation 1 Step L) (0.32 mmol, 1.2 eq.), 3.1 mg Pd(OAc)2 (0.05 eq.), 11 mg AtaPhos (0.1 eq.) and 262 mg cesium carbonate (0.8 mmol, 3 eq.) were stirred at 70 °C until no further conversion was observed. Reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgSC^, filtered and concentrated under reduced pressure. Crude product was purified by flash chromatography using EtOAc/MeOH (containing 1.2 % NH3) as eluents to obtain ethyl (2i?)-2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl) ethoxy]phenyl]-6-(4-f uorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy-3-[2-[[2-[2-(2-hydroxy ethoxy)phenyl]pyrimidin-4-yl]methoxy]phenyl]propanoate. MS: [M+H]+= 933.2 Step E: Example 26
To a solution of 120 mg product of Step D (0.13 mmol) in 4 mL dioxane/H20 (1 : 1) 100 mg LiOH x H20 (2.6 mmol, 20 eq.) was added and it was stirred at r.t. until no further conversion was observed. Then it was neutralized with 2M HC1 and then directly was injected to an RP18 column using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 26. HRMS calculated for C48H46CIFN6O7S: 904.2821; found 453.1496 (M+2H)2+
Example 27: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{2- [(2,3- dihydroxypropoxy)methyl] phenyl} pyrimidin-4-yl)methoxy] phenyl}propanoic acid Starting from Preparation 1 and Preparation 4f using General Procedure I, after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed. Then it was neutralized with 10 %> aqueous K2C03 solution, diluted with brine, extracted with DCM. The combined organic phases were dried over MgS04, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 27. HRMS calculated for CsoHsoClFNeOgS: 948.3083; found 475.1621 (M+2H)2+
Example 28 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2-[3- (phosphonooxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
To a THF solution of 444 mg Preparation 2 (0.5 mmol, 1 eq.) and 210 μΐ, TEA (1.5 mmol, 3 eq.) in 5 mL dry THF, 140 (1.5 mmol, 3 eq.) POCI3 was added dropwise at r.t. After 15 minutes stirring, 5 mL sodium hydroxide (10 mmol, 2M in water) was added, and then it was stirred at 50 °C until no further conversion was observed. The reaction mixture was injected directly to a preconditioned (EtOAc/MeOH [containing 1.2 % NH3] - 80/20) 220 g flash silica gel column using EtOAc /MeOH (containing 1.2 % NH3) as eluents with gradient method giving the desired product as a mixture of the diastereoisomers. The diastereoisomers were separated via preparative reversed phase chromatography using 50 mM aqueous NH4HC03 solution and MeOH as eluents. The diastereoisomer eluting later was collected as Example 28. HRMS calculated for C46H43N609FPSC1: 940.2222; found 471.1 194 (M+2H)2+ Example 29: 4-[4-({2-[(2R)-2-carboxy-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methyl piperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy} ethyl] phenoxy}methyl)pyrimidin-2-yl] phenyl phosphate
To a THF solution of 444 mg ethyl Preparation 3 (0.5 mmol, 1 eq.) and 210 TEA (1.5 mmol, 3 eq.) in 5 mL dry THF, 140 μΐ, (1.5 mmol, 3 eq.) POCl3 was added dropwise at r.t. After 15 minutes stirring, 5 mL sodium hydroxide (10 mmol, 2M in water) was added, and then it was stirred at 50 °C until no further conversion was observed. The reaction mixture was injected directly to a preconditioned (EtOAc/MeOH [containing 1.2 % NH3] - 80/20) 220 g flash silica gel column using EtOAc /MeOH (containing 1.2 % NH3) as eluents with gradient method giving the desired product as a mixture of the diastereoisomers. The diastereoisomer eluting later was collected as Example 29 after lyophylisation. HRMS calculated for C46H43 6O9FPSCI: 940.2222; found 471.1188
(M+2H)2+ Example 30: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2-[3-(2- hydroxyethoxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Step A: Ethyl (2JL)-2- [5- [3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl] - 6- ( 4-fluorophenyl) thienof 2, 3-dJpyrimidin-4-ylJoxy-3-f 2-f [ 2-f 3-f 2-(p-tolylsulfonyloxy) ethoxy] phenyl] pyrimidin-4-yl]methoxy] phenyl] propanoate
To a DMF solution of 178 mg Preparation 2 (0.2 mmol), 195 mg cesium carbonate (0.6 mmol) and 222 mg 2-(p-tolylsulfonyloxy)ethyl 4-methylbenzenesulfonate (0.6 mmol) were added and the mixture was stirred at 60 °C until no further conversion was observed. The reaction mixture was diluted with EtOAc and brine. After extraction the organic phase was washed with brine and dried over MgSC^, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using EtOAc and MeOH (containing 1.2 % NH3) as eluents to obtain ethyl (2i?)-2-[5-[3-chloro-2-methyl-4- [2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl] -6-(4-fluorophenyl)thieno [2,3 - ]pyrimidin-4-yl] oxy-3-[2-[[2-[3-[2-( ?-tolylsulfonyloxy)ethoxy]phenyl]pyrimidin-4-yl]methoxy]phenyl] propanoate. MS: [M+H]+= 1087.2
Step B: Example 30
To a solution of 120 mg product Step A (0.1 1 mmol) in 4 mL dioxane/f^O (1 : 1), 92 mg LiOH x H20 (2.2 mmol) was added and it was stirred at 60 °C until no further conversion was observed. Then it was neutralized with 2M HC1 and then was injected directly to an RP18 column using using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 30. HRMS calculated for C48H46CIFN6O7S: 904.2821; found 453.1475 (M+2H)2+ Example 31 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{4- [2- (2-methoxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 3 and 2-(2-methoxyethoxy)ethanol using General procedure II, Example 31 was obtained. HRMS calculated for
Figure imgf000062_0001
962.324; found 482.1703 (M+2H)2+
Example 32 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{4- [2- (2-hydroxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid Starting from Preparation 3 and 10 eq. of 2-(2-hydroxyethoxy)ethanol using General procedure II, Example 32 was obtained. HRMS calculated for CsoHsoNeOsFSCl: 948.3083; found 475.1613 (M+2H)2+
Example 33 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-(2-{[2-(4-{2- [2-(2-methoxyethoxy)ethoxy] ethoxy}phenyl)pyrimidin-4-yl] methoxy}phenyl) propanoic acid
Starting from Preparation 3 and 2-[2-(2-methoxyethoxy)ethoxy]ethanol using General procedure II, Example 33 was obtained. HRMS calculated for C53H56N6O9FSCI: 1006.3502; found 504.183 (M+2H)2+ Example 34: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3-{2- [(2-{4- [2- (dimethylamino)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 3 and 2-(dimethylamino)ethanol using General procedure II, Example 34 was obtained. HRMS calculated for CsoHsiNyOeFSCl: 931.3294; found 466.6709 (M+2H)2+ Example 35 : (2R)-2- { [(5S«)-5- {3-chloro-2-methyl-4- [3-(4-methylpiperazin- 1-yl) propoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3-{2- [(2-{3- [(2,2- dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl} propanoic acid Starting from Preparation 2 and (2,2-dimethyl-l,3-dioxolan-4-yl)methanol using General procedure II, Example 35 was obtained. HRMS calculated for C52H52N608FSC1: 974.324; found 488.1677 (M+2H)2+
Example 36: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[3-(15-hydroxy- 3-oxo-2,7,10,13-tetraoxa-4-azapentadec-l-yl)phenyl]pyrimidin-4-yl}methoxy)phenyl] propanoic acid
Starting from Preparation 5 and 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol as the appropriate amine using General procedure III, Example 36 was obtained. HRMS calculated for CseHeiClFNyOnS: 1093.3822; found 547.7006 (M+2H)2+ Example 37: (2R)-3-(2-{[2-(3-{[(l,4,-bipiperidin-l,-ylcarbonyl)oxy]methyl}phenyl) pyrimidin-4-yl]methoxy}phenyl)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy}propanoic acid
Starting from Preparation 5 and l-(4-piperidyl)piperidine as the appropriate amine using General procedure III, Example 37 was obtained. HRMS calculated for C58H62CIFN8O7S: 1068.4135; found 1069.419 (M+H)+
Example 38: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-(2-{ [2-(3-{2- [2-(2- hydroxyethoxy)ethoxy] ethoxy}phenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid Starting from Preparation 2 and 10 eq. of 2-[2-(2-hydroxyethoxy)ethoxy]ethanol using General procedure II, Example 38 was obtained. HRMS calculated for C52H54CIFN6O9S: 992.3345; found 497.1748 (M+2H)2+
Example 39: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{3-[2-(2-hydroxy ethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 2 and 10 eq. of 2-(2-hydroxyethoxy)ethanol using General procedure II, Example 39 was obtained. HRMS calculated for CsoHsoClFNeOsS: 948.3083; found 475.1604 (M+2H)2+ Example 40: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{3-[2-(2-methoxy ethoxy)ethoxy] phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Starting from Preparation 2 and 2-(2-methoxyethoxy)ethanol using General procedure II, Example 40 was obtained. HRMS calculated for
Figure imgf000064_0001
962.324; found 482.1675 (M+2H)2+
Example 41 : (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{3-[({[2-(4- methylpiperazin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid Starting from Preparation 5 and 2-(4-methylpiperazin-l-yl)ethanamine as the appropriate amine using General procedure III, Example 41 was obtained. HRMS calculated for CssHsgClFNgOyS: 1043.3931; found 522.7052 (M+2H)2+
Example 42: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-{2-[(2-{3- [({ [2- (morpholin-4-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Starting from Preparation 5 and 2-morpholinoethanamine as the appropriate amine using General procedure III, Example 42 was obtained. HRMS calculated for C54H56CIFN8O8S: 1030.3615; found 516.1871 (M+2H)2+
Example 43: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-{2-[(2-{3- [({ [2- (dimethylamino)ethyl] carbamoyl} oxy)methyl] phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid Starting from Preparation 5 and N',N'-dimethylethane-l,2-diamine as the appropriate amine using General procedure III, Example 43 was obtained. HRMS calculated for
Figure imgf000065_0001
988.3509; found 989.3586 (M+H)+
Example 44: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-{2-[(2-{3- [({ [2- (pyrrolidin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Starting from Preparation 5 and 2-pyrrolidin-l-ylethanamine as the appropriate amine using General procedure III, Example 44 was obtained. HRMS calculated for C54H56C1FN807S: 1014.3665; found 508.1916 (M+2H)2+ Example 45: (2R)-3-[2-({2-[3-({[bis(2-methoxyethyl)carbamoyl]oxy}methyl)phenyl] pyrimidin-4-yl}methoxy)phenyl]-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy}propanoic acid Starting from Preparation 5 and 2-methoxy-N-(2-methoxyethyl)ethanamine as the appropriate amine using General procedure III, Example 45 was obtained. HRMS calculated for C54H57N7O9FSCI: 1033.3611; found 517.6883 (M+2H)2+
Example 46: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-(2-{[2-(3-{[(l,4,7,10,13- pentaoxa- 16-azacyclooctadecan- 16-ylcarbonyl)oxy] methyl}phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid
Starting from Preparation 5 and l,4,7,10,13-pentaoxa-16-azacyclooctadecane as the appropriate amine using General procedure III, Example 46 was obtained. HRMS calculated for
Figure imgf000066_0001
1163.4241; found 582.7187 (M+2H)2+
Example 47: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl) ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3- [2-({2- [3-(2,3- dihydroxypropoxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Starting from Preparation 2 and (2,2-dimethyl-l,3-dioxolan-4-yl)methanol using General procedure II, after completion of the reaction in Step B the pH was set to 1 with 2M aqueous HC1 solution and it was stirred until no further conversion was observed. Then it was neutralized with 10 % aqueous K2CO3 solution, diluted with brine, extracted with DCM. The combined organic phases were dried over MgSC^, filtered and the filtrate was concentrated under reduced pressure. The crude product was purified via preparative reversed phase chromatography using 5 mM aqueous NH4HCO3 solution and MeCN as eluents. The diastereoisomer eluting later was collected to obtain Example 47. HRMS calculated for C49H48 6O8FSCI: 934.2927; found 468.1538 (M+2H)2+
Example 48: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-(2-{ [2-(3-{2- [2-(2- methoxyethoxy)ethoxy]ethoxy}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid Starting from Preparation 2 and 2-[2-(2-methoxyethoxy)ethoxy]ethanol using General procedure II, Example 48 was obtained. HRMS calculated for C53H56N6O9FSCI: 1006.3502; found 504.1829 (M+2H)2+
Example 49 : (2R)-3-(2-{ [2-(3- {2- [bis(2-hydr oxyethyl)amino] ethoxy}phenyl)pyrimidin- 4-yl]methoxy}phenyl)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy}propanoic acid
Starting from Preparation 2 and 10 eq. of 2-[bis(2-hydroxyethyl)amino]ethanol using General procedure II, Example 49 was obtained. HRMS calculated for C52H55N7O8FSCI: 991.3505; found 496.6833 (M+2H)2+ Example 50: (2R)-2-{[(5Sfl)-5-{2,3-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-{2-[(2-{3- [({ [2- (piperidin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl} propanoic acid
Starting from Preparation 5 and N-(2-aminoethyl)piperidine as the appropriate amine using General procedure III, Example 50 was obtained. HRMS calculated for C55H58C1FN807S: 1028.3822; found 1029.3893 (M+H)+
Example 51: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{3-[2- (morpholin-4-yl)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid Starting from Preparation 2 and N-(2-hydroxyethyl)morpholine using General procedure II, Example 51 was obtained. HRMS calculated for C52H53C1FN707S: 973.3400; found 487.6785 (M+2H)2+
Example 52: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{3-[2-(dimethyl amino)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid Starting from Preparation 2 and 2-dimethylaminoethanol using General procedure II, Example 52 was obtained. HRMS calculated for CsoHjiClFNyOeS: 931.3294; found 466.6722 (M+2H)2+
Example 53 : (2R)-3-(2-{ [2-(4- {2- [bis(2-hydr oxyethyl)amino] ethoxy}phenyl)pyrimidin- 4-yl]methoxy}phenyl)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}propanoic acid
Starting from Preparation 3 and 2-[bis(2-hydroxyethyl)amino]ethanol using General procedure II, Example 53 was obtained. HRMS calculated for C52H55N7O8FSCI: 991.3505; found 496.6822 (M+2H)2+ Example 54: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-(2-{ [2-(4-{2- [2-(2- hydroxyethoxy)ethoxy] ethoxy}phenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid
Starting from Preparation 3 and 10 eq. of triethyleneglycol using General procedure II, Example 54 was obtained. HRMS calculated for C52H54 6O9FSCI: 992.3345; found 497.1743 (M+2H)2+
Example 55: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{4-[(2,2- dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl} propanoic acid Starting from Preparation 3 and (2,2-dimethyl-l,3-dioxolan-4-yl)methanol using General procedure II, Example 55 was obtained. HRMS calculated for C52H52N6O8FSCI: 974.3240; found 488.1689 (M+2H)2+ Example 56: (2R)-2-{[(5S«)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{4-[2- (morpholin-4-yl)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid
Starting from Preparation 3 and N-(2-hydroxyethyl)morpholine using General procedure II, Example 56 was obtained. HRMS calculated for C52H53N7O7FSCI: 973.3400; found 487.6775 (M+2H)2+
Example 57: 4- [4-({2- [(2R)-2-carboxy-2-{ [(5S«)-5-{3-chloro-2-methyl-4- [3-(4-methyl piperazin-l-yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl phosphate disodium salt To a THF solution of 444 mg Preparation 3 (0.5 mmol, 1 eq.) and 210 μΐ, TEA (1.5 mmol, 3 eq.) in 5 mL dry THF, 140 μΐ, POCl3 (1.5 mmol, 3 eq.) was added dropwise at r.t. After 15 minutes stirring, 5 mL sodium hydroxide (10 mmol, 2M in water) was added, and then it was stirred at 50 °C until no further conversion was observed. Then the pH was adjusted to 6 with TFA, and then this reaction mixture directly was injected to an RP18 column using 50 mM aqueous NH4HCO3 solution and MeOH as eluents. The diastereoisomer eluting later was collected. After liophilisation the remaining white solid was suspended in 5 mL dioxan / saturated NH4HC03 (1 : 1). After 1 hour stirring at r.t., reaction mixture directly was injected to an RP18 column using water and MeCN as eluents giving Example 57. HRMS calculated for C46H43N609FPSC1: 940.2222; found 469.1054 (M-2H)2".
Example 58: (2R)-3-(2-{[2-(2-{2-[bis(2-hydroxyethyl)amino]ethoxy}phenyl)
pyrimidin-4-yl]methoxy}phenyl)-2-{[(5S«)-5-{3-chloro-2-methyl-4-[2-(4- methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy}propanoic acid Example 59: (2R)-3-(2-{[2-(4-{[bis(2-hydroxyethyl)amino]methyl}phenyl)pyrimidin- 4-yl]methoxy}phenyl)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4-yl]oxy}propanoic acid Example 60: (2R)-3-(2-{[2-(3-{[bis(2-hydroxyethyl)amino]methyl}phenyl)pyrimidin- 4-yl]methoxy}phenyl)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-</] pyrimidin-4-yl] oxy}propanoic acid
Example 61: (2R)-3-(2-{[2-(2-{[bis(2-hydroxyethyl)amino]methyl}phenyl)pyrimidin- 4-yl]methoxy}phenyl)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl]oxy}propanoic acid
Example 62: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{4-[(2-hydroxy ethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid Example 63: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{2-[2-(2-hydroxy ethoxy)ethoxy] phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Example 64: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] oxy}-3-(2-{ [2-(2-{2- [2-(2- hydroxyethoxy)ethoxy] ethoxy}phenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid
Example 65: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-{2-[(2-{3-[(phosphono oxy)methoxy] phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoic acid
Example 66: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3-(2-{ [2-(3-{ [(phosphono oxy)methoxy] methyl}phenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid
Example 67: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i ] pyrimidin-4-yl] oxy}-3-(2-{ [2-(3-{ [(phosphono oxy)carbonyl] oxy}phenyl)pyrimidin-4-yl] methoxy}phenyl)propanoic acid Example 68: (2R)-2-{[(5S«)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[3-({[(phosphono oxy)carbonyl]oxy}methyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid
Example 69: l-[(ethoxycarbonyl)oxy] ethyl (2R)-2-{[(5S«)-5-{3-chloro-2-methyl-4-[2- (4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i ]pyrimidin-4- yl]oxy}-3-{2-[(2-{3-[(l,3-dimethoxypropan-2-yl)oxy]phenyl}pyrimidin-4-yl)methoxy] phenyl}propanoate
Step A: ethyl l-chloroethyl carbonate
1 eq. of ethanol and 1.2 eq. pyridine were dissolved in dichloromethane (1.2 mL/mmol). 1.05 eq. l-chloroethyl chloro formate was slowly added at -78 °C under nitrogen and the reaction mixture was stirred at -78 °C for 3 hours. The cold mixture was filtered and the filtrate was concentrated under reduced pressure. The crude product was used without further purification.
Step B: Example 69
1 eq. of Example 13 was dissolved in DMF (20 ml/mmol) under nitrogen. 6.7 eq. CS2CO3 and 8 eq. of ethyl l-chloroethyl carbonate from Step A was added. The reaction mixture was stirred at room temperature until no further conversion was observed. The mixture was diluted with brine and it was extracted with DCM, dried with Na2S04, filtered and concentrated under reduced pressure. The crude product was purified via preparative reverse phase chromatography using 5 mM aqueous NH4HCO3 solution and acetonitrile as eluents to obtain Example 69. HRMS calculated for CseHgoClFNeOnS: 1078.3713; found 1079.3796 and 1079.3786 (M+H)
Example 70: l-[(dimethylcarbamoyl)oxy] ethyl (2R)-2-{[(5S«)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin- 4-yl]oxy}-3-{2-[(2-{3-[(l,3-dimethoxypropan-2-yl)oxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoate Example 71: (2R)-2-{[5-{2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]phenyl}-6- (4-fluorophenyl)thieno [2,3- \ pyrimidin-4-yl] oxy}-3- [2-({2- [3-(hydroxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Example 72 : (2R)-2- { [5- {3,5-dichloro-2,6-dimethyl-4- [2-(4-methylpiperazin- 1-yl) ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2- [3- (hydroxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Example 73 : (2R)-2- { [5- {2,6-dimethyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl}-6- (4-fluorophenyl)thieno [2,3- \ pyrimidin-4-yl] oxy}-3- [2-({2- [4-(phosphonooxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid Example 74: (2R)-2-{[5-{3,5-dichloro-2,6-dimethyl-4-[2-(4-methylpiperazin-l-yl) ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-i j pyrimidin-4-yl] oxy}-3- [2-({2- [4- (phosphonooxy)phenyl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Example 75 : 2- { [(5Sfl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-hydroxy-3-[2-({2-[3- (hydroxymethyl)phenyl] pyrimidin-4-yl}methoxy)phenyl] propanoic acid
Example 76 : 2- { [(5Sfl)-5-{3-chloro-2-methyl-4- [2-(4-methylpiperazin- l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-4-hydroxy-3-[2-({2-[3- (hydroxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] butanoic acid
Example 77: 2-0-[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno [2,3-d\ pyrimidin-4-yl] -3,4-dideoxy-3- [2-({2-[3- (hydroxymethyl)phenyl] pyrimidin-4-yl} methoxy)phenyl] pentonic acid
Example 78: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[2-(hydroxy methyl)pyridin-4-yl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid Example 79: (2R)-2-{[(5S«)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[5-(hydroxy methyl)pyridin-3-yl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Starting from Preparation 1 and [5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3- pyridyl]methanol using General procedure I, Example 79 was obtained. HRMS calculated for C46H43CIFN7O6S: 875.2668; found 438.6428 (M+2H)2+
Example 80: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[6-(hydroxy methyl)pyridazin-4-yl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid Example 81: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-[2-({2-[6-(hydroxy methyl)pyrazin-2-yl] pyrimidin-4-yl} methoxy)phenyl] propanoic acid
Example 82: (2R)-2-{[(5Sfl)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-i |pyrimidin-4-yl]oxy}-3-(2-{[2,-(hydroxy methyl)-2,5'-bipyrimidin-4-yl]methoxy}phenyl)propanoic acid
Starting from Preparation 1 and Preparation 4q using General procedure I, Example 82 was obtained. HRMS calculated for C45H42CIFN8O6S: 876.2621; found 439.1402
(M+2H)2+
PHARMACOLOGICAL STUDY
EXAMPLE A: Inhibition of Mcl-l by the fluorescence polarisation technique
The relative binding potency of each compound was determined via Fluorescence Polarisation (FP). The method utilised a Fluorescein labelled ligand (Fluorescein- pAla- Ahx-A-REIGAQLRRMADDLNAQY-OH; mw 2,765) which binds to the Mcl-l protein (such that Mcl-l corresponds to the UniProtKB® primary accession number: Q07820) leading to an increased anisotropy measured in milli-polarisation (mP) units using a reader. The addition of a compound which binds competitively to the same site as the ligand will result in a greater proportion of unbound ligand in the system indicated by a decrease in mP units.
An 11 point serial dilution of each compound was prepared in DMSO and 2 μΐ transferred into flat bottomed, low binding, 384-well plate (final DMSO concentration 5 %). 38 μΐ of buffer (10 mM 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid [HEPES], 150 mM NaCl, 0.05 % Tween 20, pH 7.4), containing the Fluorescein labelled ligand (final concentration 1 nM) and Mcl-l protein (final concentration 5 nM) was then added.
Assay plates were incubated ~2 hours at r.t. before FP was measured on a Biomek Synergy2 reader (Ex. 528 nm, Em. 640 nm, Cut off 510 nm) and mP units calculated. The binding of increasing doses of test compound was expressed as a percentage reduction in mP compared to a window established between '5 % DMSO only' and Ί00 % inhibition' controls. 11 -point dose response curves were plotted with XL-Fit software using a 4- Parameter Logistic Model (Sigmoidal Dose-Response Model) and the inhibitory concentrations that gave a 50 % reduction in mP (IC50) were determined. Results obtained are presented in Table 1 below.
The results show that the compounds of the invention inhibit interaction between the Mcl- 1 protein and the fluorescent peptide described hereinbefore. EXAMPLE B: In vitro cytotoxicity
The cytotoxicity studies were carried out on the H929 multiple myeloma tumour line.
The cells are distributed onto microplates and exposed to the test compounds for 48 hours. The cell viability is then quantified by a colorimetric assay, the Microculture Tetrazolium Assay (Cancer Res., 1987, 47, 939-942).
The results are expressed in IC50 (the concentration of compound that inhibits cell viability by 50%) and are presented in Table 1 below.
The results show that the compounds of the invention are cytotoxic.
Table 1: ICgn of Mcl-1 inhibition (fluorescence polarisation test)
and of cytotoxicity for H929 cells
IC50 (M) Mcl-1 FP IC50 (M) MTT H929 IC50 (M) Mcl-1 FP IC50 (M) MTT H929
Example 1 8.4E-09 9.31E-09 Example 19 4.95E-09 2.47E-09
Example 2 1.32E-08 1.59E-08 Example 20 4.35E-09 5.68E-08
Example 3 4.05E-09 4.08E-09 Example 21 4.85E-09 >1.50E-07
Example 4 4.9E-09 3.64E-09 Example 22 5.5E-09 5.97E-09
Example 5 3.7E-09 1.65E-09 Example 23 2.7E-09 3.97E-08
Example 6 1.57E-08 3.25E-09 Example 24 3.15E-09 2.55E-09
Example 7 3.75E-09 4.45E-09 Example 25 3.45E-09 1.00E-08
Example 8 7.35E-09 2.07E-09 Example 26 3.45E-09 1.72E-09
Example 9 8.15E-09 1.40E-09 Example 27 2.2E-09 1.39E-08
Example 10 1.09E-08 2.79E-09 Example 28 4.15E-09 4.84E-08
Example 11 4.05E-09 1.99E-09 Example 29 4.6E-09 2.27E-08
Example 12 4.25E-09 3.82E-09 Example 30 4.5E-09 3.60E-09
Example 13 5.1E-09 3.59E-09 Example 31 3.85E-09 1.68E-09
Example 14 6.15E-09 3.37E-09 Example 32 1.53E-08 1.68E-09
Example 15 2.75E-09 3.59E-09 Example 33 2.24E-08 1.18E-09
Example 16 7.2E-09 3.71E-08 Example 34 7.1E-09 4.76E-09
Example 17 4.8E-09 3.03E-09 Example 35 5.15E-09 4.76E-09
Example 18 4.1E-09 1.39E-08 Example 36 4.65E-09 7.59E-08 IC50 (M) Mcl-1 FP IC50 (M) MTT H929 IC50 (M) Mcl-1 FP 1C50 (M) MTT H929
Example 37 6.3E-09 2.05E-08 Example 60 ND ND
Example 38 2.8E-09 2.76E-09 Example 61 ND ND
Example 39 3.05E-09 3.25E-09 Example 62 ND ND
Example 40 3.75E-09 6.15E-09 Example 63 ND ND
Example 41 3.45E-09 9.08E-08 Example 64 ND ND
Example 42 4.45E-09 4.45E-08 Example 65 ND ND
Example 43 4.55E-09 3.11E-08 Example 66 ND ND
Example 44 3.7E-09 2.87E-08 Example 67 ND ND
Example 45 3.2E-09 4.58E-09 Example 68 ND ND
Example 46 2.55E-09 2.34E-08 Example 69 7.6E-08 ND
Example 47 4.05E-09 1.82E-08 Example 70 ND ND
Example 48 3.85E-09 ND Example 71 ND ND
Example 49 4.65E-09 ND Example 72 ND ND
Example 50 6.6E-09 ND Example 73 ND ND
Example 51 4.15E-09 ND Example 74 ND ND
Example 52 3.7E-09 ND Example 75 ND ND
Example 53 4.65E-9 ND Example 76 ND ND
Example 54 4.6E-09 ND Example 77 ND ND
Example 55 6.35E-09 ND Example 78 ND ND
Example 56 4.75E-09 ND Example 79 7.6E-09 ND
Example 57 4.6E-09 2.27E-08 Example 80 ND ND
Example 58 ND ND Example 81 ND ND
Example 59 ND ND Example 82 7.7E-09 ND
ND: not determined
EXAMPLE C: Quantification of the cleaved form of PARP in vivo
The ability of the compounds of the invention to induce apoptosis, by measuring cleaved PARP levels, is evaluated in a xenograft model of AMO-1 multiple myeloma cells. 1.107 AMO-1 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain). 12 to 14 days after the graft, the animals are treated by intraveinous or oral routes with the various compounds. After treatment, the tumour masses are recovered and lysed, and the cleaved form of PARP is quantified in the tumour lysates.
The quantification is carried out using the "Meso Scale Discovery (MSD) ELISA platform" test, which specifically assays the cleaved form of PARP. It is expressed in the form of an activation factor corresponding to the ratio between the quantity of cleaved PARP in the treated mice divided by the quantity of cleaved PARP in the control mice.
The results show that the compounds of the invention are capable of inducing apoptosis in AMO-1 tumour cells in vivo.
EXAMPLE D: Anti-tumour activity in vivo
The anti-tumour activity of the compounds of the invention is evaluated in a xenograft model of AMO-1 multiple myeloma cells.
lxlO7 AMO-1 cells are grafted sub-cutaneously into immunosuppressed mice (SCID strain).
6 to 8 days after the graft, when the tumour mass has reached about 150 mm3, the mice are treated with the various compounds in a daily schedule (5 -day treatment). The tumour mass is measured twice weekly from the start of treatment.
The results obtained using ΔΤ/C (i.e. qualification parameter of the activity of a product, which is defined as the ratio tumour volume of the treated group / tumour volume of the untreated control group) show that the compounds of the invention induce significant tumour regression during the treatment period. EXAMPLE F: Pharmaceutical composition: Tablets
1000 tablets containing a dose of 5 mg of a compound selected from Examples 1 to 82 5 g
Wheat starch 20 g
Maize starch 20 g Lactose 30 g
Magnesium stearate 2 g
Silica 1 g
Hydroxypropylcellulose 2 g

Claims

1. Compound of formula (I):
Figure imgf000079_0001
in which 1 is linked to the oxygen atom and 2 is linked to the phenyl ring,
♦ Ri represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (Ci-Ce)alkoxy group, a -S-(Ci-Ce)alkyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a hydroxy(Ci-Ce)alkyl group, a cyano group, -NR12R12', -Cy5, or a halogen atom,
♦ R2, R3, R4 and R5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a hydroxy(Ci-C6)alkyl group, a linear or branched (Ci-C6)alkoxy group, a -S-(Ci-Ce)alkyl group, a cyano group, a nitro group, -alkyl(C0-C6)-NRioRio', -0-alkyl(Ci-C6)-NRi0Rio', -0-alkyl(Ci-C6)-Rn, -C(O)-ORi0, -O-C(O)-Ri0,
Figure imgf000079_0002
-NRi0-C(O)-Ri0', -NRio-C(0)-ORio', -alkyl(Ci-C6)-NRio-C(0)-Rio', -S02-NRi0Rio', -S02-alkyl(Ci-C6),
or the substituents of one of the pairs (R2, R3), (R3, R4), (R4, R5), when grafted onto two adjacent carbon atoms, form together with the carbon atoms carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that resulting ring may be substituted by a group selected from a linear or branched (Ci-C6)alkyl group, -NRi2Ri2', -alkyl(Co-C6)-Cyi, or an oxo,
♦ 5 represents -0-alkyl(Ci-C6)-Rn,
♦ R7 represents a hydrogen atom, a halogen atom, a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (Ci-Ce)polyhaloalkyl, a hydroxy group, a linear or branched (Ci-C6)alkoxy group, a -S-(Ci-Ce)alkyl group, a cyano group, a nitro group, -alkyl(C0-C6)-NRioRio', -0-alkyl(Ci-C6)-NRi0Rio', -O-Cyi, -alkyl(C0-C6)-Cyi, -alkenyl(C2-C6)-Cyi, -alkynyl(C2-C6)-Cyi, -0-alkyl(Ci-C6)-Rn, -C(0)-ORio, -0-C(0)-Rio, Ri0-C(O)-Ri0', -NRi0-C(O)-ORi0', -alkyl(C1-C6)-NR1o-C(0)-R
Figure imgf000080_0001
-S02-alkyl(C1-C6),
♦ Rs represents a hydrogen atom, a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C6) group, or a heteroarylalkyl(Ci-Ce) group,
♦ R9 represents a linear or branched (Ci-Ce)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, -alkyl(Ci-C6)-Cy3, -alkenyl(C2-C6)-Cy3, -alkynyl(C2-C6)-Cy3, -Cy3-Cy4, -alkynyl(C2-Ce)-0-Cy3, -Cy3-alkyl(Co-C6)-0-alkyl(Co-C6)-Cy4, a halogen atom, a cyano group, -C(0)-Ri3, or -C(0)-NRi3Ri3',
♦ Rio and Rio' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, -alkyl(Co-Ce)-Cyi,
or the substituents of the pair (Rio, Rio') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by from 1 to 2 groups representing a hydrogen atom, or a linear or branched (Ci-Ce)alkyl group, and it being understood that one or more of the carbon atoms of the possible substituents, may be deuterated,
♦ Rii represents -Cy5-alkyl(Co-C6)-0-alkyl(Co-C6)-Cy6, -Cy5-alkyl(C0-C6)-Cy6, -Cy5-alkyl(Co-C6)-NR12-alkyl(Co-C6)-Cy6,
♦ Ri2, R12' , Ri3 and R13 ' independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-C6)alkyl group,
♦ Ri4 represents a hydrogen atom, a hydroxy group, or a hydroxy(Ci-C6)alkyl group,
♦ Ra represents a hydrogen atom or a linear or branched (Ci-C6)alkyl group,
♦ Rb represents a -0-C(0)-0-Rc group, a -0-C(0)-NRcRc' group, or a -0-P(0)(ORc)2 group,
♦ Rc and Rc' independently of one another represent a hydrogen atom, a linear or branched (Ci-C8)alkyl group, a cycloalkyl group, a (Ci-C6)alkoxy(Ci-C6)alkyl group, a (Ci-C6)alkoxycarbonyl(Ci-C6)alkyl group,
or the substituents of the pair (Rc, Rc') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a linear or branched (Ci-C6)alkyl group,
♦ Cyi, Cy2, Cy3, Cy4 and Cy5 independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group,
♦ Cy6 represents
Figure imgf000081_0001
or Cy6 represents a heteroaryl group which is substituted by a group selected from -O-P(O)(OR20)2; -0-P(0)(0 )2; -(CH2)p-O-(CHR18-CHR19-O)q-R20; hydroxy; hydroxy(Ci-C6)alkyl; -(CH2)r-Y-(CH2)s-heterocycloalkyl; or -Y-(CH2)q-NR2iR2i ',
♦ Ri5 represents a hydrogen atom; a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a linear or branched (Ci-C6)alkoxy(Ci-C6)alkyl group; a -Y-(CH2)q-NR2iR2i ' group; or a -(CH2)r-Y-(CH2)s-heterocycloalkyl group,
♦ Ri6 represents a hydrogen atom; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a (CH2)r-Y-X-0-P(0)(OR2o)2 group; a -0-P(0)(0")2 group; a -(CH2)p-O-(CHR18-CHR19-O)q-R20 group; a -(CH2)p-0-C(0)-NR22R23 group; or a -Y-(CH2)q-NR2iR2i ' group,
♦ Ri7 represents a hydrogen atom; a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a -0-P(0)(OR2o)2 group; a -0-P(0)(0")2 group; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a -Y-(CH2)q-NR2iR2i ' group; or an aldonic acid,
♦ X represents a -(CH2)S- group or a -C(O)- group,
♦ Y represents a bond or an oxygen atom,
♦ Ri8 represents a hydrogen atom or a (Ci-C6)alkoxy(Ci-C6)alkyl group,
♦ Rig represents a hydrogen atom or a hydroxy(Ci-Ce)alkyl group,
♦ R2o represents a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,
♦ R2i and R21 ' independently of one another represent a hydrogen atom, a linear or branched (Ci-Ce)alkyl group, or a hydroxy(Ci-C6)alkyl group,
or the substituents of the pair (R2i, R2i ') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C6)alkyl group,
♦ R22 represents a (Ci-C6)alkoxy(Ci-C6)alkyl group, a -(CH2)P-NR24R24 ' group, or a -(CH2)p-O-(CHR18-CHR19-O)q-R20 group,
♦ R23 represents a hydrogen atom or a (Ci-C6)alkoxy(Ci-Ce)alkyl group,
or the substituents of the pair (R22, R23) form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 18 ring members, which may contain in addition to the nitrogen atom from 1 to 5 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom, a linear or branched (Ci-C6)alkyl group or a heterocycloalkyl group,
♦ R24 and R24' independently of one another represent a hydrogen atom or a linear or branched (Ci-Ce)alkyl group,
or the substituents of the pair (R24, R24') form together with the nitrogen atom carrying them an aromatic or non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from one to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the resulting ring may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C6)alkyl group,
♦ n is an integer equal to 0 or 1 ,
♦ p is an integer equal to 0, 1 or 2,
♦ q is an integer equal to 1 , 2, 3 or 4,
♦ r and s are independently an integer equal to 0 or 1, with the proviso that R 5, Ri6 and R 7 cannot represent together a hydrogen atom and, when Ri represents a methyl group, R15 cannot represent a methoxyethoxy group, it being understood that:
"aryl" means a phenyl, naphthyl, biphenyl, indanyl or indenyl group,
"heteroaryl" means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
"cycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,
"heterocycloalkyl" means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems, it being possible for the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, to be substituted by from 1 to 5 groups selected from optionally substituted linear or branched (Ci-C6)alkyl, optionally substituted linear or branched (C2-Ce)alkenyl group, optionally substituted linear or branched (C2-Ce)alkynyl group, optionally substituted linear or branched (Ci-C6)alkoxy, optionally substituted (Ci-C6)alkyl-S-, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, -C(0)-OR', -0-C(0)-R', -C(0)-NR'R", -NR'R", -(C=NR')-OR", linear or branched (Ci-Ce)polyhaloalkyl, trifluoromethoxy, or halogen, it being understood that R' and R" independently of one another represent a hydrogen atom or an optionally substituted linear or branched (Ci-Ce)alkyl group, and it being understood that one or more of the carbon atoms of the preceding possible substituents, may be deuterated, their enantiomers, diastereoisomers and atropisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
2. Compounds according to claim 1 , wherein at least one of the groups selected from R2, R3, R4 and R5 does not represent a hydrogen atom.
3. Compounds according to claim 1 , wherein n is an integer equal to 1.
4. Compounds according to claim 1 , wherein Ri represents a linear or branched (Ci-C6)alkyl group or a halogen atom.
5. Compounds according to claim 1 , wherein R14 represents a hydrogen atom, a hydroxy group, a hydroxymethyl group or a hydroxy ethyl group.
6. Compounds according to claim 1 , wherein R2 represents a halogen atom, a hydroxy group, a linear or branched (Ci-C6)alkoxy group.
7. Compounds according to claim 1 , wherein R3 represents a hydrogen atom, a hydroxy group, a linear or branched (Ci-C6)alkoxy group or -0-alkyl(Ci-C6)-NRioRio'.
8. Compound according to claim 1 , wherein R4 and R5 represent a hydrogen atom
9. Compounds according to claim 1 , wherein
Figure imgf000085_0001
wherein Ri, Rio and Rio' are as defined in claim 1.
10. Compounds according to claim 1 , wherein
Figure imgf000085_0002
wherein Rio and Rio' are as defined in claim 1.
11. Compound according to claim 1 , wherein the substituents of the pair (Rl s R5) are identical and the substituents of the pair (R2, R4) are identical.
12. Compound according to claim 1 , wherein
Figure imgf000085_0003
wherein Ri 1 is as defined in claim 1.
13. Compound according to claim 1 , wherein R7 represents a hydrogen atom
14. Compounds according to claim 1 , wherein R8 represents a hydrogen atom, a -CHRaRb group, an optionally substituted linear or branched (Ci-Cs)alkyl group, or a heteroarylalkyl(Ci-Ce) group.
15. Compounds according to claim 1 , wherein Rg represents a linear or branched (Ci-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, an aryl group or a heteroaryl group.
16. Compounds according to claim 1 , wherein Rio and Rio' independently of one another represent a linear or branched (Ci-C6)alkyl group,
or the substituents of the pair (Rio, Rio') form together with the nitrogen atom carrying them a non-aromatic ring composed of from 5 to 7 ring members, which may contain in addition to the nitrogen atom from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom or a linear or branched (Ci-C6)alkyl group.
17. Compounds according to claim 1 , wherein Rn represents -Cy5-alkyl(Co-C6)-Cy6.
18. Compounds according to claim 1 , wherein Cy5 represents a heteroaryl group, particularly, a pyrimidinyl group, a pyrazolyl group, a triazolyl group, a pyrazinyl group or a pyridinyl group.
19. Compounds according to claim 1 , wherein Cy6 represents
Figure imgf000086_0001
wherein R15, Ri6 and Ri7 are as defined in claim 1.
20. Compounds according to claim 1 , wherein Ri6 and Rn represent a hydrogen atom and Ri5 represents a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a linear or branched (Ci-C6)alkoxy(Ci-C6)alkyl group; a -Y-(CH2)q-NR2iR2i ' group; or a -(CH2)r-Y-(CH2)s-heterocycloalkyl group.
21. Compounds according to claim 1 , wherein Ri5 and Rn represent a hydrogen atom and Ri6 represents a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a -O-P(O)(OR20)2 group; a -0-P(0)(0")2 group; a -(CH2)p-O-(CHR18-CHR19-O)q-R20 group; a -(CH2)p-0-C(0)-NR22R23 group; a (CH2)r-Y-X-O-P(O)(OR20)2 group or a -Y-(CH2)q-NR2iR2i ' group.
22. Compounds according to claim 1 , wherein Ri5 and Ri6 represent a hydrogen atom and Rn represents a -(CH2)p-0-(CHRi8-CHRi9-0)q-R2o group; a -O-P(O)(OR20)2 group; a -0-P(0)(0")2 group; a hydroxy group; a hydroxy(Ci-C6)alkyl group; a -(CH2)r-Y-(CH2)s-heterocycloalkyl group; a -Y-(CH2)q-NR2iR2i ' group; or an aldonic acid.
23. Compounds according to claim 1 , which are:
- (2R)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2- (3 -hydroxyphenyl)pyrimidin-4-yl]methoxy } phenyl)propanoic acid;
- (2R)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2- (4-hydroxyphenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid;
- (2R)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [3-(hydroxymethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [4-(hydroxymethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid; (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2 {2-[(2,2-dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
(2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2 {2-[2-(2-methoxyethoxy)ethoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
(2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2-{[2 (2- {2- [2-(2-methoxyethoxy)ethoxy] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid;
(2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2 [2-(methoxymethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid; (2R)-2- { [(5Sa)-5 - {3 -chloro-2-methyl-4- [3 -(4-methylpiperazin- 1 -yl)propoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy} -3- {2-[(2- {2-[(2- methoxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2R)-2- { [(5Sa)-5 - {3 -chloro-2-methyl-4- [3 -(4-methylpiperazin- 1 -yl)propoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {2-[(2- hydroxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2-{[2 (2-{[(2,2-dimethyl-l,3-dioxolan-4-yl)methoxy]methyl}phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid;
(2i?)-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl)propoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[(2- hydroxyethoxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2 {3 - [( 1 ,3 -dimethoxypropan-2-yl)oxy]phenyl} pyrimidin-4- yl)methoxy]phenyl}propanoic acid; - (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4- [( 1 ,3 -dimethoxypropan-2-yl)oxy]phenyl} pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [4-(2,3-dihydroxypropoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- methyl 6-0- {3-[4-( {2-[(2i?)-2-carboxy-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl} -a-D- mannopyranoside;
- methyl 6-0- {3-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-2,3,4-tri-0- methyl-a-D-mannopyranoside;
- methyl 6-0- {4-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-a-D- mannopyranoside;
- methyl 6-0-{4-[4-({2-[(2i?)-2-carboxy-2-{[(55* iJ)-5-{3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]
pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-2,3,4-tri-0- methyl-a-D-mannopyranoside;
- 6-0- {4-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-
4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl}-D-mannopyranose;
- 6-0- {2-[4-( {2-[(2i?)-2-carboxy-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin- 4-yl]oxy} ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl} -D-mannonic acid;
- l,2-0-[(li?)-l-({4-[4-({2-[(2i?)-2-carboxy-2-{[(5¾-5-{3-chloro-2-methyl-4-[3-(4- methylpiperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i] pyrimidin-4-yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]benzyl}oxy)ethylidene]- β-D-mannopyranose;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[(a-D-mannopyranosyloxy)methyl]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [4-(2-hydroxyethyl)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [2-(2,3-dihydroxypropoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [2-(2-hydroxyethoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {2-[(2,3-dihydroxypropoxy)methyl]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [3-(phosphonooxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- 4-[4-({2-[(2i?)-2-carboxy-2-{[(5¾)-5-{3-chloro-2-methyl-4-[3-(4-methyl
piperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl phosphate;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2- [3-(2-hydroxyethoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2R)-2- {[(55e)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2-
{4-[2-(2-methoxyethoxy)ethoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid; - (2i?)-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl)propoxy] phenyl} -6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[2-(2- hydroxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2-{[2- (4- {2- [2-(2-methoxyethoxy)ethoxy] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)propanoic acid;
- (2i?)-2-{[(55'iJ)-5-{3-chloro-2-methyl-4-[3-(4-methylpiperazin-l-yl)propoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[2- (dimethylamino)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[3-(4-methylpiperazin- 1 - yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[(2,2-dimethyl-l,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
- (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3-[2-( {2-[3-(l 5- hydroxy-3-oxo-2,7, 10, 13-tetraoxa-4-azapentadec- 1 -yl)phenyl]pyrimidin-4- yl}methoxy)phenyl]propanoic acid;
- (2R)-3-(2- {[2-(3- {[(1 ,4'-bipiperidin- -ylcarbonyl)oxy]methyl}phenyl)
pyrimidin-4-yl]methoxy}phenyl)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}propanoic acid;
- (2i?)-2-{[(55'ii)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2-{[2-(3-{2-[2-(2- hydroxyethoxy)ethoxy]ethoxy}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid;
- (2i?)-2-{[(55'ii)-5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2-(2- hydroxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; - (2R)-2- {[(5Se)-5 - {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2-(2- methoxyethoxy)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2-(4- methylpiperazin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2- (morpholin-4-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy phenyl}propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2- (dimethylamino)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)meth phenyl}propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2- (pyrrolidin-l-yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy^ phenyl}propanoic acid;
(2R)-3 - [2-( {2-[3 -( { [bis(2-methoxyethyl)carbamoyl]oxy} methyl)phenyl] pyrimidin-4-yl}methoxy)phenyl]-2- {[(55'iJ)-5- {3-chloro-2-methyl-4-[2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2-(3- {[(1 ,4,7,10, 13-pentaoxa- 16-azacyclooctadecan- 16- ylcarbonyl)oxy]methyl}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid; (2R)-2- {[(5Sa)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} - 6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-[2-({2-[3-(2,3- dihydroxypropoxy)phenyl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
(2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy] phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2- {[2-(3- {2-[2-(2- methoxyethoxy)ethoxy]ethoxy} phenyl)^
acid; (2R)-3 -(2- { [2-(3 - {2-[bis(2-hydroxyethyl)amino] ethoxy } phenyl)pyrimidin-4- yl]methoxy}phenyl)-2- {[(55'a)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}propanoic acid;
- (2R)-2- {[(5Sa)-5- {2,3-dimethyl-4-[2-(4-methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4- fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3- {2-[(2- {3-[({[2-(piperidin-l- yl)ethyl]carbamoyl}oxy)methyl]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2-
(morpholin-4-yl)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {3-[2- (dimethylamino)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; - (2i?)-3-(2- {[2-(4- {2-[bis(2-hydroxyethyl)amino]ethoxy}phenyl)pyrimidin-4- yl]methoxy}phenyl)-2- {[(55'iJ)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l- yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl}-6-(4-fluorophenyl)thieno[2,3- ]pyrimidin-4-yl]oxy}-3-(2- {[2-(4- {2-[2-(2- hydroxyethoxy)ethoxy]ethoxy}phenyl)pyrimidin-4-yl]methoxy}phenyl)propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[(2,2- dimethyl- 1 ,3-dioxolan-4-yl)methoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl} propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3- {2-[(2- {4-[2- (morpholin-4-yl)ethoxy]phenyl}pyrimidin-4-yl)methoxy]phenyl}propanoic acid; - 4-[4-({2-[(2i?)-2-carboxy-2- {[(5¾)-5- {3-chloro-2-methyl-4-[3-(4-methyl
piperazin- 1 -yl)propoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4- yl]oxy}ethyl]phenoxy}methyl)pyrimidin-2-yl]phenyl phosphate disodium salt; - l-[(ethoxycarbonyl)oxy]ethyl (2R)-2- {[(5Se)-5- {3-chloro-2-methyl-4-[2-(4- methylpiperazin- 1 -yl)ethoxy]phenyl} -6-(4-fluorophenyl)thieno[2,3-(i]pyrimidin-4- yl]oxy} -3- {2-[(2- {3-[(l ,3-dimethoxypropan-2-yl)oxy]phenyl}pyrimidin-4- yl)methoxy]phenyl}propanoate;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl} -6-(4-fluorophenyl)thieno[2,3-<i]pyrimidin-4-yl]oxy} -3-[2-( {2-[5-(hydroxy methyl)pyridin-3-yl]pyrimidin-4-yl}methoxy)phenyl]propanoic acid;
- (2i?)-2- {[(55'ii)-5- {3-chloro-2-methyl-4-[2-(4-methylpiperazin-l-yl)ethoxy]
phenyl}-6-(4-nuorophenyl)thieno[2,3-(i]pyrimidin-4-yl]oxy}-3-(2- {[2'-(hydroxy methyl)-2,5'-bipyrimidin-4-yl]methoxy}phenyl)propanoic acid.
24. Process for the preparation of a compound of formula (I) according to claim 1 , characterised in that there is used as starting material the compound of formula (II):
Figure imgf000094_0001
wherein A is as defined for formula (I) in which 1 is linked to the chlorine atom and 2 is linked to the bromine atom, which compound of formula (II) is subjected to coupling with a compound of formula (III):
Figure imgf000094_0002
wherein R^, R7, i4 and n are as defined for formula (I), and Alk represents a linear or branched (Ci-C6)alkyl group, to yield the compound of formula (IV):
Figure imgf000095_0001
wherein R^, R7, Ri4, A and n are as defined for formula (I) and Alk is as defined before, compound of formula (IV) which is further subjected to coupling with compound of formula (V):
Figure imgf000095_0002
wherein RL S R2, R3, R4 and R5 are as defined for formula (I), and RBI and RB2 represent a hydrogen atom, a linear or branched (Ci-C6) alkyl group, or RBi and RB2 form with the oxygen carrying them an optionally methylated ring, to yield the compound of formula (VI):
Figure imgf000095_0003
wherein Rl s R2, R3, R4, R5, R5, R7, R14, A and n are as defined for formula (I) and Alk is as defined before, the Alk-O-C(O)- ester function of which compound of formula (VI) is hydrolysed to yield the carboxylic acid, which may optionally be reacted with an alcohol of formula P 8'-OH or a chlorinated compound of formula Rs'-Cl wherein Rs' represents a linear or branched (Ci-Cs)alkyl group, a -CHRaRb group, an aryl group, a heteroaryl group, an arylalkyl(Ci-C6) group, or a heteroarylalkyl(Ci-Ce) group, Ra and Rb are as defined for formula (I), to yield the compound of formula (I), which may be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and which is optionally separated into its isomers according to a conventional separation technique,
it being understood that at any moment considered appropriate during the course of the process described above, some groups (hydroxy, amino...) of the starting reagents or of the synthesis intermediates can be protected, subsequently deprotected and functionalized, as required by the synthesis.
25. Pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 23 or an addition salt thereof with a pharmaceutically acceptable acid or base in combination with one or more pharmaceutically acceptable excipients.
26. Pharmaceutical composition according to claim 25 for use as pro-apoptotic agents.
27. Pharmaceutical composition according to claim 26 for use in the treatment of cancers and of auto-immune and immune system diseases.
28. Pharmaceutical composition according to claim 27 for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non- small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
29. Use of a pharmaceutical composition according to claim 25 in the manufacture of medicaments for use as pro-apoptotic agents.
30. Use of a pharmaceutical composition according to claim 25 in the manufacture of medicaments for use in the treatment of cancers and of auto-immune and immune system diseases.
31. Use of a pharmaceutical composition according to claim 25 in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
32. Compound of formula (I) according to any one of claims 1 to 23 , or an addition salt thereof with a pharmaceutically acceptable acid or base, for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
33. Use of a compound of formula (I) according to any one of claims 1 to 23 or an addition salt thereof with a pharmaceutically acceptable acid or base, in the manufacture of medicaments for use in the treatment of cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, cancer of the colon, oesophagus and liver, lymphoblastic leukaemias, acute myeloid leukaemias, lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer, pancreatic cancer and small-cell lung cancer.
34. Combination of a compound of formula (I) according to any one of claims 1 to 23 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors, kinase inhibitors and antibodies.
35. Pharmaceutical composition comprising a combination according to claim 34 in combination with one or more pharmaceutically acceptable excipients.
36. Combination according to claim 34 for use in the treatment of cancers.
37. Use of a combination according to claim 34 in the manufacture of medicaments for use in the treatment of cancers.
38. Compound of formula (I) according to any one of claims 1 to 23 for use in the treatment of cancers requiring radiotherapy.
PCT/EP2016/064417 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them WO2016207216A1 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
NZ738469A NZ738469A (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CUP2017000162A CU20170162A7 (en) 2015-06-23 2016-06-22 DERIVATIVES OF PHENYL-TIENO (2,3-D) PIRIMIDINA-HIDROXIÁCID USEFUL IN THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES, METHOD OF PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES16731155T ES2944942T3 (en) 2015-06-23 2016-06-22 New hydroxy acid derivatives, a procedure for their preparation and pharmaceutical compositions containing them
HRP20230472TT HRP20230472T1 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
TNP/2017/000529A TN2017000529A1 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
US15/738,601 US10322131B2 (en) 2015-06-23 2016-06-22 Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PL16731155.4T PL3313849T3 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
LTEPPCT/EP2016/064417T LT3313849T (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MYPI2017704890A MY190243A (en) 2015-06-23 2016-06-22 Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MA42231A MA42231B1 (en) 2015-06-23 2016-06-22 New hydroxy acid derivatives, process for their preparation, and pharmaceutical compositions containing them
RU2018102361A RU2745430C9 (en) 2015-06-23 2016-06-22 Novel hydroxy acid derivatives, a method for production thereof and pharmaceutical compositions containing them
AU2016282827A AU2016282827B2 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
BR112017027831A BR112017027831A2 (en) 2015-06-23 2016-06-22 hydroxy acid derivatives, a process for their preparation and pharmaceutical compositions containing them
UAA201800619A UA124759C2 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MDE20180439T MD3313849T2 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
KR1020187002026A KR102620976B1 (en) 2015-06-23 2016-06-22 Novel hydroxy acid derivatives, methods for producing them and pharmaceutical compositions containing them
SI201631700T SI3313849T1 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
DK16731155.4T DK3313849T3 (en) 2015-06-23 2016-06-22 NEW HYDROXY ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP16731155.4A EP3313849B8 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CA2990083A CA2990083C (en) 2015-06-23 2016-06-22 Hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
EA201890124A EA036503B1 (en) 2015-06-23 2016-06-22 Hydroxyacid derivatives, process for their preparation and pharmaceutical compositions containing them
JP2017566288A JP6773695B2 (en) 2015-06-23 2016-06-22 A novel hydroxy acid derivative, a method for producing the same, and a pharmaceutical composition containing the same.
FIEP16731155.4T FI3313849T3 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CN201680048558.4A CN107922432B (en) 2015-06-23 2016-06-22 Novel hydroxy acid derivatives, process for their preparation and pharmaceutical compositions containing them
CR20170590A CR20170590A (en) 2015-06-23 2016-06-22 NEW HYDROXY ACID DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
RS20230299A RS64131B1 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017017008A MX2017017008A (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them.
PH12017502314A PH12017502314A1 (en) 2015-06-23 2017-12-14 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
CONC2017/0012845A CO2017012845A2 (en) 2015-06-23 2017-12-14 New hydroxy acid derivatives, a process for their preparation and pharmaceutical compositions containing them
IL256320A IL256320A (en) 2015-06-23 2017-12-14 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
ECIEPI201782825A ECSP17082825A (en) 2015-06-23 2017-12-15 NEW HYDROXIACID DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ZA2017/08626A ZA201708626B (en) 2015-06-23 2017-12-18 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
SA517390586A SA517390586B1 (en) 2015-06-23 2017-12-21 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
HK18109701.1A HK1250233A1 (en) 2015-06-23 2018-07-26 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
HK18113626.5A HK1254477A1 (en) 2015-06-23 2018-10-24 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1555753 2015-06-23
FR1555753A FR3037958B1 (en) 2015-06-23 2015-06-23 NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Publications (1)

Publication Number Publication Date
WO2016207216A1 true WO2016207216A1 (en) 2016-12-29

Family

ID=54260902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/064417 WO2016207216A1 (en) 2015-06-23 2016-06-22 New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them

Country Status (46)

Country Link
US (1) US10322131B2 (en)
EP (1) EP3313849B8 (en)
JP (1) JP6773695B2 (en)
KR (1) KR102620976B1 (en)
CN (1) CN107922432B (en)
AR (1) AR105104A1 (en)
AU (1) AU2016282827B2 (en)
BR (1) BR112017027831A2 (en)
CA (1) CA2990083C (en)
CL (1) CL2017003316A1 (en)
CO (1) CO2017012845A2 (en)
CU (1) CU20170162A7 (en)
DK (1) DK3313849T3 (en)
DO (1) DOP2017000304A (en)
EA (1) EA036503B1 (en)
EC (1) ECSP17082825A (en)
ES (1) ES2944942T3 (en)
FI (1) FI3313849T3 (en)
FR (1) FR3037958B1 (en)
GE (1) GEP20207076B (en)
HK (2) HK1250233A1 (en)
HR (1) HRP20230472T1 (en)
HU (1) HUE061758T2 (en)
IL (1) IL256320A (en)
JO (1) JO3807B1 (en)
LT (1) LT3313849T (en)
MA (1) MA42231B1 (en)
MD (1) MD3313849T2 (en)
MX (1) MX2017017008A (en)
MY (1) MY190243A (en)
NZ (1) NZ738469A (en)
PE (1) PE20180949A1 (en)
PH (1) PH12017502314A1 (en)
PL (1) PL3313849T3 (en)
PT (1) PT3313849T (en)
RS (1) RS64131B1 (en)
RU (1) RU2745430C9 (en)
SA (1) SA517390586B1 (en)
SI (1) SI3313849T1 (en)
SV (1) SV2017005590A (en)
TN (1) TN2017000529A1 (en)
TW (2) TWI715593B (en)
UA (1) UA124759C2 (en)
UY (1) UY36735A (en)
WO (1) WO2016207216A1 (en)
ZA (1) ZA201708626B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
WO2018127575A1 (en) 2017-01-06 2018-07-12 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
CN108424417A (en) * 2017-12-21 2018-08-21 河南美泰宝生物制药有限公司 Thienopyrimidine derivative, preparation method and application in preparation of anti-tumor drugs
WO2018234433A1 (en) 2017-06-22 2018-12-27 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
WO2019101144A1 (en) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Selective mcl-1 inhibitor and preparation and use thereof
IL267791A (en) * 2017-01-06 2019-09-26 Novartis Ag Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
WO2020078875A1 (en) 2018-10-15 2020-04-23 Les Laboratoires Servier New process for the synthesis of piperazinyl-ethoxy-bromophenyl derivates and their application in the production of compounds containing them
WO2020099542A1 (en) 2018-11-14 2020-05-22 Les Laboratoires Servier Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
WO2020236817A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
EP3567043A4 (en) * 2017-01-05 2020-12-02 Henan Genuine Biotech Co., Ltd. Thienopyrimidine derivative, preparation method therefor, and application thereof in manufacturing of antitumor drugs
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
CN112533598A (en) * 2017-08-15 2021-03-19 艾伯维公司 Macrocyclic MCL-1 inhibitors and methods of use
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
RU2804353C2 (en) * 2018-10-15 2023-09-28 Ле Лаборатуар Сервье New method for synthesis of piperazinyl-etoxy-bromophenil derivatives and their application in obtaining compounds containing them
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037958B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3037959B1 (en) * 2015-06-23 2017-08-04 Servier Lab NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037957B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037956B1 (en) * 2015-06-23 2017-08-04 Servier Lab NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CN113024577B (en) * 2019-12-09 2023-06-30 首药控股(北京)股份有限公司 Preparation method of anti-apoptosis protein selective inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072694A1 (en) * 2011-11-15 2013-05-23 Xention Limited Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
WO2013110890A1 (en) * 2012-01-24 2013-08-01 Les Laboratoires Servier New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
CN102464667B (en) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 Five-membered heterocycle pyrimidine compounds, preparation method and application thereof
EP2886545A1 (en) * 2013-12-23 2015-06-24 Les Laboratoires Servier New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2682733A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
FR3037957B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037956B1 (en) * 2015-06-23 2017-08-04 Servier Lab NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037958B1 (en) * 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3037959B1 (en) * 2015-06-23 2017-08-04 Servier Lab NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3046792B1 (en) * 2016-01-19 2018-02-02 Les Laboratoires Servier NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464667B (en) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 Five-membered heterocycle pyrimidine compounds, preparation method and application thereof
WO2013072694A1 (en) * 2011-11-15 2013-05-23 Xention Limited Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors
WO2013110890A1 (en) * 2012-01-24 2013-08-01 Les Laboratoires Servier New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
EP2886545A1 (en) * 2013-12-23 2015-06-24 Les Laboratoires Servier New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEROUKHIM R. ET AL., NATURE, 2010, pages 899 - 905
CANCER RES., vol. 47, 1987, pages 939 - 942
CORY S. ET AL., NATURE REVIEW CANCER, vol. 2, 2002, pages 647 - 656
HANAHAN D. ET AL., CELL, vol. 100, 2000, pages 57 - 70
KOHL ET AL., PNAS, vol. 100, no. 4, 2003, pages 1700 - 1705
SKERRA A., J. BIOTECHNOL., vol. 74, no. 4, 2001, pages 257 - 75
SKERRA A., J. MOL. RECOGN., vol. 13, 2000, pages 167 - 187

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
EP3567043A4 (en) * 2017-01-05 2020-12-02 Henan Genuine Biotech Co., Ltd. Thienopyrimidine derivative, preparation method therefor, and application thereof in manufacturing of antitumor drugs
US10765680B2 (en) 2017-01-06 2020-09-08 Les Laboratories Servier Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
AU2018205735B2 (en) * 2017-01-06 2024-02-01 Les Laboratoires Servier Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
RU2763544C2 (en) * 2017-01-06 2021-12-30 Ле Лаборатуар Сервье Combination of mcl-1 inhibitor and taxane compound, their applications and pharmaceutical compositions
IL267791A (en) * 2017-01-06 2019-09-26 Novartis Ag Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
TWI674898B (en) * 2017-01-06 2019-10-21 法商施維雅藥廠 Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
WO2018127575A1 (en) 2017-01-06 2018-07-12 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
WO2018234433A1 (en) 2017-06-22 2018-12-27 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
CN111032050B (en) * 2017-06-22 2024-01-19 法国施维雅药厂 Combination of an MCL-1 inhibitor with standard treatment for hematological cancer, use and pharmaceutical composition thereof
CN111032050A (en) * 2017-06-22 2020-04-17 法国施维雅药厂 Combination of MCL-1 inhibitors with standard treatments for hematologic cancers, uses and pharmaceutical compositions thereof
CN112533598A (en) * 2017-08-15 2021-03-19 艾伯维公司 Macrocyclic MCL-1 inhibitors and methods of use
US10676485B2 (en) 2017-08-15 2020-06-09 Abbvie Inc. Macrocyclic MCL-1 inhibitors and methods of use
CN111372936A (en) * 2017-11-23 2020-07-03 北京赛林泰医药技术有限公司 Mcl-1 selective inhibitors, their preparation and use
CN111372936B (en) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1 selective inhibitors, their preparation and use
WO2019101144A1 (en) * 2017-11-23 2019-05-31 北京赛林泰医药技术有限公司 Selective mcl-1 inhibitor and preparation and use thereof
CN108424417A (en) * 2017-12-21 2018-08-21 河南美泰宝生物制药有限公司 Thienopyrimidine derivative, preparation method and application in preparation of anti-tumor drugs
WO2020078875A1 (en) 2018-10-15 2020-04-23 Les Laboratoires Servier New process for the synthesis of piperazinyl-ethoxy-bromophenyl derivates and their application in the production of compounds containing them
RU2804353C2 (en) * 2018-10-15 2023-09-28 Ле Лаборатуар Сервье New method for synthesis of piperazinyl-etoxy-bromophenil derivatives and their application in obtaining compounds containing them
RU2818453C2 (en) * 2018-11-14 2024-05-02 Ле Лаборатуар Сервье Combination of mcl-1 inhibitor and midostaurin, its applications and pharmaceutical compositions
WO2020099542A1 (en) 2018-11-14 2020-05-22 Les Laboratoires Servier Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
WO2020236825A3 (en) * 2019-05-20 2021-02-18 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020236817A3 (en) * 2019-05-20 2020-12-30 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020236825A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
CN114728077A (en) * 2019-05-20 2022-07-08 诺华股份有限公司 MCL-1 inhibitor antibody-drug conjugates and methods of use
WO2020236817A2 (en) 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2022115451A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
US11957693B2 (en) 2021-06-11 2024-04-16 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-cancer agents
WO2023225359A1 (en) 2022-05-20 2023-11-23 Novartis Ag Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Also Published As

Publication number Publication date
AR105104A1 (en) 2017-09-06
DK3313849T3 (en) 2023-05-30
HUE061758T2 (en) 2023-08-28
US20180185369A1 (en) 2018-07-05
FI3313849T3 (en) 2023-05-11
UA124759C2 (en) 2021-11-17
KR102620976B1 (en) 2024-01-05
RU2745430C1 (en) 2021-03-25
ECSP17082825A (en) 2018-02-28
JP6773695B2 (en) 2020-10-21
MX2017017008A (en) 2018-08-15
SA517390586B1 (en) 2022-02-20
MY190243A (en) 2022-04-07
LT3313849T (en) 2023-05-10
BR112017027831A2 (en) 2018-09-04
CU20170162A7 (en) 2018-06-05
EP3313849B8 (en) 2023-05-10
ES2944942T3 (en) 2023-06-27
EP3313849A1 (en) 2018-05-02
HK1254477A1 (en) 2019-07-19
JO3807B1 (en) 2021-01-31
PL3313849T3 (en) 2023-07-10
IL256320A (en) 2018-02-28
SV2017005590A (en) 2018-06-01
PH12017502314B1 (en) 2018-06-25
CO2017012845A2 (en) 2018-03-28
RS64131B1 (en) 2023-05-31
HK1250233A1 (en) 2018-12-07
PH12017502314A1 (en) 2018-06-25
EA036503B1 (en) 2020-11-17
HRP20230472T1 (en) 2023-07-21
KR20180015263A (en) 2018-02-12
DOP2017000304A (en) 2018-02-28
CN107922432B (en) 2021-05-04
CL2017003316A1 (en) 2018-04-27
TW201712019A (en) 2017-04-01
FR3037958A1 (en) 2016-12-30
TWI715593B (en) 2021-01-11
EA201890124A1 (en) 2018-05-31
FR3037958B1 (en) 2019-01-25
GEP20207076B (en) 2020-03-10
CN107922432A (en) 2018-04-17
TW202108590A (en) 2021-03-01
ZA201708626B (en) 2022-06-29
US10322131B2 (en) 2019-06-18
RU2745430C9 (en) 2021-06-28
AU2016282827B2 (en) 2020-07-09
AU2016282827A1 (en) 2018-01-18
MA42231B1 (en) 2023-04-28
UY36735A (en) 2016-12-30
PE20180949A1 (en) 2018-06-11
JP2018527296A (en) 2018-09-20
SI3313849T1 (en) 2023-07-31
EP3313849B1 (en) 2023-02-22
CA2990083C (en) 2021-05-25
PT3313849T (en) 2023-04-18
NZ738469A (en) 2024-08-30
TN2017000529A1 (en) 2019-04-12
MD3313849T2 (en) 2023-07-31
CA2990083A1 (en) 2016-12-29
MA42231A (en) 2018-05-02

Similar Documents

Publication Publication Date Title
AU2016282827B2 (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
AU2016282836B2 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
AU2016387870B2 (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
AU2016282828B2 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
EP3313850A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
OA18892A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them.
OA19003A (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
OA18889A (en) New Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16731155

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: NC2017/0012845

Country of ref document: CO

Ref document number: 11201710401U

Country of ref document: SG

Ref document number: 12017502314

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2017-000161 I

Country of ref document: NI

Ref document number: 002741-2017

Country of ref document: PE

ENP Entry into the national phase

Ref document number: 2990083

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: CR2017-000590

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/017008

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2017566288

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016282827

Country of ref document: AU

Date of ref document: 20160622

Kind code of ref document: A

Ref document number: 14680

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 20187002026

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201800619

Country of ref document: UA

Ref document number: 201890124

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2018102361

Country of ref document: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017027831

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017027831

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171222